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Tropomyosin is one of the components of the thin filaments of muscle, binding to actin,
and, together with troponin, regulating contraction in a calcium-dependent manner (Cho

et al.,l990). The.-e are at least four distinct tropomyosin genes in ·1ertebrates and each
may encode at least six different isoforms of tropomyosin by alternate splicing (Novy et
aL, 1993; MacLeod et al., 1988). The alpha-tropomyosin gene TPM1 has recently been
localised to 15q22 (Eyre et aL, 1994) and has been shown to be mutated in some cases of
familial hypertrophic cardiomyopathy (Thierfelder et al., 1994). The alpha-tropomyosin
gene TPM3 has been recently localised to 1q22-q23 (Wilton et aL, 1994) and has been
shown to be mutated in a family with autosomal dominant nemaline myopathy (Laing,
1994, unpublished observations).

Each muscle-specific gene is possibly associated with an inherited muscle disease, if

there is a disease causing mutation in the gene. Precise mapping of muscle genes
therefore becomes important in relation to mapping muscle diseases (Eyre et al., 1993).

A sequence tagged site (STS) (Olson eta!., !989) was developed for the hnman beta
tropomyosin gene (TPM2). The STS was used to ampi::fy DNA from somatic cell
hybrids to localise TPM2 to human chromosome 9. Genomic dones isolated with the
STS product were in tum used in fluorescent in situ hybridisation (Callen et al., 1992) to
metaphase chromosome spreads to further localise TPM2 to 9pl3.1 (Hunt eta!., 1995).

This project should assist those laboratories searching for candidate genes of inherited
muscular diseases that are linked within the region of the TPM2 gene and may assist in
the precise diagnosis of people with these diseases (Akkari, 1994). Localising TPM2
also lays a foundation for a better understanding of the role of tropornyosins in muscle
and nonmuscle cells.
:
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A polymorphism was also discovered in the 3'UTR of TPM2, using single strnnded

conformation

analysis

(SSCA).

5'-AAGTCTATGCCAGAAGATG-3'

The
and

the

pnmers

used

were

complementary

strand

5'-CCGTGACCGAAGTAGGAAAT-3' creating a 259 bp sequence tagged site (STS).

Sequencing of the STS revealed that there were two variations of the 11th base in the
3'UTR: a guanine and an adenine. Genomic DNA from 97 unrelated individuals was
screened by SSCA and the allelic frequency was detennined to be for the common allele
(gunnine) 0.91 nnd the rare allele (adenine) 0.09. The heterozygosity was 0.16. There is

a Bgl I restriction site at the common allele polymorphic location. A Bgl I restriction
digest of the 259 bp STS produces two fragments (88 & 171 bp) for homozygous
individuals with the common allele, three fragments (88, 171 and 259 bp) for

heterozygous individuals and a single fragment (259 bp) for homozygous individual with
the rare allele.

The discovery of this polymorphism will be entered on the CEPH map and is useful for
researchers as a linkage and physical marker in the human genome project, especially
since the TPM2 gene has now been localised to 9p13.1.
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CHAPTER 1
INTRODlJCTION
1.1 THE TROPOMYOSIN PROTEIN

Tropomyosin (TPM) is an important component of the contractile unit in skeletal muscle,
playing a pivotal role in regulating the interaction between actin and myosin filaments
(Gunning, et al., 1990). Tropomyosins are rod-like, actin-binding proteins found in most

muscle and nonmuscle tissues. In muscle, tropomyosin's structure is two alpha-helical
chains (except for the extreme ends) wound around the long pitch grooves of the helical

actin filament, in a coiled-coil structure, head to tail (see Figure 1.1) (Wolfe, 1993).
Muscle tropomyosin is 284 amino acids long, spans seven actin monomers and makes
seven half-turns per molecular length. In nonmuscle cells tropomyosins are associated

with the actin-containing microfilaments of the cytoskeleton (MacLeod, et al., 1987).
Certain non-muscle tropomyosins, the best studied being platelet, are shorter, only 247
amino acids in length and have a length corresponding to six half-turns per molecule and
six instead of seven actin monomers (Hitchcock-DeGregori & Varnell, 1990). Different
isoforms of tropomyosin have been described, though a specific function for the protein
is best defined in skeletal muscle (Cho, eta!., 1990; MacLeod & Gooding, 1988).

1.2 TROPOMYOSIN'S ROLE IN MUSCLE CONTRACTION

Striated muscle contraction is regulated by Ca2+ through the troponin-tropomyosin
complex (see Figure 1.2). For muscJes at rest, tropomyosin nonnally blocks all the actin
binding sites with myosin on the actin microfilaments. The troponin subunits Tnl and
TnT normally bind to tropomyosin holding it in the myosin blocking position (a&c).
When a nerve impulse causes a voltage change in a muscle cell plasma membrane, the

I

FIGURE 1.1

Tropomyosin and its Association with Troponin.

(a) The coiled-coil structure of Tropomyosin
-j

(b) Sequence structure of striated and smooth forms of

tropomyosin, showing the locations in which the amino acid sequence
is conserved (C) and variable (V) among different tropomyosin types.

Nonmuscle tropomyosins are shorter in length but have conserved
segments at equivalent distances from the C-tenninal end.
(c) The arrangement of tropomyosin and the TnC, Tnl and TnT subunits

of troponin on striated muscle microfilaments.

(After Wolfe, 1993)
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FIGURE 1.2

Calcium Ion Regulation in Muscle Contraction

The actin-linked control mechanism involving blockage by tropomyosin of
the crossbridge binding sites on rnicrofilarnents, as seen in a cross section

of a microfilament.

(a) In the blocking position, tropomyosin covers binding sites for myosin
crossbridges.
(b) Movement of tropomyosin toward the microfilament groove exposes

the myosin-binding sites and triggers the crossbridging cycle (c) and (d).

(After Wolfe, 1993)
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actin

movement
inLO groove

a- when low [Ca2+]
tropomyosin blocks
myosin-actin interaction

b- when high [Ca2+]
tropomyosin moves into
actin groove

ltopomyosin
i;

I

-~

I
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c - tropomyosin binds with
Tnl and TnT, in blocking
position, when low [Ca2+]

d - when released Ca2+ binds
TnC, the tropomyosin and
Tnl and TnT bonds break

impulse travels via the transverse tubule (T tubule) to the sarcoplasmic reticulum and
causes a release in Ca2+ from the Ca2+ -ATPase pump. The Ca2+ binds with the third
troponin subunit, TnC, and it undergoes conformational changes and increases its affinity

to Tnl and TnT, weakening the tropomyosin and Tn! and TnT bonds (b&d).
Tropomyosin then moves towards the actin microfilament groove exposing the myosin
binding sites, allowing a series of processes so the muscle contracts (Borovikov, et al.,

1993; MacLeod & Gooding, 1988; Wolfe, 1993).

Hitchcock-DeGregori and Varnelli, (1990) have experimentally shown that muscle
tropomyosin has periodic binding sites with actin in two sets of seven sites. This
corresponds to the seven actin monomers it spans and the two states it exists in, ie. either
muscle contraction or rest. One set of seven sites function in actin binding and both sets
of seven function in the calcium regulation via troponin of muscle contraction (Hitchcock-

DeGregori & Varnell, !990).

1.3 THE TROPOMYOSIN GENES AND ALTERNATIVE SPLICING OF
DIFFERENT ISOFORMS

There are at least four separate, non overlapping tropomyosin genes, that encode at least
six different isoforms of tropomyosin in muscle and non-muscle human fibroblasts (see

Table I) (Clayton, eta!., !988; Gunning, eta!., 1990). Three of the four tropomyosin
genes have been sequenced from expressed mRNA encoding the human skeletal muscle

isoforms, TPMI (MacLeod & Gooding, 1988), TPM2 (Widada, eta!., !988), TPM3
(MacLeod, eta!., 1986; Reinach & Macleod, 1986). TPM4 was sequenced from a 248
amino acid eDNA, cytoskeletal nonmuscle isoform (MacLeod, et al., 1987). Isofonns are
different expressions of a tropomyosin gene. Each tropomyosin gene encodes different
isoforms in the. different types of muscle.

There are basically two types of muscle, striated and smooth muscle. Striated muscle
consists of three major types, fast (psoas-glycolitic fast or gastrocenemius-·oxidative
4

---------------------r

fast), slow (soleus) and cardiac muscle. There are two subtypes of cardiac muscle, atrial
and ventricle muscle (Gunning, et al., 1990; Wolfe, 1993). This accounts for the six
different possible isoforms produced by the tropomyosin genes ie. (1. fast, 2. slow, 3.
atrial, 4. ventricle, 5. smooth, 6. non-muscle). The expression ofTPMl, 2, and 3 is well

defined in mammalian muscle fibroblasts. There is little data on the expression of TPM4
in muscle e:otcept for the detection of muscle-like exons in the human gene and the
observation of a different sized transcript in total rat skeletal muscle. In contrast, nonmuscle isoforms are poorly defined (see Table l.l for a summary of the TPM isoforms)
(Gunning, et al., 1990; Libri, et al., 1990).

Eukaryotic genes consist of exons and introns, while prokaryotic genes have no introns.
The exons are the regions of the gene that are transcribed to produce mature mRNA and
usually contain coding information for protein translation. Introns are regions in between
the exons that are not translated to produce a protein product. The gene is transcribed by
the protein RNA polymerase into mRNA or the complementary sequence of the gene
strand transcribed. The mRNA strand sequence is then spliced so the introns are removed
and the mature mRNA is translated into a protein by ribosomes (Gelehrter & Collins,
1990; Micklos & Freyer, 1990; Wolfe, 1993).

The TPM isoforms in the different types of muscle and non muscle are produced by
differential RNA splicing of the genes. This means the gene has the same number of
exons or protein coding regions, but when the whole gene is transcribed, the mRNA is
spliced alternatively into different messenger RNA (mRNA) fragments, which are then
translated into the different protein isoforms. TPM3 consists of thirteen exons and the
gene is around 42 kb long (see Figures 1.3 & 1.4) . Five exons are common to muscle
and non-muscle cells, while three are unique to non-muscle cells (Clayton, et al., 1988;
Gunning, et al., 1990; MacLeod & Gooding, 1988; MacLeod, et al., 1987). Alternative
splicing occurs at three distinct points in the gene family, as seen on Figure 1.4. It is
suggested the other TPMs have a similar gene structure with alternative splicing
producing the different isoforms. In particular, TPM2's alternative splicing only occurs

5

on exons 6 and 9, while exon 2 does not undergo alternative splicing (Widada, et al.,
1988). Two groups of tropomyosin isofonns have been described: there are 284 amino
acids present in muscle and non-muscle isoforms and there are 248 amino acids that are
unique to non-muscle cells (see Table I) (Clayton, eta!., !988; Gunning, eta!., 1990;
MacLeod & Gooding, 1988; MacLeod, eta!., 1987; Novy, eta!., 1993; Ruiz-Opazo &
Nadal-Ginard, 1987; Ruiz-Opazo, el a!., 1985).
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Table 1.1

Organisation Of The Human Tropomyosin Gene

GENE

AMINO ACIDS

ISO FORMS

TPM1

284

(i)

a-Tmf (fast twitch muscle}

Chrom. 15

284

(ii)

Tm2 (non-muscle)

(Eyre, et al., 1994)

284

(iti)

Tm3 (non-muscle)

TPM2

284

(iv)

~-Tm

284

(v)

Tm1 (non-muscle)

TPM3

284

(vi)

a-Tms (slow twitch muscle)

Chrom. 1

248

(vii)

Tm5 (non-muscle)

TPM4*

248

(viii)

Tm4 (non-muscle)

19?

285?

(ix)

Has the potential to encode a

(striated muscle)

(Wilton, et al., 1995)

(Laing, 1994b)

muscleTm

*(Tropomyosin 4 may be different in the number of exons and the splicing pattern)

(Gunning, et al., 1990; Libri, et al., 1990)
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FIGURE 1.3

The Exons and Introns in TPM3.
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Vll-70bp
lkb

4kb

42kb

(After Clayton et al., 1988)

l Okb

FIGURE 1.4

Alternative SplicinR of the TPM3 Gene

The gene consists of 13 exons, only five of which (open) are common to
both isoforms. The remaining exons are alternatively spliced to produce the
sL

..d muscle and non-muscle isofonns. Alternative splicing occurs at 3

distinct points in the gene and on a mutually exclusive basis. The 3'

untranslated region is indicated as 3'UTR (After Clayton eta!., 1988).
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1.4 SIGNIFICANCE OF LOCALISING TPM2

There are many inheritecl muscular diseases which have been localised in the genome by
linkage analysis, but for wt.ich no disease-causing mutation in a gene has been found.

Each muscle-specific gene is possibly associated with an inherited muscle disease.
Precise mapping and localisation of muscle genes in the human genome, therefore
becomes important in relation to mapping inherited muscle diseases (Eyre, et al., 1993).

The alpha-tropomyosin gene TPM I has recently been localised to 15q22 (Eyre, et a!.,

1994) and has been shown to be mutated in some cases of familial hypertrophic
cardiomyopathy (Thierfelder, eta!., 1994). The alpha-tropomyosin gene TPM3 has been
recently localised to lq22-q23 (Wilton, et al.,!995) and has been shown to be mutated in
a family with autosomal dominant nemaline myopathy (Laing, eta!., 1994).

Mapping muscle geues may also have implications for developing diagnostic tests for
these diseases, especially prenatal tests and genetic counselling for people affected
(Akkari, et al., 1994). By localising TPM2 it also lays a foundation for better
understanding the role of tropomyosins in muscle and non-muscle tissues.

The

contex~

of this project in collaboration with the Australian Neuromuscular :!{esearch

Institute (ANRI) was to localise TPM2, a possible candidate gene for the inherited mu~cle
disease, autosomal dominant nemaline myopathy. While this project was being carried
out, it was found that a point mutation in TPM3 caused one form of autosomal dominant
nemaline myopathy in a Western Australian family (Laing, eta!., 1994). Yet it is still
important to map TPM2, as it may be a candidate gene for other muscle diseases,
including other nemaline myopathies.

!0

1.5 PROJECT OUTLINE

There we-re six major components of the project:

1. To produce a sequence tagged site (STS) that is unique to only the TPM2
gene.

2. To physically map the human skeletal TPM2 gene by initially using this STS in
a somatic cell hybrid panel.
3. To refine the mapping by using the STS in FISH to human metaphase

chromosome spreads, or if 3 does not work, to:
4. Use the STS as a probe to isolate pure genomic clones from a genomic library,
for use in FISH of human metaphase chromosome spreads, to physically map

the location of the TPM2 gene more precisely.

5. To identify a polymorphism in the TPM2 gene, so it could be used in linkage
studies and entered on the CEPH map.

II

CHAPTER 2
DEVELOPMENT OF AN STS FOR HUMAN SKELETAL
MUSCLE

~-TROPOMYOSIN

(TPM2)

2.1 INTRODUCTION

The aim of developing a specific STS for human skeletal P-tropomyosin (TPM2) was to
use it on a somatic cell hybrid panel, for use in FISH directly, or as a probe to isolate a
larger genomic clone from a library that contains all or part of the TPM2 gene, for use in

FISH.

2.1.1 The Polymerase Chain Reaction

The polymerase chain reaction (PCR) is a fairly recent development in molecular biology
that amplifies a short sequence of DNA around a billion times between two primers
(Mullis, et al., 1986). The standard PCR can amplify a product up to approximately 6 kb
and from less than picograms (lQ-l2g) amounts of specific DNA, to around microgram
(IQ-6g) amounts, which can then be easily measured by agarose gel electrophoresis. The
primers are chemically synthesised oligonucleotides, 20-35 nucleotides long with a free
hydroxyl group present on the 3' end of the primer. The 3' end of a DNA strand, is
where the ribose sugar tenninates the alternate phosphate-sugar DNA backbone. The
opposite 5' end of the strand terminates with a phosphate group, except that primers are
synthesised with the 5' end dephosphorylated (Wilton, 1993).

If a primer is 20 nucleotides long with a random sequence, then because there are four
nucleotides possible at each site, the chance that a primer will have the same sequence in
two places in the genome is (1/4)20 x (1/4)20 or lxJ0-26, Because there are 3x109 bases
in the genome, then a 20mer primer should usually have more than enough sequence to
be unique in the genome, by a factor of JOl7. The specific amplified PCR product is
12

referred to as a STS as the primers and the sequence amplified between them is unique
(Olson, eta!., 1989).

The reaction takes place by heating the target DNA which denatures the strands. The
reaction is ihen cooled and the primers which are present in high concentration anneal to
their complementary sequence. A polymerase enzyme attaches to the 3' hydroxyl group
of the primer and extends along the target sequence adding complementary nucleotides
present in the reaction mixture to make the template double stranded. DNA synthesis
proceeds in the 5' to 3' direction (see Figure 2.1). The polymerase does this about one
thousand bases per minute. The particular polymerase enzyme, is derived from a bacteria

(Thermus aquaticus) found in hot springs, so it can withstand high temperatures. The
second primer is designed to anneal to the complementary strand of the first primer and
its hydroxyl group is also on the 3' end of the primer. In this way the polymerase extends
the template between the two primers. With alternate heating and cooling the template
DNA is continually denatured and extended and therefore is multiplied in an exponential
fashion, with the new product acting as a template for the next. The polymerase will
extend past the other primer but in an arithmetic fashion, while the template between the
primers will increase in an exponential fashion, so most of producl DNA is of a defined
length and can bt. measured by gel electrophoresis. After 30 cycles, taldng about five
minutes each, the target DNA between the primers is increased a billion fold in a small
10-100

~L

eppendorf tube. The reaction efficiency is reduced after about 40 cycles,

unless new enzyme and primers are added (Doggett, 1994; Gelehrter & Collins, 1990;
Saiki, 1990; Wilton, 1993).

2.1.2 Primer Selection and Criteria

The exon sequence of TPM2 had already been determined (Widada, et al., 1988).
Widada ru1d his colleagues achieved this by obtaining transcribed mRNA of TPM2 in
muscle tissue and using

th~ ~nzyme

reverse transcriptase to produce a complementary

strand of DNA or eDNA copy of the TPM2 gene. They produced a complete eDNA
'.i

i

"i

l __
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FIGURE 2.1
The Polymerase Chain Reaction (After Doggett, 1994 ).
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the 3' end of a strand of the
target sequence.
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direction.

CYCLE2

5'3~~
5'

5'

5'

s

Phase 3
Synthesize new strands.

lllerilsa

6 ,_,~

3'

. _
3

Phases 1 and 2
Denature products of Cycle 1 and
anneal primers to template strands.

Prime

-<,_'?.

s

.

I

5 II !II aD i1!11111111 ii 111111111!11 IIIII illllili!lli!i Ill!!! ill II Ill

5'

s

5' milhllili!!IW.dlllli!illiliitllliU!!!!!!!''!! 5• ~
First two template strands that
..

5 ·@II II II I Ill!llijj II Ill! Ill Ill! II 1111 II II! Iill! ill .
5
5'

span the target sequence only

i!ililllilili!iiilillllllll!lll!!ijjlll!llllllii!llillllj!il!ll!!l

5'

I

CYCLE3

Phases 1 and 2
Denature products of Cycle 2 and
anneal primers to template strands.

5'
5'

mrrrmrrr

111!1!1111!1 5'

5'
5'

5'
5'
5'

5'

5'
5'
5'

5'

5'

Phase 3
Synthesize new strands.

5

'

liilllliiililillililili!lllllllilillllliltliili!lilllllil!ll!l!![[ 5'

--

5'

lliiijjll!illliilllllillllliili!lljjil!lllll!ll!!!!l

5'

5'

5'

5'

iiljjiiiliililj!!lllllllliljl!!lllillll!ll!!!!lll!!i
!liilliiiill!iiiiljlllliii!l!jiiiii!llil!lll!!ll!!l!

5' -

5'

!!i!!i!!B!\Ii!!l!!!l\!!!i!l!l\\llii\1\I!\!\IJ!liUl

5•

5'

iililiiilli!iliillilli!l!l!llilll!il!j!!!!lll!ll!!ll

5'

5'

!TIII!iiiilliiii!OIIiillijliil!ljllliii!!l!!lll!!ii

•
5

5'

i!ililil!illi!l!lilllilllillill!llllllililll!llll!illllllillliiiil 5'

===~
Eight template strands that
span the target sequence only

Continue for 20 to 30 cycles to produce over 106 copies of target sequence.

sequence of the adult skeletal isofonn of human skeletal muscle P-tropomyosin, or

TPM2. Likewise, the exon sequence of TPM 1 (MacLeod & Gooding, 1988), TPM3
(Clayton, et al., 1988) and TPM4 (MacLeod, et al., 1987) have been determined. Using
the TPM2 sequence, primers can be selected and synthesised for use in the polymerase

chain reaction (PCR), to amplify a segment of the TPM2 gene.

Primers must be specific for amplifying a segment of the human skeletal muscle TPM2
gene, so no other non-muscle TPM2 isoforms or pseudogenes are amplified. Primers
were synthesised that had the following criteria:

2.1.2.1 Primer sequence unique from other TPM genes

The primers must be designed to have a unique sequence that is different from the other
three tropomyosin genes, so the other genes are not mistakenly amplified.

2.1.2.2 Primer sequence unique to muscle TPM2 isoform to avoid
amplifying pseudogenes

A primer that includes specific skeletal muscle exon sequence that is spliced with the
human skeletal TPM2 gene, will ensure that no nonmuscle TPM2 isoforms are amplified

and that the STS is muscle specific (Clayton, et al., 1988; Widada, et al., 1988). This
will also avoid amplifying pseudogenes.

Pseudogenes are DNA sequences that have the structure of expressed genes and were,
presumably, once functional, but have acquired one or more mutations during evolution
that render them incapable of producing a functional protein product. There are two major

classes of pseudo genes (Singer & Berg, 1991).

The

f.~st

class of pseudogenes can be silent, or they may be transcribed and even

translated into aberrant polypeptides. They are often found closely linked to the
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corresponding functional gene and may be flanked by sequences homologous to those
that flank the corresponding functional gene. Such pseudogenes usually contain introns
and appear to be the result of tandem duplications of DNA segments (Singer & Berg,
199 I). An example of these types of pseudogenes are those found in the

a and p-globin

gene clusters (Gelehrter & Collins, 1990). Most gene families or clusters have members
that are pseudogenes that usually represent a small minority of the total gene number
(Lewin, 1994). Usually these types of pseudo genes do not affect the localisation of a
gene, because they are so close to the real gene and FISH mapping is broad scale,
local ising a gene to a chromosomal band. On metaphase spreads, FISH resolution is
20 million bp, or to a chromosomal band, which is
approximately

8~ 16%

0.3~0.6%

10~

of the genome, or

of an average chromosome (Davies & Read, 1992). So if this type

of pseudogene was mistakenly amplified and used as a probe for FISH, it would usually
not affect the mapping location of the real gene.

There is another class of pseudogenes, called processed pseudogenes which have a
similar sequence to the real gene, except only the exon sequence of the gene is conserved
like a eDNA copy (ie. there are no introns and no protein product is produced). They are
not generally linked to the corresponding functional gene but are dispersed throughout the
genome, even to different chromosomes (Lewin, 1994; Singer & Berg, 1991). A theory
for the presence of this type of pseudogene is that they were expressed mRNA that has
been reverse transcribed back into DNA by the enzyme reverse transcriptase, which is
present in retroviruses and reinserted in the genome. Since they may occur in other parts
of the genome it is important that they are net mistakenly amplified or this will interfere
with loca!ising the TPM2 gene (Gelehrter & Collins, !990; Singer & Berg, 1991). To
detect this class of pseudogenes, primers

~an

be used to amplify from genomic DNA,

which includes the exons and introns and this can be compared using the same primers
on eDNA, which only includes exon sequence. Any pseudogenes amplified would be
smaller than the expected STS as they don't include the introns and their size can be
predicted from the eDNA sequence. A pseudogene could then be detected by agarose
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electrophoresis since their products would be smaller and migrate faster than the genomic
STS (Eyre, et al., 1994; MacLeod & Gooding, 1988).

For processed pseudogenes to be inherited, they had to be mRNA that was reverse
transcribed in the germ line cells, or in the cells that gave rise to genn cells. Usually, it is
only transcribed general metabolic genes that produce this class of pseudogenes. Because
muscle genes are not expressed in genn line cells, then there are likely to be no musclespecific TPM2 exons present as pseudogenes. Therefore, primers synthesised from
unique muscle specific exon sequence, should exclude amplifying processed
pseudogenes. However, the non-muscle TPM2 isoforms are likely to produce
pseudogenes as they are present in germ line cells. Clayton et al. (1988) found at least
seven non-allelic TPM3 pseudogene sequences in the human genome, all derived from
the nonrnuscle isoform Tm5 (see Table 1). No such pseudogene sequences were found
being derived from the TPM3 muscle specific exons. Therefore, by including a primer in
a muscle-specific exon, specific to human skeletal muscle TPM2 and not the nonmuscle
isofonns, excludes the chance of localising a pseudo gene (Eyre, et al., 1994; Singer &
Berg, 1991).

2.1.2.3 STS to include intronic sequence

If one primer is located in one exon and the other primer in another exon so intronic
sequence is included, that will make the STS unique to TPM2. Intronic sequence is less
conserved over evolutionary time than the exon sequence, as introns are not essential to
protein synthesis and have little selection pressure at the phenotypic level (Lewis, 1994).
This means the intron sequence in the STS will make it more unique than just having
exon sequence alone. Ideally the primers should be designed to have intron sequence, but
because the intron sequence was not known, only exon sequence could be used. By
having intronic sequence in the STS, when it is used as a probe, excludes the possibility
of isolating processed pseuc!ogenes in a genomic library and localising processed
_j

,;

:-;,,'

pseudogenes for FISH (Eyre, et al., 1994).

2.1.2.4 Primer's GC ratio

The guanine and cytosine ratio of the primers (GC ratio) should ideally be 50:50 with the
adenine and thymine ratio (AT ratio). This is because guanine and cytosine form three
hydrogen bonds in double stranded DNA, while adenine and thymine form two hydrogen
bonds (Freifelder, 1987). If the GC ratio is higher than the AT ratio then the primer will
anneal at a higher temperature because there are more hydrogen bonds. If the AT ratio is
higher then a lower annealing temperature is required, as there would be less hydrogen

bonds. The GC ratio should be noted so the cycling conditions can be altered accordingly
(Wilton, 1993).

2.1.2.5 Secondary and tertiary primer structures

The primers should be designed to avoid internal secondary and tertiary structures so they

don't fold upon themselves and inhibit the PCR reaction (Wilton, 1993).

2.1.2.6 Primer complementarity

The primers should be designed to avoid complementarity between them otherwise they
will bind to each other and not the target DNA, which is called a primer dimer (Wilton,

1993).

Once a human skeletal muscle specific TPM2 STS has been produced, it can be used on a
somatic cell hybrid panel to localise the TPM2 gene to a chromosome, or part of a
chromosome. An STS produced that is larger than I kb can be used directly in FISH for
more precise mapping. If it is smaller than 1 kb, or it does not work in FISH, then the
STS can be used to isolate a larger clone from a human genomic library (Akkari, et al.,

1994).
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2.2 MATERIALS AND METHODS

2.2.1 Primer Selection

The sequence of TPM2 is given in Appendix 1, from which the primers were selected
and chemically synthesised, by ANRI.

Table 2.1
Primers Used F'or Amplifying TPM2

Sequence

5'~

3'

AACGCCATCGACCGCGCCGAG

Primer No.

Ex on

DS 840.1skF

I (Skeletal muscle-specific)

Forward
AAGTATTCTGAATCCGTGAAG

DS 841.2skR

2 ("Muscle-specific) Reverse

TTGAAATCCCTGGAGGCCCAG

DS 752.5skF

5 ("Muscle-specific) Forward

ATTCCACCAAAGAAGATAAA

DS 869.6F

6 (Forward)

GCTGAGACCCGAGCAGAGTT

DS 868.7F

7 (Forward)

GAAAACCATCGATGACCTAGAA

DS 753.7R

7 (Reverse)

AAGTCTATGCCCAGAAGATG

DS 870.8skF

8 ("Muscle-specific) Forward

AGTTACTGTAGTGGAGGGAG

DS 866.8skR

8 (" Muscle-specific) Reverse

CCGTGACCGAAGTAGGAAAT

DS867. 3'UTR.R

3'UTR (Reverse)

A combination of these primers (see Table 2.1) were used in a PCR reaction on genomic
DNA to see if a TPM2 STS was produced. The combination of primers was selected

: ,,
'

according to the criteria listed in the introduction (2.1.2). The expected STS size (see
Tab!e 2.2) was deduced from the structure of the TPM3 gene in Figure 1.3.
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Table 2.2
Primer Combinations Used To Produce An STS

Primers

Expected STS Size lkb)

lskF (DS 840) · 2skR

(DS 841)

-0.2

SskF (DS 752) -7R

(DS 753)

-1.0

SskF (DS 752) - 8skR

(DS 866)

-2.0

SskF (DS 752)- 3'UTR.R (DS 867)

-2.2

6F

(DS 869) - 8skR

(DS 866)

-1.4

6F

(DS 869)- 3'UTR.R (DS 867)

-1.5

7F

(DS 868) - 3'UTR.R (DS 867)

-1.0

8skF (DS 870)- 3'UTR.R (DS 867)

259 bp

2.2.2 TPM2 PCR Conditions

Final Cone.

For a 25 flL Reaction:-

Target Genomic DNA (50 ng)

5.0 f!L

2 ng/f!L

5X 2200 Buffer (buffer, nucleotides and MgCI2)

5.0 flL

2 mM, 200f1M

Tth DNA polymerase (!liotech) (5.5 units/mL)

O.lf!L

0.2~

Primer mix (10 ng/f!L of each primer)

2.0 f!L

0.8 ng/flL

H20 to 25 f1L

12.9 uL

TOTAL

25.o uL

(5X Ttlz buffer, 10 mM MgCh, I mM dNTP's)

20

u/f!L

2.2.2.1 PCR cycling conditions: 2 step on automatic thermal cycler

Two thermal cyclers were used throughout the project for PCR reactions. The MJ

Research MinicyclerTM (Bresatec) required the additicn of paraffin oil to the reactions to
prevent evaporation during cycling. The other cycler was the MJ Research PTC-100
Programmable Thennal Controller (Bresatec), which had a hot bonnet, so the addition of

paraffin to the reactions was not necessary.

time
temp 94°C 5 min 30 sec (denaturing)
58°C

# cycles

6 min (annealing and extension)

xi

4°C

x35
indefinitely

2.2.3 Agarose Gel Electrophoresis

Agarose gel electrophoresis separates a wide range of DNA fragments depending on the

agarose concentrations.

0.7% agarose

10 to 0.8 kb

1.0% agarose

6 to 0.4 kb

2.0% agarose

4 to 0.2 kb

3.0% agarose

2 to 0.1 kb

(Wilton, 1993)

Because the PCR STS was 1.5 kb, a 2% agarose gel was chosen. 4

~L

of PCR product

was run with 1 ~L 5X agarose loading buffer on 2% agarose gel, in IX TAE buffer, at
IOOV, for 45 min (see Appendix 2 for buffers used). The Biorad 3000Xi power pack

was most often used, with Biorad agarose gel buffer tanks, gel trays and combs, though
other power packs and gel trays were used.
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2.2.4 Staining Agarose Gels

The gel was then stained in 0.5 Jlg/mL of ethidium bromide for 10 min to observe the
DNA bands on a ultraviolet (UV) light, 305 nm transilluminator (Fotodyne Inc.). The
ethidium bromide interchelates between the G:C bases of DNA and becomes

associ:~~ed

with the DNA bands in the geL The DNA absorbs the UV light and transfers this energy
to the ethidiurn bromide and emits light in the red-orange region of the visible spectrum
(Wilton, 1993). The gel was photographed using a mounted Polaroid CU-5 Land Camera
(focal length 127 mm) at maximum aperture (4.7) for 0.25 sec. The black and white film
used was Polaroid Type 667.

2.2.5 DNA markers

To determine the size of the DNA fragments in agarose gel electrophoresis, DNA markers
of known sizes are run with the PCR products. Four markers were used in this project
for agarose gel electrophoresis. Lambda (A) bacteriophage when cut with the restriction
enzyme Hind III provided a high molecular weight marker and when cut with Pst I
provided high to medium weight markers. The plasmid pUC 19 cut with the restriction
enzyme Hpa ll and pGEM® (Promega) produce low molecular weighl markers.

2.2.5.1 Lambda bacteriophage cut with Hind III

For a 50 lJ.L Reaction

lOX Buffer B (Promega)

5!lL

Acetylated BSA (I mg/mL)

5!lL

Spermidine (0.1 M)

0.8 IlL

A. Phage (400 ng/~LL) (Promega)

38.21!L

Hind III (12 uii!L)

ii'L
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2.2.5.2 Lambda bacteriophage cut with Pst I

For a 50 JlL Reaction

lOX Buffer H (Promega)

5 f!L

Acetylated BSA (I mg!mL)

5 f!L

Spermidine (O.IM)

0.8 f!L

A, Phage (400 ngii!L) (Promega)

38.2 f!L

Pst I (12 uii!L)

I f!L

2.2.5.3 pUC 19 cut with Hpa II

For a 50 JlL Reaction

lOX Buffer A (Prornega)

5 f!L

Acetylated BSA (lrng!mL)

5 f!L

Spermidine (O.IM)

0.8 f!L

pUC 19 (500 ng/f!L) (Promega)

38.2 f!L

Hpa II (12 u/I!L)

I f!L

(Promega. 1991)

Note, enzymes have specific pH, temperature and ionic requirements, hence the lOX
buffer which contains Na+ and Mg2+ ions, Tris-HCI as a pH buffer and diothiothreitol.

The acetylated bovine serum albumim (BSA) is a source of neutral protein to add to

enzyme reactions. Enzymes in a reaction containing less than 0.1 mg/mL protein, rapidly
denature in dilute reactions. BSA should be used at a final concentration of 0.1 mg/mL

(Sambrook, et al., 1989).
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FIGURE 2.2
DNA Molecular Weight Markers Used
DNA Source

Restriction Enzymes

(A) A. DNA

Pstl

(B) A. DNA

Hind Ill

(C) pUC 19

HpaiT

(D)pGEMI

Hinf I, R.w 1, Sin I

l(Promega, 1993/94)

24

(A) Lambda cut with Psi I

(C) pUC 19 cut with H pa II
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III
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560bp
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The restriction digest reactants were mixed lightly in a 0.6 mL eppendorf and incubated at
370C for l hour to allow the enzyme digestions to take place. One unit of restriction
enzyme activity is defined as the amount of enzyme required to produce a complete digest
of one microgram of substrate DNA (or fragments) in 60 minutes at the appropriate assay

temperature in a 50

~L

reaction volume (Promega, 1993/94). Therefore, I

~of

each

restriction enzyme was more than enough to ensure complete digestion. The tubes were
then heated to 950C for 5 min to denature and deactivate the enzymes. Each restriction

digest was then added to 50

~L

of Ficoll IX loading buffer. Usually 3

~L

of a marker

was loaded in a well for agarose electrophoresis, or was determined empirically. Note

that pOEM marker was supplied by Promega.

2.2.6 Purifying the TPM2 PCR STS DNA

Once a TPM2 PCR STS had been developed, it had to be confirmed that the STS was
from the TPM2 gene. The most precise method for doing this was to sequence the STS.
Before this could be done, the PCR product had to be purified for sequencing. This

involved running the PCR product on a low melting point agarose gel (LMPAG) (Biorad)
and cutting the DNA band out. The DNA in the agarose was then purified in a resin
column (Wizard1M PCR Preps Purification System- Promega). The purified DNA was
re-run on a gel and the absorbance of the purified DNA was checked to measure the DNA
concentration, before the template was used for sequencing.
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2.2.6.1 Low melting point ag3rose gel (LMPAG)

The TPM2 PCR STS is firstly amplified in a 50 IlL reaction to produce sufficient
template.

For a 50 uL Reaction:-

Final Cone.

Target Genomic DNA (50 ng)

5.0 11L

I ng/I!L

5X 2200 Buffer (buffer, nucleotides and MgCI2)

10.0 IlL

2 mM,200 11M

Tth DNA polymerase (Biotech) (5.5 units/mL)

0.2 11L

0.22 uii'L

Primer mix (I 0 ngii!L of each primer)

4.0 11L

0.8 ngii!L

H20 to 251!L

.l1.2..J.tL

TOTAL

50.0 IlL

(5X Tth buffer, 10 mM MgCiz, I mM dNTP's)

The cycling conditions were the same as those used in 2.2.2.1.

The amplification was run first on a nonnal 2% agarose gel to see if it had worked, as
LMPAG is very expensive. 3 ~L ofPCR product was run with 0.6 J.LL 5X Ficoll agarose
loading buffer on a 2% agarose gel, in IX TAE buffer, at lOOV, for45 min. The gel was
stained in ethidium bromide for 10 min and photographed. 5 J.LL of 5X Ficollloading
buffer was added to the rest of the reaction (47 J.LL) and run on a thickly poured (-1 em)

2% LMPAG (Bio-Rad), as for a normal2% agarose gel (2.2.3).

The LMPAG was then stained with 0.5 l!gimL ethidium bromide for 10 min and the
DNA bands were observed on the UV transilluminator. The bands were cut out using a
clean sterile scalpel b.iade as quickly as possible, because the UV light can nick the DNA
strands. The band was isolated in about 300 IlL of agarose.
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2.2.6.2

Purification

of DNA

using

Wizard™

PCR Preps DNA

Purification System (Promega)

The Wizard™ PCR Preps System (Promega) purifies double-stranded DNA from

contaminants such as primer-dimers and amplification primers, unincorporated
nucleotides and enzymes (Promega, 1993).

For each PCR product:-

I.

The DNA band was excised quickly (to avoid nicking the DNA) from the gel and

placed into a 1.5 mL centrifuge tube.

2.

The tube was heated at 700C until the agarose completely melted.

3.

I mL of Magic PCR Preps Resin was added to the melted agarose and

vortexed for 20 sec to mix.

4.

The minicolumn was placed on the end of a 3 mL syringe barrel, by the luer-lock

extension of the minicolumn.

5.

The plunger was removed and the resin/DNA mix was pi petted into the syringe

barrel.

6.

The syringe plunger was inserted slowly and the slurry was pushed through the

minicolurnn and into a 1.5 mL centrifuge tube.

7.

The syringe was removed from the minicolurnn and then the plunger was
removed from the syringe.
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8.

The syringe barrel was reattached to the minicolumn and 2 rnL of 80% isopropyl
alcohol was pipetted into the syringe barrel to wash the column. The plunger was

inserted and the isopropyl alcohol was pushed through the minicolumn.

9.

The minicolumn was removed and placed on a 1.5 mL centrifuge tube and
centrifuged at 12 000 xg, to dry the resin.

10.

The minicolumn was transferred to a new 1.5 mL tube and 50 )lL of HzO was

added to the minicolumn for approximately 1 minute (the DNA would remain

intact on the minicolumn for up to 30 minutes).

11.

The minicolumn and tube were centrifuged for 20 seconds at 12 000 xg, to elute
the DNA into the tube.

12.

The minicolumns and all old 1.5 mL tubes were discarded.

13.

The sample was kept at 4°C or -zooc.

14.

2 J.LL of the Wizard prep sample was run on a 2% agarose gel with a marker to see
the recovery of the product.

(Promega, 1993)

2.2.7 Measuring the absorbance of nucleic acids on a spectrophotometer

The absorbance of the purified DNA was measured on a Beckman DU 650
spectrophotometer and the concentration of DNA was calculated.
Aa absorbance of 1 at 260 nm lA260 for double stranded DNA (dsDNA) is 50 ng/~
"

"

,

,

lA260 for single stranded DNA (ssDNA) is 33

ng/~

lA260 for RNA is 40 ng/~L
(Promega, 1991; Wilton, 1993)
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Therefore, dsDNA concentration : : : absorbance x dilution factor x 50 ng/J!L

and

ssDNA

"

"

X

"

"

X

33 ng/!lL

Note, that any contaminating RNA at IA20o will be read at 40 ng/!lL and contaminating
primers being ssDNA will be read at 35 ngi!lL. So it was important to run the purified
DNA on a gel to see if there was any contaminating RNA at the bottom of the lane in the
gel.

The purity of the DNA sample can be measured for contaminants such as protein or
phenol by the A20o/A28o ratio. Pure DNA will have en A26o/A2so ratio of 1.8-2.0.
Phenol absorbs strongly at 270 nm and proteins absorb at 280 nm (Wilton, 1993). The
absorbance curve can be observed on the spectrophotometer for peaks at 270 nm and 280
nm suggesting phenol and protein contamination respectively (Wilton, 1993).

2.2.8 Dideoxy Chain Termination Automatic Cycle Sequencing

2.2.8.1 Introduction

Automatic cycle sequencing is based on the Sanger dideoxy sequencing method (Sanger,
1981). The PRISMfM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit
(Applied Biosystems) was used. The kit produces chain terminated fragments from
unlabelled primers extended by the thermostable Taq DNA polymerase. Each
dideoxynucleotide (ddNTP) is labelled with a different fluorescent dye; ddATP-green,
ddCTP-blue, ddGTP-yellow and ddTTP-red. These four ddNTPs are present in the
reaction at approximately 1-2% of the concentration of the normal deoxynucleotides
(dNTP's). The Taq polymerase extends the DNA from a single primer by incorporating
the dNTP's until a fluorescently labelled ddNTP is incorporated in the chain causing the
chain to terminate (Applied-Biosystems, 1993). This occurs at random, so from the
primer, different chain lengths will be produced each with different fluorescently labelled
ends (see Figure 2.3). A dideoxynucleotide has a hydrogen instead of an -OH group
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linked to the 3'-carbon in the ribose sugar. Therefore there is an oxygen missing from the
3'-carbon. Dideoxynucleotides can be inserted during DNA replication, but synthe.;is

stops at an insertion point because there is no 3'-0H for the addition of the next
nucleotide in the chain (Wolfe, 1993). The four base reactions occur simultaneously in

the one tube. Alternate heating and cooling in a thermal cycler causes the DNA to

denature and become single stranded when heated. Cooling causes the primers to anneal
to the template DNA and the polymerase extends the complementary DNA strand with

dNTP's until a fluorescently labelled ddNTP is incorporated and causes the chain to stop.
Heating again releases the primers, denatures the DNA and the cycle continues (see
Figure 2.3). Because only a single primer is used per reaction, the DNA templates are
linearly amplified. This is unlike the normal PCR that exponentially amplifies the target
DNA. The accuracy of the sequencing can be compared by using the complementary
primer to sequence in the reverse direction, as long as the other primer is within
approximately 500 bases (Applied-Biosystems, 1993; Brown, 1994; Manomi, et al.,
1992).

The uninc::n})orated dye terminators are removed by organic extraction. The reaction
products were loaded into a single lane and separated by acrylamide gel electrophoresis
on the automatic sequencer. The smallest DNA end labelled chains travel the fastest
through the gel, while the larger fragments take longer. As the fragments separate by size
they pass through a fixed position in the gel. A laser excites the fluorescent dye of each
coloured end-labelled DNA fragment as it scans back and forth across this area of the gel.
A photomultiplier tube (PMT) detects the fluorescent light colours and converts it into an
electrical signal that is transmitted to a computer for storage and processing. Each scan
consists of four passes, once through each of the four coloured filters, which measures
the colour of each end-labelled base as it passes through the gel. The raw data is analysed
by the computer, which then prints the analysed sequence of the DNA template (AppliedBiosystems, 1993; Brown. 1994; Manorni, et al., 1992).
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FIGURE 2.3
Dideoxy Chain Termination in Sequencing
(After Brown, 1994)
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2.2.8.2 Cycle sequencing - dyedeoxy terminator cycle

For a 15

~L

Reaction:-

IlL
"Prism Cocktail"

7.5

Primer (20 ng!ML)

2

Template (50-300 ng)
H20 up to 15 ML

Paraffin overlay

I drop

"Prism Cocktail" contains:-

~

ddATP-

Green

ddCTP-

Blue

ddGTP-

Yellow

ddTTP-

Red

Taq polymerase enzyme
dNTP' s and buffer

Cycline Conditions

time

temp

94oc 15 sec 30 sec denaturing
500C

I min (annealing)

6QOC

4 min (extension)

#cycles
4°C

xl

x35

indefinitely
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2.2.8.3 Applied Biosystems Inc. sequencing clean-up to remove
unincorporated ddNTPs

Upon completion of the cycling:-

Transferred sequencing reaction to a fresh tube (0.6 mL eppendorf) with minimal
oil carryover

Added 80 ~ water

Added 100 ~ ABI phenol

Mixed thoroughly and centrifuged at 12 000 rpm for 5 min at 40C

Transferred aqueous phase (top phase) to fresh tube

Repeated phenol extraction

Transferred aqueous phase to a fresh tube

Added 151!L 2M Na Acetate pH 5.0
300 11L absolute ethanol

Mixed well and spun 12 000 rpm, 15 min, 4°C
(pre-chilling is not necessary)

Discarded supernatant (above pellet)

Washed pellet (small, clear and not coloured) with 70% Ethanol and used a pipet
to remove as much ethanol as possible
33

Centrifuged again 12 000 rpm, 5 min, 4°C

Brief vacuum dried for 5-10 min (Speedvac Model SVC 100- Savant)

Eppendorfs wem capped and reactions can be left at this stage ready for
sequencing loading
(ANRI, 1994)

The 1.5 kb product was sequenced using an ABI 373A DNA sequencer to confirm that
the STS product was part of the TPM2 gene.

2.2.9 Using the Radioactive Random Labelled TPM2 STS on a Genomic
Hybridisation Membrane

2.2.9.1 Random primer labelling introduction

The TPM2 STS was radioactively labelied and hybridised with a genomic blot to see if

the STS would hybridise to genomic DNA before it was used for FISH.

This Prime-a-Gene labelling system was developed by Feinberg and Volgelstein (1984),

and is where a mixture of random hexanucleotides primers is used to prime DNA
syntf.·)sis in vitro from any linear double stranded DNA template. The hexamer primers
anneal to the DNA template at random positions and Klenow DNA polymerase extends
from the random primers. A radioactive nucleotide such as (a-3 2P) dCTP and normal
nucleotides (dATP, dGTP, dTTP) are incorporated in the synthesis of a complementary
strand which is labelled radioactively as the (a-32p) dCTP is incorporated. Probes can be
generated up to 50% of the length of the original template with a high specific activity
(often> J09 cprnlp.g) (see Figure 2.4) (Feinberg & Vogelstein, 1984; Promega, 1991).
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FIGURE 2.4
Random Primer Labelling
(After Promega, 1993)
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The STS is then denatured and the radioactively labelled complementary strand

hybridises to a human genomic blot. The actual genomic blots used were prepared and

supplied by ANRI, however the process of how they were made wUI be discussed.

A genomic blot is a Southern Blot of total genomic human DNA. Isolated DNA from
different people is digested with a restriction enzyme that cuts the DNA at a specific

sequence producing different sized fragments. The digested DNA from different
individuals is electrophoresed on an agarose gel in different lanes so that the DNA
fragments separates according to size, the smallest fragments travelling the furthest and

fastest. The gel is then rinsed in an acid solution that depurinates or 'acid nicks' the
DNA, which cuts the DNA into smaller fragments at some of the purine bases (ie.
adenine and guanine) so the DNA can travel through the gel more easily. The gel is then
rinsed in an alkaline solution which denatures the DNA in the gel. The gel is then vacuum
blotted so the depurinated and denatured DNA travels on to a nitrocellulose or nylon
membrane where it hybridises to the membrane in the band paUern that was present in the

·i
\

gel. The membrane is then rinsed in a pH neutralising solution and dried (Gelehrter &
Collins, 1990; Wilton, 1993).

The radioactive STS probe is denatured by heating and hybridised to the human genomic
membrane where it anneals to the complementary sequence in the genome. The
membrane is then washed to remove the excess or unincorporated probe on the
membraiJe and then dried and autoradiographed. The probe may anneal at different bands
on the membrane because the restriction enzyme may have cut the complementary DNA
"!
i

'
i

j

sequence at two or more places where the probe would anneal, so there may be several
bands present on the autoradiograph (Gelehrter & Collins, 1990; Wilton, 1993) (see
Figure 2.5).

j
i

'

''
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FIGURE 2.5

Southern Blotting to Produce Genomic Blots
(After Gelehrter, 1990)
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2.2.9.2 Random primer labelling protocol

!

The following reaction is optimised for labelling 25 ng of DNA template, however when
25 ng of the purified TPM2 STS was used the labelling was too weak, so 5 J.LL of 24
ng/J.LL DNA template was used (ie. 120 ng).

I.

The TPM2 DNA template was denatured by heating at 95-lOOOC for 2
min, then snap chilled in an ice bath.

'

i

I

2.

The reaction was assembled on ice in a separate microcentrifuge tube by

j

.i

adding the following reagents in the order listed.

i
'

I

'

Component

Volume

Final Cone.

(a) Labelling 5X buffer

IX

(b) Mixture of unlabelled dNTP's

20 !1M each

(dGTP, dATP, dTTP, I J.lL each (3 J.LL total)
(c) Denatured DNA template (25 ng) but used

120 ng

(d) (a-32p) dCTP (Bresatec) behind perspex screen 5 J.lL

2.4 ng/J.lL
50 J.!Ci

(50 J.LCi, 3000 Ci/mmole)
(d) Acetylated (nuclease free) BSA (lO mg/mL)
(e) Klenow enzyme

0.4J.Lg!J.LL
5 units

0.1 u/J.LL

(f) Sterile H20 to final volume 50 J.LL

3.

The reaction was mixed gently and incubated at room 1cmpt•rature (250C)

for 60 min in a PCR minicycler.

4.

The reaction was terminated by heating to 95·1 00°C for 2 min and chilling

in an ice bath. EDTA was added to 20 mM and used direcUy in the
hybridisation reaction or stored at -20°C.
(Promega, 1991)
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2.2.9.3 PEl strip test

The percentage incorporation of 32p into the probe by random priming was checked by
using PEl Cellulose thin layer chromatography (see Figure 2.6).
1. An approximate 8 em strip of PEl paper was cut and a line was drawn in
pencil! em from the bottom of the strip and an "x" was marked in the middle
of the line.

2. 0.5 ~of the random priming reaction was placed on the "x".

3. Approximately 5 mL cf 0.75 M KzHzP04 (pH 3.0) was pipetted into a
Coplin jar and !he labelled PEl strip was placed in the jar so that only the top of
}

i

the strip touched the side of the jar.

4. The KzHzP04 solvent front was allowed to move to the top of the strip.

5. The cpm of the strip were measured at the "x" and up the strip where the
solvent had moved the unincorporated 32p in dCTP in a tear fashion.

Efficiency labelled= cpm at "x" I (cpm up the strip+ cpm at "x")

If the labelling efficiency was too low (0-20%) then the random priming reaction

was repeated using more template (ie. >25 ng DNA).

2.2.9.4 Sephadex G-50 Spin Column

The purpose of the Sephadex G-50 spin column is to remove the unincorporated (a-32p)
'

'i

1

1

dCTP in the random priming reaction. This step is not necessary unless the incorporation
levels are low in the random priming reaction. The unincorporated (a-32p) dCTP can be
removed by size exclusion chromatography on Sephadex G-50 beads. The spin column
39

FIGURE 2.6
PEl Strip Test to Measure the %Incorporation of the Radioactive Nucleotide in
the Probe
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leaves the probe free of unincorporated (a32p) dCTP and also reduces the content of
DNA oligomers less than 70 bases in length. This therefore, reduces the background
radiation whe.n using hybridisation probes (Promega, 1991).

Protocols

1. A spin column was prepared by plugging a 3 mL syringe with a small piece of
sterile nonRabsorbent cotton wool.

2. The 3 mL syringe was filled with Sephadex G50 and compacted with the
plunger until it measured about 2 mL and the plunger was then removed.

3. I mL of STE (DNA buffer- see Appendix 2) was added to the top of the
syringe and the syringe was placed in a 15 mL polypropylene conical tube and
centrifuged at 2000 rpm for 5 min on a Beckman model TJ-6 centrifuge.

4. The syringe was placed in a new 15 mL tube and the random priming reaction
(stopped) was added to the syringe and centrifuged at 2000 rpm for 5 min on a
IEC model HN-5 centrifuge.

5. The syringe containing the unincorporated (a-32p) dCTP was discarded which
also contained DNA oligomers less than 70 bases in length.

6. The purified probe was pipetted from the 15 mL tube into a 0.6 mL eppendorf
tube and denatured by heating to 94°C for 5 min and then snap chilled on ice
for 1 min.

7. The denatured probe was added to the prehybridisation solution and genomic
blot.
(ANRI, 1994)
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2.2.9.5 Prehybridisation of the genomic blot

The human genomic blots are prehybridised in a solution that is used to block nonspecific binding of the probe to the membrane. The prehybridisation solution contains
salmon sperm DNA that binds to the membrane everywhere else the imrnobilised
genomic DNA did not bind, therefore blocking any unincorporated probe from nonspecifically hybridising to the membrane (Wilton, 1993).

Prehybridisation solution protocol

10-20 mL of prehybridisation solution was used per membrane. The reagents were added
in the following order:

Hybridisation Solution

for 1 membrane

final concentration

I. 5 MNaCI

4mL

!M

2. De-ionised fonnamide

10mL

IM

3. I M Tris pH 7.5

I mL

50mM

4. 10% SDS

2mL

1%

5. 10 mg/mL Salmon Sperm DNA

0.2mL

0.1 mg/mL 1

6. 50% dextran sulphate

4mL

10%2

Store at -zooc in alil{uots

1 The salmon sperm DNA was boiled at lOQOC for 5 min, and then snapped chilled on
ice before adding to the solution. Salmon spenn DNA should have been cut to an average
size of 500-700 bp.

2 The formamide was freshly deionised by mixing for one hour at room temperature,
with two spoonfuls of Mixed Bead Resin (Bio-Rad), then filtered through 305 mm
diameter Postlip Paper (Hollingsworth & Vose Co. Ltd).
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Fonnamide acts to keep the DNA probe single stranded (Wilton, 1993). The 10% dextran
sulphate increases the rate of hybridisation approximately ten-fold, because the nucleic
acids are excluded from the volume of the solution occupied by the polymer and their
effective concentration is therefore increased (Sambrook, et al., 1989).

The 1 M NaCl maximises the rate of annealing of the probe with its target as
hybridisation is increased in solutions of high ionic strength (Sambrook, et al., 1989).

The 1% SDS solution is a detergent and acts as a surfactant so the probe will anneal to the
membrane target more easily (Sarnbrook, et al., 1989).

The 15 x 20 em genomic blot was placed in a plastic envelop and 20 mL of
prehybridisation solution was added to the bag and mixed around. The bag was heat
sealed and air bubbles in the bag were pushed to one corner and heat sealed in. The bag
with the prehybridisation solution and the genomic blot were placed in a 42oc shaking
water bath (Grant model SU 5/6) for I hour. For newly made genomic blots or
imrnobilised DNA on nylon membranes, the first time they are used for hybridisation
they had to be prehybridised for approximately 4 hours (ANRI, 1994).

2.2.9.6 Hybridisation of the radiolabelled TPM2 STS probe to the
genomic blot

The 50

rtL of radiolabelled TPM2 STS probe (2.2.9.2) was then added to the

prehybridisation solution after cutting one corner of the bag with scissors. The air
bubbles were again removed by heat sealing in one corner and the probe was mixed
around the bag with a glass rod. The air bubbles were removed to ensure every part of
the membrane would come in contact with the probe. To avoid contaminating the water
bath, the hybridisation bag was placed in a large tupperware container filled with water
and placed in the water bath at 420C and left shaking for 16 hours (ANRI, 1994).
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2.2.9.7 Washing the membrane at increasing stringencies

The membrane was then washed at 42°C at increasing stringencies to remove the nonspecific binding of the probe to the membrane. After each wash the membranes
radioactivity was measured using a geiger counter (Mini Instruments Series 400 -minimonitorGM tube). The membranes were washed until the counts per minute (cpm) fell to
approximately 10-20 cpm.

1. The membrane was first washed in 200 mL of 2X SSC, the least stringent

wash for 15 min at 42°C shaking in the water bath.

2. The second wash was in 2X sse and I% SDS for 15 min at 42oe shaking in
the water bath.

3. The third wash was with O.IX sse and 0.1% SDS, the most stringent
wash, for 15 min at 42°C. If the cpm's were already around 20 cpm then the
third wash was not necessary.

(ANRI, 1994).

Note that increasing the temperature of the wash also increases the washing stringency.
The membrane was then blot dried with Whatman 3MM paper and wrapped in Glad
Wrap. Autoradiography was perfonned with Dupont Cronex 4 X-ray film with Quanta
III autoradiography intensifying screens at -sooc for an empirically determined time
(Akkari, et al., 1994).
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2.2.9.8 Stripping the genomic blots

The genomic blots after autoradiographing were !>tripped to remove the probe and all
unspecific labelled DNA, so they could be used again.

I. The membrane was gently agitated in 500 rnL of 0.4 M NaOH fc 30 min at
42oe.

2. The membrane was transferred to a clean dish and gently agitated in 500
rnL of 0.1X SSe, 0.1% SDS and 0.2 M Tris (pH 7.5) for 30 min at 42oe.

3. The membrane was briefly rinsed in O.!X SSe and 0.1% SDS.

4. The activity of the membrane was checked and if at background, it was blotted
dry and stored at 4oe.

2.3 RESULTS

The only primer combination in Table 2.1 that produced an STS from genomic DNA
initially were primers 869 (exon 6) and 866 (exon 8sk) which amplifi<d a 1.4- 1.6 kb
(1.5 kb) product (see Figure 2.7A). A blank was run where all the reactants were added

except the genomic DNA.

This STS was then amplified in a 50

~L

reaction and run on a 2% LMPAG (see Figure

2.7B). The DNA band was cut out and purified using Wizard™ PCR Preps DNA
Puritication System (Promega). 2 ~L of the purified DNA was run on a 2% agarose gel,
IOOV for 30 min to determine how much product there was after purification (see Figure
2.7C) and the absorbance of the purified DNA was measured on a spectrophotometer
(Beckmilll DU 650) to calculate the DNA concentration (see Table 2.3). The measured
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FIGURE 2.7
-1.5 kb TPM2 STS From exon 6 to 8sk (skeletal muscle specific

exon)
(A) The STS Amplified from Two Genomic DNA Samples and Run on a 2%
Agarose Gel at IOOV, for I hr.

(B) The Pooled STS Samples Run on a 2% Low Melting Point Agarose Gel
(LMPAG) at !OOV, for I hr.

(C) The STS cut out from the LMPAG and Purified usH:.~ Promega WizardTM
PCR Purification Preps System. 2% Agarose Gel, at lOOV for 30 min.

46

:;;:;"' "'
OC?O?
'() '()
c:: c::

0

0

>< ><

~~
Vl Vl

1-1Vl Vl

(A)

(B) 2% Low Melting Point Agarose Gel

1.5 k b TPM2 STS
(exons 6-8sk) ____.

(C) DNA After Purification
).

p

s

1.5 kb TPM2 STS
(exo ns 6-8sk) __.

. -- . ......
._

-~~----·----·-···"-~--

-·-

····- ·-·----· ··-····"'-·--·-- --- - ··--·

,_

-

-- -

,_.

"

___ .,

-

----· _,_. _____ .... .. _.
_.

_.

..............

._,_

"'

--

-... ·-----

purified DNA concentration of 24 ng/!lL matches the faint band seen in Figure 2.7C
which was 2 J.lL (-50 ng) of product run on the gel. The recovery of STS product in the
purification process was quite low.

Table 2.3
TPM2 STS DNA Concentration on Spectrophotometer
Mean

Dilution Concentration
(ng/~tL)

A2so
TPM2 STS 1.5 kb

0.0095

0.0078

1.22

sox

24

4 IlL of this template (ie. - 100 ng) was used in the cycle sequencing reaction. Primers
DS 869 ex on 6 and DS 866 exon 8sk were used to sequence in both directions to verify
that the STS was indeed from TPM2 human skeletal muscle. The sequencing results
extended for about 450 bases from one primer (exon 6 forward, see Figure 2.8) and
about 350 bases from the reverse primer (exon 8sk reverse, see Figure, 2.9). From
primer DS 869 in exon 6, sequence was obtained from exon 6, all of intron 6, exon 7 and
approximately the first 150 bases of intron 7. When the sequencing results were
compared with the TPM2 sequence of Widada et al. (1988), out of 70 bases in exon 7
only three bases were different as they could not be read (ie. N). The sequencing in exon
7 was 96% similar to Widada et al.'s TPM2 sequence (see Table 2.4A). The STS and
other TPM bases that were different

lO

the TPM2 sequence of Widada et al., are

underlined. The eight balded bases in the STS were unique only to TPM2. Therefore,
one can be confident that the 1.5 kb STS was unique to TPM2.

The sequencing results from the reverse primer (DS 866.8R) in exon 8sk, was not as
good. The sequence was only readable for 350 bases and included exon 8sk going into
intron 7. Out of 48 readable bases for exon 8sk, eight bases differed from the published
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FIGURE 2.8

Sequence ofTPM 1.5 kb STS from Primer DS 869.6F (Exon 6 Forward)
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EGURE 2.9

Sequence ofTPM 1.5 kb STS from Primer DS 866.8R (Exon 8sk Reverse)
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Table 2.4

A. Sequence of TPM2 STS from primer DS 869 (exon 6 forward)
compared to TPM2 and other TPMs

EXON 6

TPMl

t£,£tttccga caagctgaag gag

TPM3

ttcttactga ,taag_ct,g,aag gag

TPM4

ttctgtctga Q.aaactgaaa gag

TPM2

tgttggagga gaagctgaag gag

TPM2 STS

tgttgg.t_gga gaagntgaag gag

EXON 7

TPMl

gctgagac.t.c gggctgagtt tgcggagagg tcg_gtaac.t.a

TPM3

gcg_gagaccc g.t_gctgagtt tgc_tgagagg_ tcggtggcga

TPM4

gctgagaccc g,tgctgaatt tgcg_gagagg_ gcggt.:!;;.gcaa

TPM2

gctgagaccc gagcagagtt tgccgagagg tctgtggcaa

TPM2 STS

gctgagaccc gagcagagtt tgccgagagg tctn.tggcaa

TPMl

ag_ttggagaa aagcat.t.gat gac.ttagaag

TPM3

aggtggag_aa gacg_at_tgat gacctggaag

TPM4

aactgga§,aa gacQ._at!;_gat gacctggaag

TPM2

agttggagaa aaccatcgat gacctagaag

TPM2 STS

ngttggagaa naccatcgat gacctagaag
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B. Sequence of TPM2 STS from primer DS 866 (exon 8sk reverse)
compared to TPM2 and other TPM's

EXON8sk

TPMl

aggaggtgta Qgctcagaag gtgaagtaca aagccattag

TPM3

atgaggtcta tgcccagaag gtgaagtaca aggccattag

TPM2

atgaagtcta tgcccagaag atgaagtaca aggccattag

TPM2 STS

gtgaagtcta tncccagnag atgaagnaca agnccattaa

TPMl

cgaggaactg gacgacgc

TPM3

cgaggagctg gacgacgc

TPM2

cgaggaactg gacaacgc

TPM2 STS

cgaggnactg gaciacgc

sequence of Widada et al., (1988) (see Table 2.4B). The two balded bases for the STS

were unique to TPM2.

Sequencing of the 1.5 kb TPM STS was also performed by ANRI. From the forward
primer (DS 869.F) the sequencing results in exon 6 and 7 had only one out of 104 bases
which was different to Widada et al.'s published sequence (anN where the sequencer
could not distinguish a base). This also confirmed that the STS was specific to TPM2.
The 1.5 kb purified TPM2 STS was radiolabelled and used as a probe on a genomic blot
(see Figure 2.10). The efficiency of the labelling after the random priming reaction using
the PEl strip was approximately 50%. The actual blot membrane had two digests on it.
Lanes 1-6 and 8 was total human genomic DNA that was digested with the restriction
enzyme BamH I. Lanes 9-16 was human genomic DNA that was cut with
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FIGURE 2.10

Radiolabelled 1.5 kb TPM2 STS Used as a Probe on a Genomic Blot
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FIGURE 2.11

Distances of Lambda Hind III Marker Fragments from the Well
to Compare with the Autoradiograph in Figure 2.12

53

Pvu II. Lane 7 was the 'Allind Ill marker and the different sized fragments in bp from the
well can be seen in Figure 2.11. These were determined from a photograph of the digests
when they were run on a gel by ANRI.

One faint band can be seen on the BamH I digest at 23 mm or approximately 23 kb (see
Figures 2.10 & 2.11). Three bands can be seen on the Pvu II digest. Two faint bands can
be seen at 17 mm or greater than the 23 kb t..Hind ill fragment and 25 mrn or around 18
kb. A strong band was

se~n

at 87 rnm and represents an approximate 1.8 kb fragment.

Most lanes had a lot of non-specific smearing.

2.4 DISCUSSION

The only TPM2 primer combination in Table 2.1 that produced an STS were primers DS

869 (exon 6) and DS 866 (exon 8sk) which amplified an approximate 1.4 - 1.6 kb
(average 1.5 kb) product (see Figure 2.7 A). The expected STS size from Figure 1.3 and
Table 2.2, using the gene structure for TPM3 (Clayton, et al., 1988), was approximately
1.4 kb. Therefore, the amplified 1.5 kb PCR product was close to the expected size and
contained introns 6 and 7.

Because only one band was visible in Figure 2.7A, then there were no pseudogenes
amplified. If pseudogenes were amplified it would be expected that more than one band
would be visible when amplifying genomic DNA. A pseudogene that contained no
introns 6 and 7 would have an expected size of 200 bp, but this was not observed.

Sequencing the TPM2 1.5 kb PCR product did confirm that the STS was unique to
human skeletal muscle TPM2. Sequencing confirmed two introns (6 and 7) were
included in the amplified STS. It was the first time intron 6 had been sequenced. From
the reverse primer (DS 866.R in exon 8sk) sequence was obtained from exon 8sk and
into intron 7, but it did not reach exon 7 after approximately 450 bases. In TPM3 intron 7
is about 1 kb (Figure 1.3) and it would seem TPM2 is comparable to this.
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The sequence differed from the other TPM genes (see Table 2.4 and Appendix 1). This
meant the TPM2 STS could confidently be used as a probe for FISH and to isolate a

larger clone from a genomic library. The TPM2 STS can also be used on a somatic cell
hybrid panel as the sequence was unique.

The 1.5 kb radiolabei!Dd TPM2 STS used as a probe on a genomic blot (Figure 2.!0)
showed some bands where il was annealing the human genomic DNA There was also a
lot of non-speci fie binding. The purpose of the TPM2 STS hybridisation to a genomic
blot was to see if it hybridiscd well to genomic DNA, for use in FISH. From the results

there was some hybridisation, but the bands were not as defined and clear as it was
hoped.

The TPM2 exon sequence from primers DS 869.6F in exert G, to DS 870.8skk in exon
8sk (see Table 2.4 and Appendix I) was typed into the application package DNA Strider
version 1.0. The restriction map of the eDNA between these two primers is given in
Figure 2.12. As can be seen in Figure 2.12, there were no BamH I and Pl'll .ti restriction
sites in these exons, so the bands from the genomic blot in Figure 2.10 must have been
from restriction sites present in the approximate 1.3 kb of intronic sequence.
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FIGURE 2.12

Graphic Map of Restrictton Sites in TPM2 Exon Sequence
from Exons 6-8sk (eDNA) 212 bp.
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CHAPTER 3
USING THE TPM2 STS IN A SOMATIC CELL HYBRID
PANEL

3.1 INTRODUCTION

A somatic cell is any cell of an organism not involved in the germ line. Somatic cell
hybrids are made from fusing together cells from different species. For human gene
mappiag, human and rodent cells hybrids are commonly used, such as fusing together
human and mouse, or human and hamster cells. These somatic cell hyhrids can be used
for human gene mapping. After several generations, a cell line becomes fairly stable
maintaining a specific set of human chromosomes, or a part of the human genome
(Gelehrter & Collins, 1990). Human STS markers used on the somatic cell hybrid panel
can localise the STS markers.

As long as the panel is representative of the human genome, then performing a PCR of
the panel using the human skeletal muscle specific TPM2 primers, should amplify the
STS for cell lines containing that part of the TPM2 gene and therefore localise the gene
(Dubois & Naylor, 1992; Gelehrter & Collins, 1990).

All work on the somatic cell hybrids was performed by Shelly Dorosz (a research
assistant at ANRI) except for the PCR optimisation conditions for the 1.5 kb TPM2 STS,
which was supplied by work done in section 2.2.2. The somatic cell hybrid work is
described here as 1t relates to localising the TPM2 gene.
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3.2 Materials and Methods

A panel of rodent-human somatic cell hybrids was obtained from the National Institute of
General Medical Sciences Human Genetic Mutant Cell Repository [NIGMS/mapping

panel #2]. The construction of the mouse-human hybrid cell lines was described by
Dubois & Naylor (1992) (see Table 3.1). Amplification by PCR was performed with
50 ng of hybrid DNA and the TPM2 STS primers DS 869.6F and DS 866.8skR as in
2.2.2-4. The PCR and amplification conditions used, were those that had been optimised

in 2.2.2.

3.3 RESULTS AND DISCUSSION

Table 3. I shows the percentage of a particular chromosome(s) in each of the hybrid cell

lines as determined by both cytogenetic and Southern blot analyses. The panel of 24
hybrid cells is
con~ains

~.:m

the most part mono-chromosomal, except GM/NA07299 which

chromosomes 1 and X, and GM/NAI0478 which contains chromosomes 4 and

20 (Dubois & Naylor, 1992).

Initially it was difficult to obtain the 1.5 kb TPM2 STS, however a product was obtained
when the amplification conditions that had been optimised in 2.2.2, were used (see
Figure 3.1). The TPM2 STS gave an amplification product from only the control human
genomic DNA (a & o) and the somatic cell hybrid GM/NA10611 (n) (Dubois et al.,
1992). Only chromosome 9 was unique to this cell line (see Table 3.1) indicating that
TPM2 is on human chromosome 9.

pand y were

mouse and hamster genomic DNA

respectively, which showed that the primers were specific to human DNA from these
three species.
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TABLE 3.1

Cytogenetic Analysis of NIGMS Human/Rodent
Somatic Cell Mapping Panel 2

(After Dubois & Naylor, 1993)
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TABLE 3.1

Cytogenetic Analysis of NIGMS Human/Rodent Somatic Cell Mnppinc: Panel 2 (from Camden Literature)
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FIGURE 3.1
1.5 kb TPM2 STS vs NIGMS Human Rodent Somatic
Cell Hybrid Mapping Panel 2 by PCR
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CHAPTER 4
USING THE TPM2 STS IN FISH
4.1 INTRODUCTION

Fluorescent in situ hybridisation (FISH) mapping is where a fluorescently labelled probe
hybridises to human metaphase spreads, so its location can be detennined.

Cells are grown in culture and treated with colchicine to arrest cells at the metaphase stage
of mitosh:. Colchicine is believed to prevent the formation of spindle fibres (Biochemica,
1992). The chromosomes remain within the nuclear membrane and are fixed and spread
on to a microscope slide. (Davies & Read, 1992).

The probe is labelled by coupling biotin covalently to it. Although probes can be directly
conjugated with fluorescent molecules, the most widespread approach is to label the
probes with

report~r

molecules such as biotin or digoxigenin that, after hybridisation,

bind fluorescent affinity agents. The reporter molecules are labelled to the probe using
nick translation (Trask, 1991 ).

Nick translation was originally described by (Rigby, eta!., 1977). The process is where
free 3'-hydroxyl ends or 'nicks' are created within unlabelled double stranded DNA by
DNase I. DNA polymerase I then catalyses the addition of a nucleotide to the 3'-hydroxyl
terminus of the nick. At the same time, the 5' to 3' exonuclease activity of this enzyme
removes the nucleotide from the 5'-phosphoryl terminus of the nick. A new nucleotide
with a 3'-0H group is incorporated at the position where the original nucleotide was
excised and results in the movement of the nick (nick lranslation) along the DNA 5' to 3',
as new nucleotides labelled with biotin are incorporated (Promega, 1991; Sambrook, et

)]

a!., 1989). Usually biotinylatect nucleotides adenosine and cytosine triphosphates are
synthesised for incorporation (Biochemica, 1992). Incorporation can be up to 65%.

61

(Promega, 1991). Nick translation reduces the size of the probe after the reaction to 200500 bp fragments (Biochemica, 1992).

Chromosomes within the nuclpar membrane are then denatured by heat or by altering the
pH on the slide, without destroying the morphology of the chromosomes (Trask, 1991).
Simultaneously, the probe is also denatured by heat or altering the pH. The slide is then
incubated with the labelled single-stranded probe which hybridises to any matching
sequences in the denatured chromosomes. The accuracy of annealing depends on the
stringency of the hybridising conditions. High stringency hybridisation allows only exact
complementary stra'lds to rejoin (Davies & Read, 1992; Leversha, 1993). Any unbound
probe is then washed off the slide at increasing stringencies. Probe segments which bind
to chromosomal sequences with the greatest similarity (or homology) will withstand
more stringent washing than those which happen to bind to less closely matched
sequences (Leversha, 1993).

After washing, the slides are incubated in immunofluorescent reagents to produce a
fluorescent signal at the sites of biotin-labelled probe hybridisation (Trask, 1991). The
signal is developed using a streptavidin or avidin-carrying fluorescent reporter molecule
that binds to the biotin. One or more layers of antibodies may be included to amplify the
signal. The antibodies bind to the avidin 30d then allow more avidin-carrying fluorescent
molecules to bind to the antibody. With successive layers of antibody and avidin, the
signal is amplified (see Figure 4.1) (Davies & Read, 1992; Leversha, 1993). Avidin or
specific antibodies can also be linked to fluorochromes such as fluorescein isothiocyanate
(FITC) or Texas Red. The biotin labelled probe is detected with imrnunochcmicals linked
t0

different fluorochromes such as FITC-conjugated A vi din in Figure 4.1 (Leversha,

1993).
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FIGURE 4.1

Biotin-Avidin Detection Systems for Fluorescence In Situ Hybridisation (FISH)

63

, I

, I ,

'f,-

-,~
FITC-conjugated
(\-Avidin
Biotinylated
Anti-avidin Antibody ... 1 _ -Fluorescent Ends

J

-,~ ~_

Biotin
Probe

I-

---G

FITC-conjugated
Avidin

Chromosomal DNA
(After Leversha, 1993)

The chromosomes are then stained with propidium iodide (red), as a counterstain to
outline the chromosomes and 4', 6-diamidino-2-phenylimdole DAPI (blue), which gives
a pattern of dark and light G-bands (the same as Giemsa banding) for chromosomal
identification (Biochemica, 1992; Trask, 1991).

The FITC signal (494 nm maximum excitation yellow) can be detected by a range of
fluorescent microscopy equipment. One of the latest and most sensitive systems is digit ...l
imaging microscopy, where a cooled, charged coupled device (CCD) camera cov :Jt.>
emitted photons over a broad spectrum. The signal is computer enhanced to give a

(WO-

dimensional analysis (Biochernica, 1992).

On metaphase spreads, FISH resolution is 10-20 million bp, which is 0.3-0.6% of the
genome or 8-16% of an average chromosome lDavies & Read, 1992).

In interphase nuclei, fluorescent dots can be seen by FISH. These cannot reveal the
chromosomal location, but if sets of probes with different fluorescent labels are used,
their distance apart and their order can be established with a resolution as precise as 40 kb
(Davies & Read, 1992).

If the TPM2 STS probe is larger than l kb lhen it can be used for fluorescent in situ
hybridisation (FISH). FISH was carried out on a metaphase spread of normal human
male chromosomes. Male chromosomes are used because they have both the X and Y
chromosomes, so every chromosome is included. The STS will anneal to a chromosome
at a particular band where the gene will be localised. FISH was .:::arrieJ out at the Adelaide
Children's Hospital by Helen Eyre anrl Dr David Callen, as lhe techniques require
considerable expertise, beyond the scope of this project (Akkari, et al., 1994; Eyre, et a!.,
!993).
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4.2 MATERIALS AND METHODS

The TPM2 STS was larger than 1 kb (1.5 kb) so it was used for fluorescent in situ
hybridisation (FISH).

The probes were nick-translated with hiotin-14-dATP and each was hybridised in situ at a
final concentration of 20 ngllll to metaphases from two nonnal males. The fluorescence

in situ hybridisation (FISH) method was modified from that previously described
(Callen, eta!., 1990). Only two rounds of amplification with fluorescein-conjugated
avidin and biotinylated goat anti-avidin were required. The chromosomes were stained

before analysis with both propidiurn iodide (as counterstain) and (DAPI) (for
chromosome identification). Images of metaphase preparations were captured by a CCD
camera and computer enhanced (Callen, et al., 1992; Eyre, ct al., 1993).

4.3 RESULTS AND DISCUSSION

The 1.5 kb TPM2 STS yielded unspecific hybridisation results of this probe to the
metaphase spreads from two normal males. The probable cause was that the prcbe did
not have enough sequence, as usually a minimum of 1 kb is required for FISH (Akkari,
et a!., 1994) and the TPM2 probe was only slightly longer than the minimum required.

Two approaches could have been taken from here. The first would have been to try to
amplify a longer TPM2 STS for FISH, but a range of primers had already been tried
unsuccessfully. The maximum expected STS size with conventional PCR techniques is
around 4-6 kb (Gelehrter & Collins, 1990; Hayashi, 1994; Saiki, 1989) and there was no
guarantee another PCR STS would work for FISH. The second approach was to use the
STS as a labelled probe to isolate a larger genomic clone from a genomic library for usc
in FISH. In bacteriophage, genomic clones have human inserts of between 8-21 kb that
would have more DNA sequence to hybridise to the human metaphase spread and so give
a stronger labelled signal (Clontech, 1994)
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CHAPTER 5
ISOLATION OF A CLONE FROM A GENOMIC LIBRARY
5.1 INTRODUCTION

The radiolabelled 1.5 kb TPM2 STS was used as a probe to isolate a clone from a
genomic library. The clone would contain a larger portion of the TPM2 gene and perhaps

the flanking region for use in FISH. The genomic library was constructed in EMBL3
SP6ff7 (Clontcch). The DNA was partially digested with Sau3A I and the fragments
were separated on a sucrose gradient to produce a size range between 8 and 22 kb before
cloning into the BamH I site of EMBL3 SP6ff7. The average insert size was 15 kb. The

insert DNA could be excised with Xho I, Sac I, or Sfi I (see Figure 5.1) (Clontech,
1994). The human insert replaces the stuffer fragment or central portion of phage DNA.
The stuffer region is not essential for phage growth and reproduction.

The supplied host strain was Escherichia coli K802 (Clontech, 1994). Bacteriophage
adsorb to receptors in the outer membrane of£. coli that are encoded by the bacterial

lamB gene which are normally used to transport maltose into the cell. When culturing the
host strain on an agar medium, maltose must he included as it induces the synthesis of
these receptors, so the host strain can be infected by the bacteriophage. Adsorption of
bacteriophage to

maltos~

receptors is facilitated by magnesium ions and occurs within a

few minutes at room temperature and at 37°C. The bacteriophage DNA is inserted
through the cell membrane and undergoes lytic growth. The genome of bacteriophage is
double stranded linear DNA, approximately 45 kb long. After infection, the lifiear DNA
forms a closed circular molecule that serves as the template for transcription. During lytic
growth, the circular DNA is replicated many times and a large number of bacteriophage
gene products are synthesised.
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FIGURE 5.1

EMBL3, EMBLA & EMBL3 SP6m Vector Maps
(After Cion tech, 1994)
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Progeny phage particles are assembled and the cell eventually lyses, releasing hundreds
of new infectious viruses (Clarke & Carbon, 1976; Hayes, 1968; Primrose & Dimmock,
1980; Sambrook, et al., 1989). This process from infection to lysis takes approximately
15 min at 370C (Clontech, 1994).

The EMBL3 SP6ff7 vector is a virulent phage so it only undergoes the lytic cycle. The
phage are plated out by incubating a relatively small number of phage particles ( l-100
000) to a large number of concentrated bacteria (eg. 100xl06) so that it is likely each
bacterium is infected by only one phage. The mixture is poured over a nutrient agar plate
and incubated so the uninfected bacteria forms a confluent film over the plate. Each
infected bacterium, lyses after a short time releasing several hundred progeny phages
which then infect adjacent bacteria, which in turn are lysed. This process spreads loca!ly
through the bacterial population until the bacterial population reaches the stationary phase
where no more bacteria mulliply and bacterial metabolism declines. The result is a visible
circumscribed area of clearing in the bacterial growth, known as a plaque (Fraser, 1967;
Hayes, 1968; Primrose & Dimmock, 1980). This plaque is a clone containing only one
type of recombinant DNA or human insert. A probe specific to TPM2 was used to isolate
plaque(s) or done(s) that contained a part of the TPM2 gene so it could be amplified and
the DNA extracted for use in FISH.

Firstly, though, the 1.5 kb TPM2 STS primers were used on the EMBL3 library, to see

if that segment of the TPM2 gene was present in the library.

5.2 MATERIALS AND METHODS

5.2.1 Determining if the 1.5 kb TPM2 STS was in the Library

The 1.5 kb TPM2 STS primer.s that were developed in chapter 2, were used to determine
if that segment of the tropomyosin 2 gene was present in the library (ie. exons 6 - 8sk). A
PCR was set up as in chapter 2.2.2 using I
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~L

of the neat EMBL3 SP6ff7 library, as

tho target DNA, for primers DS 869.6F to DS 866.8skR. 50 ng of total genomic DNA

was also used as a positive control. The PCR for each different target DNA was repeated

three times to verify the experiment.

Assuming the EMBL3 SP6ff7 vector had an average human DNA insert of 15 kb and
that I ~L of the 'neat' library contains 5xto6 pfu/f.LL (Clontech, 1994) and the,re are

3xl09 bp in the human genome, then:

The No. of human genomes in l

No.

pfu/~L

~L

of the EMBL3 SP6ff7 library =

x A veragr. No. bp per human insert I No. bp in human genome

The No. of genomes in I f.LL of the EMBL3 SP6ff7 library

= 5x to6 pfu/uL x

15 000 bp

3xiQ9 bp

= 25 genomes
Using 1 ~L of the EMBL3 SP6ff7 library on average represents 25 genomes of human

DNA and should provide enough representative samples of the human genome to amplify
the 1.5 kb TPM2 STS, using the primers.

5.2.1.1 Protocol

Reartion Mixture

IX 20 uL

SX

Tth Buffer (5.2200)

5 f.LL

40~L

Primer mix (DS 869 + 866)

2~L

16~

0.1 f.LL

0.8 f.LL

HzO

12.9 uL

to3.2 uL

Total

2o.o uL

t6o.o uL

Tth (5.5

u/~L)

Lanes 1-3

3X EMBL3 SP6m bacteriophage

Lanes 4-6

3X Human genomic DNA (D90-224)

Lane7

!X Blank (HzO)

LaneS

A. Pst I Marker
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The 8X reaction mixture was added with the target DNA to make a 25 Jl.L reaction. So
20 ~L of the reaction mixture was added to 1 ~L EMBL3 SP6/T7 and 4 ~L HzO, and 20

J.1L of the reaction mixture was added to 5 J1L of the human genomic DNA and

blank.

Cycling conditions and agamse electrophoresis were the same as 2.2.2-4.

5.2.2 Aliquots of the Library

The vector and host stain were stored at -80°C. An aliquot of the EMBL3 SP6ff7 library
was made as a backup by aliquoting 200

~L

of the neat library using aseptic techniques

into a 0.6 rnL eppendorf tube and storing it in a different -&OOC freezer.

5.2.3 Bacterial Culture Plating and Propagating the Host Strain (K802)

Using aseptic techniques, 5 ~of the host strain K802 was streaked onto a MgS04- free
2X YT 1.5% bottom agar plate containing 0.2% maltm:e. This was incubated at 37oc
overnight. From the agar plate a single isolated colony was picked and propagated in 10
mL 2X YT liquid media and 10 mM MgS04 and 0.2% maltose in a 50 mL polypropylene
tube. The broth was incubated at 370C on a shaker at 200 rpm (B. Braun Model
Centornat H), well aerated overnight, for approximately 16 hours, or until the optical
density at 600 nm (OD6oo) reached 2.0, or until the stationary phase of the culture was
reached. 850 ~L of the broth culture was added to 150 ~L of glycerol to make a glycerol
stock. Two glycerol stocks were prepared and stored at -2QOC. Ali working samples
were taken from the glycerol stocks, while the original host strain was stored at -sooc
(Clontech, 1994).

5.2.4 Lil>rary Plating/Titering

15 em petri dishes were used to plate out the EMBL3 SP6/T7 library requiring
approximately 50 000 pfu. The library therefore needed to be diluted to yield 50 000 pfu
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per plate. Since I ~L of the library had between I-9xi06 pfu/~L then to dilute 1 ~L of
this library to produce 50 000 pfu per plate required:
l-9x 1Q6 pfu!LtL = ISO ~L of IX lambda dilution buffer (see Appendix 2)
50 000 pfu

If 1 ~L of the neat library contained 25 genomes worth of human DNA then I

~L

of the

(!/!SOX) dilution would have:

25/ISO = 0.14 of the human genome

Therefore, to plate out one genome's worth of human DNA requires:

1/0.14 = 7.2 or eight 15 em plates

The number of clones required (N) to screen to get a particular clone with a probability P.
N=

lnii-Pl
In (l-l/n)

where n =

genome size Cbpl
average size of insert (bp)

and P = 0.95, 0.99 etc
(Clarke & Carbon, I 976)

N=

In (! -0.95)
In (1-15 000/3x!09)

=

600 000 clones

If each 15 em petri dish has 50 000 pfu, then the number of plates required to plate out
the library to 95% certainty that at least one clone will contain part of the TPM2 gene is:

600 000/50 000 = 12 plates
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However, it was decided to plate out at least one genome's worth of the genomic library
(8 plates) at first, to see if the radiolabelled TPM2 STS would at least give a positive
signal to some clones.

Using 8 plates of 50 000 pfu/plate, then rearranging the formula, the probabiiity that at

least one plaque will contain part of the TPM2 gene is:

p

~

P~

P

~

1- 0 (N.In(I-Jin)

]-e(400000.In(I-15000/3>J09)

0.86 or 86%

I. Eight 15 em 2X YT 1.5% agar plates were poured having 10 mM MgS04 and 0.2%

maltose concentration. Using aseptic techniques, enough agar was poured to cover the
bottom of a 15 em diameter petri dish (-30 mL). When necessary, the top of the agar was
flamed to remove bubbles and then left to set for approximately 15 min.

2. A 10 mL 2X YT broth (+10 mM MgS04 and 0.2% maltose) was inoculated with the
host strain (K802) from the glycerol stock. It was incubated on a shaker (200 rpm) at
370C overnight.

3. To each of eight 50 mL polypropylene tubes was added 200 IlL of the overnight broth
inoculated with I

Ill of the diluted ( 1!180X) EMBL3 SP6/T7 library andre-incubated at

37oc for 20 min.

4. After 20 min 10 mL of melted (-500C) top 0.7% agarose (+10 mM MgS04 and 0.2%

maltose) was added to each of the eight tubes and mix,:d weli.
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5. The contents of each tube was poured on to the eight separate 2X YT 1.5% bottom
agar plates (+10 mM MgS04 and 0.2% maltose). The plates were quickly swirled to
allow even spreading of the agarose. Any bubbles were removed with a flame.

6. The plates were cooled to room temperature for 10 min to allow the inoculum to soak
into the agar.

7. The plates were inverted to prevent contamination and incubated at 37oc overnight or
until the plaques reached a diameter not exceeding 1.5 mrn, or were just beginning to
make contact with one another, near confluency (-8-16 hours). Confluent lysis was
deliberately avoided.

8. The plates were sealed in parafilrn and stored at 4oc.

(Clontech, 1994; Sambrook, et al., 1989).

5.2.5 Membrane Replicas of the Agar Plates

1. A 137 rnrn diameter nylon nucleic acid transfer membrane (Hybonct-N+, Arnersham)
was labelled with a ball point pen. Using sterile forceps, lhe membrane was placed onto
the 2X YT 0.7% top agarose. Trapping air bubbles was avoided. The membrane was
marked in 3 or 4 asymmetrical locations by stabbing through the membrane and into the
agar with an 18-gauge needle that was dipped into printer's black ink (see Figure 5.2).

2. After 2 min, the membrane was carefu!Iy peeled off. The filter was placed plaque side
up, onto a 15 x 15 ern Whatman 3MM chromatography paper soaked in NaOH
denaturing solution (see Appendix 2) for 2 min.

3. The membrane was then placed plaque side up on another 15 x 15 em Whatman 3MM
paper soaked in the Tris neutralising solution (see Appendix 2) for 2 min.
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FIGURE 5.2

Screening a Genomic Library
(After Deaven. 1994)
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4. The membrane was then placed between two Whatman 3MM papers to blot dry.

5. A second Hybond :r-r+ membrane (the duplicate lift) was placed onto the same plate
a.,d marked with ink in the same locations. The membrane was peeled off after 2 min and
denatured and neutralised on the same Whatman 3MM papers as described in Steps 2-4.

6. The same procedure was used for lifting tile other plates, except the membranes were
denatured and neutralised on freshly soaked Whatman 3MM papers.

7. The membranes were left to dry, at room temperature, overnight in a dark place,
stacked between Whatman 3M papers.
(Ciontech, 1994; Sambrook, et al., 1989)

5.2.6 Hybridisation of the Membrane Replicas using the Radiolabeiied
1.5 kb TPM2 STS

I. The membranes were placed in a round plastic container with prehybridisation solution

and incubated at 420C for at least four hours shaking (Stuart Scientific Hybridisation
Oven/Shaker) (as in section 2.2.9.4).

l mL of prehybridisation solution was added per

membrane.

2. The randon•ly primed 1.5 kb TPM2 STS (sections 2.2.9.2 • 2.2.9.6) was denatured
by heating to 950C and snap chilled on ice. 50 J!L of the probe was then added to the
prehybridised membranes and incubated at 42°C for between 16-20 hrs.

3. The membranes were removed and washed at increasing stringency until the cpm were
between 10-20 cpm (section 2.2.9.7).

4. The membranes were blot-dried on Whatman 3M paper and wrapped in Glad Wrap.
The duplicate membranes were paired and placed with tape to a large piece of Whatman
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3MM paper as backing paper, that was cut to fit the size of the autcradiograph cassette,
so the membranes would not move. The Whatman paper was marked in three
asyliunetrical places with a fluorescent

dy~.

The membranes were placed in a cassette for

autoradiography. Autoradiography was perfonned with Dupont Croncx 4 X~ray film and
Quanta III autoradiography i.ttensifying screens, at -80°C for an empirically determined
time, usually overnight.

5. After developing, the film wa!' aligned with the membranes to make sure they did not
move. The film was then aligned with the agar plates to select a positivt.> plaque that was
present on the film frorn the two duplicate lifts. A single

isol..:.t~d

in cases where the plaques were becoming confluent, an

ag~r

plaque was picked, but

plug was removed with

several plaques (only for the initial screening).

6. A plaque was picked by cutting off the ,.;nd of a disposable pipette tip on a 200 )lL
pipette. The tip was pushed througi . the 0.7% agarose top and bottom agar where a
positive plaque wa<; selc ... ~;::d and the agar plug was removed by the suction of the pipette.
The agar plug was placed into a sterile 1.5 mL eppendorf with 200 f!L of I X lambda
dilution buffer, so the phage eluted into solution. The agar plugs were storeJ at 4oc.

7. Using the eluted phage from each selected positive plaque, the phage were replated
(called secondary replating) and titered to obtain 200-1000 plaques on a 15 em petri dish.
This was achieved by using I, 10, and I 00 f!L of the eluted phage from the agar plug in
200 )lL of the overnight broth, to obtain the optimum titre on a plate.

8. The optimum titered plates were lifted using the nylon membranes (called secondary
lifts) and rescreened using the radiolabelled 1.5 kb TPM2 STS (called secondary rescreening). The procedure was repeated until I 00% of the plaques showed up as
positive. This would require rescreening lhree or four times for each different primary
plaque clone that was selected from the initial screening.
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9. For each clone a well isolated positive plaque was S(

_

_c:d for plate stock. This was to

grow the clone on many plates to confluency, so the DNA could eventually be extracted
and purified for use in FISH.
(Clontech, 1994; Sambrook, et al., 1989)

5.2. 7 PCR assay of DNA from Clone Eluates to Confirm Clones Contain
Part of the TPM2 Gene.

Isolated clones of the final screening were picked. Primers DS 869 (exon 6F) and DS
866 (exon 8sk.R) were used with the final picked clones to determine if the human
inserts contained that part of the TPM2 gene. A 25 !JL PCR was set up as in 5.2.1.1 and
2.2.2-4 with 5 IlL of the clones eluates used as the template DNA. 5 IlL of human
genomic DNA was used as a positive control and a blank was run as a negative control.
If the 1.5 kb TPM2 STS showed up as a band from the eluates, it meant the clones

contained that part of the TPM2 gene (exons 6-Ssk) and that they could be plated out in
mass, to isolate the DNA from phage lysates.

5.2.8 Isolation of DNA from Phage Lysates

5.2.8.1 Preparation of bacterial host (K802) cells

0.5!!L of the glycerol stock of K802 was incubated in 10 mL of 2X YT broth, 10 mM
MgS04 and 0.2% maltose. This was left shaking (200 rpm), at 37"C overnight.

5.2.8.2 High-titre phage stock preparation

The ratio of phage to bacterial host, determines the success of the phage DNA
preparation. This must be determined empirically. A yield of 20-40 !lg of phage DNA
could be expected from 100 mL of phage lysate (Clontech, 1994).
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!. A selected clone, was titered using the eluted phage from the agar plug (I, 10 and 100

I!L).

2. 10 mL of IX lambda dilution buffer and a few drops of chloroform were added to the
plates that had a tit~e of higher than I 00 pfu. These plates were left shaking overnight at
4°C to elute the phage. The chloroform lyses the bacterial cell walls so the phage were
more easily eluted.

3. The eluted phage from the plates was pooled and poured into a 50 mL Oakridge tube.

4. 2 mL of chloroform was added to the lysate and vortexed for 2 min to lyse the host
strain.

5. The lysate was centrifuged for 10 min at 7000 rpm in a Sorvall (Model RC2-B)
centrifuge with a SS-34 rotor (maximum radius 4.25 inches). The supernatant was
collected and re-titered out on a plate, and the volume required for confluent lysis was
noted.

6. Steps 1-5 were repeated for each clone.

(Ciontech, 1994; Sambrook, et al., 1989)

5.2.8.3 Plate lysate preparation

For the preparation of large quantities of phage DNA there were two methods available.
The liquid lysate method is more convenient than the plate lysate method, however phage

generally grow better in plate lysates, so this method was chosen (Ciontech, 1994).

1. For each selectr.d clone, ten 15 em petri dishes were plated out to confluent lysis,
based on the titre of the high-titre stock of each clone. These plates were incubated

overnight at 37oc.
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2. !0 mL of IX lambda dilution buffer was added to the ten plates and was left shaking
at 40C overnight.

3. The IX lambda dilution buffer was pooled from the ten plates (-100 mL). This is the
plate lysate.
(Clontech, 1994; Sambrook, eta!., !989)

5.2.8,4 Lysate processing

I. The lysate was placed into 50 mL Oakridge tubes and centrifuged at 8500 rpm on a
Sorvall for 10 min at 40C to pellet debris. A 10 mL aliquot of this lysate was kept as a
very high titre stock.

2. The supernatant was decanted and pooled and DNase was added to 0.2 J.Lg/mL and

RNase to 5 !lglmL and left at room temperature for 15 min. This was to degrade the
DNA and RNA from the host strain. The DNA of the EMBL3 SP6/T7 vector and insert

was protected from the DNase by the phage's protein coat.

3. The lysate was separated again into Oakridge tubes and chloroform was added to a
final concentration of 5% and vortexed for 30 sec. This was to lyse any cells that were
not previously lysed.

4. The lysate was then centrifuged at 8500 rpm for 10 min at 4DC, to extract the organic
components eg. lipid bilayer of cell membranes into the chJorofonn layer.

5. The aqueous supernatant was pooled and
-added solid NaCI to I M (eg. 100 mL/1000 mL x 58.44g = 5.84 g) and
-added polyethylene glycol (PEG) to 10% (eg. 10 gin 100 mL)

-The NaCI and PEG were dissolved and left on ice for at least one hour.
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6. This was then centrifuged in Oakridge tubes at 8500 rpm for 15 min •t dOC. The

supernatant was discarded. PEG and NaCl causes the phage to precipitate and form a
whitish pellet on the bottom of the OakP.dge tube. As much PEG solution was removed

as possible, as it can inhibit restriction enzyme digests.

7. 2 mL of IX lambda dilution buffer was added to each Oakridge tube, to dissolve
phage pellet.

8. The phage was pooled into Oaklidge tubes ( -4 mL each) and CsCl was added to 0.5
glm (ie. 2.0 g per Oakridge tube).

9. A CsCl step gradient was carefully layered in Beckman polyallomer centrifuge tubes

(14 mm diameter x 89 mm). 2 mL of each CsCI concentration was added for the
gradients (see Figure 5.3 & Table 5.1).

TABLE 5.1
CAESIUM CHLORIDE CONCENTRATION STEP GRADIENT
Reference Index

Density (p)

CsCl (g)

!XLDB (mLl

3

1.45

30.0

42.25

1.3768

2

!.50

33.5

41.0

1.3815

I

1.70

47.5

37.5

1.3990

(n)

Solutions 1 to 3 were consecutively added, very carefully, to the Beckman tube, using a
5 mL pipette, so the gradient interfaces were well
was added last.
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define~.

The phage in 0.5 g/mL CsCl

FIGURE 5.3

Caesium Chloride Step Gradients to Purify Bacteriophage A.

The Bacteriophage). forms a visible band at the 1.45 g/mL and 1.50 g/mL

interface.
(After Sambrook et at., 1989)
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Before centrifugation

After centrifugation
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10. The opposite centrifuge capsules were weighed and balanced to a hundredth of a
gram of each other and then centrifuged at 22 000 rpm, for 2 hrs, at 40C, on a Beckman
Model LS-M Ultracentrifuge.

II. The phage should have formed a visible band at the 1.45 g/mL and 1.50 g/mL

interface. However, all debris between the 0.5 g/mL and 1.50 g/mL interface and the
pellet on the bottom of the centrifuge tube was also collected and placed into different 1.5
mL eppendorf tubes. The different samples were collected using a 1 mL pipette with a

new tip for each sample collected in the different gradients.
(ANRI, 1994; Clontech, 1994; Sambrook, eta!., 1989)

5.2.8.5 DNA extraction

I. The collected volume from the !.45 g/mL and 1.50 g/mL interface was pooled and 2X
the volume of IX lambda dilution buffer was added to dilute the CsCI.

2. The measured volume was made to:
20mMEDTA
0.5% SDS
-_i

50 ~tg/mL Proteinase K
5~tg/mL

RNase

This was incubated at 65DC for 15 min. The purpose was to digest any protein
and RNA present.

3. Phenol/chlorofonn extraction. Equilibrated phenol:chlorofonn (I: 1) was added to the

same volume of phage DNA in an Oakridge tube and mixed together thoroughly for

5 min. This was then centrifuged at 15 000 rpm for 20 min on the Sm-vall centrifuge. The
chloroform denatures proteins and separates the protein into the organic phase and the
nucleic acids into the aqueous phase (Sambrook, et al., 1989).
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4. The supernatant was removed and Step 3 was repeated using the same volume of
chloroform:isoamyl alcohol (24:1). The mixture was shaken thoroughly for 5 min and
then centrifuged at 15 000 rpm for 20 min and the supernatant withdrawn. The isomnyl
'
alcohol reduces foaming during extraction, caused by the SDS, to give a more defined
interface (Sambrook, et al., 1989).

5. To the supernatant was added 2X volume of propan-2-ol. This was mixed thoroughly
and centrifuged at 15 000 rpm for 10 min.

7. The DNA precipitated

a~,

a whitish smear on the bottom of the Oakridge tube. The

supernatant was decanted and the DNA pellet was washed with 70% ethanol to remove
added salts.

8. The DNA was resuspended in 1 mL of TE buffer.

9. The DNA concentration was measured on a spectrophotometer and the A260/280 ratio
should be between 1.8-2.0. The DNA was also run on a 0.8% agarose gel with a

Hind III marker and should form a sharp band with some contaminating RNA.
(ANRI, 1994; C1ontech, 1994; Sambrook, et al., 1989).

10. The DNA was purified by adding RNase to 5 [!g/mL and using the WizardTM DNA
Clean-up System (Promega). The protocol was identical to the Wizard™ PCR Preps
Purification System (Promega) in 2.2.6.2.

5.2.9 Restriction Digests of Clones to Determine if they are Different

The insert DNA can be excised with Xho I, Sac I, or Sfi I as can be seen from Figure
5.1. Other restriction enzymes were also tried including BamH I, EcoR I and Hind Ill
and different combinations of two enzymes, were also used. The purpose of the
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restriction digests was to determine if the human inserts from the isolated clones were
identical or different. The protocols used for the restriction digests were:

IX 20

~L

Template (phage DNA)

empirically

!OX Buffer appropriate to

2~L

Reaction

restriction enzyme (Prornega)

Acetylated BSA (I mg/mL)

2~

Spermidine (0.1 M)

0.4

Enzyme (Promega-usually 12 u/~L)

I~

H20 to

~L

20~

All digests were at 37°C for one hour. Digests were terminated by heating to 95oc for

5 min.

5.2.10 Hybridising Radiolabelled Clones DNA to Genomic Blots

Approximately I

~g

of purified DNA from clones 2 and 4 were labelled by random

primer labelling and hybridised to genomic blots as in 2.2.9. Clone 2 was hybridised to
total human genolT'.ic DNA that had been cut with EcoR I. Clone 4 was hybridised to two
blots on the same membrane of total human genomic DNA. One had been cut with
BamH I and the other with Pvu II.
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5.2.11 Using Primers as Radiolabelled Probes on Membrane Lifts of the
Colony Plaques to Determine if the Clones had the Same Part of the
TPM2 Gene

5.2.11.1 Purpose for end-labelled primers experiment on clones

Primers DS 869.6F and 866.8skR were end~labelled radioactively and used as probes on
the duplicate secondary membrane lifts of the four clones. This was to determine if the
clones contained both exons 6 and 8sk, or if the c!ones were cut somewhere in between

these exons. One primer was used as a probe on one of the secondary membrane
duplicate lifts of the four clones. The other primer was used on the second lift. If one
primer hybridised to the clone membranes at the previous positive plaque positions and
the other primer didn't on the second lift, then it would confinn that the human insert was
cut somewhere between the two primers in exon 6 and 8sk. If the two primers hybridised
to the same plaque positions on both of the clones secondary membrane lifts, then it
would confirm that the human inserts contained both exons 6 and 8sk.

5.2.11.2 Stripping membranes and prehybridisation using oligonucleotide
hybridisation solution

The secondary membrane duplicate lifts (ie. IA+B, 2A+B. 3A+B, 4A+B) were stripped
of the previous hybridisation using the protocol in 2.:2.9.8. The membranes were
separated IA-4A to hybridise with primer DS 866 (exon 8sk) and 1B-4B to hybridise
with primer DS 869 (exon 6). The membranes were prehybridised in two separate plastic
tubs using oligonucleotide prehybridisation solution.

Oligonucleotide prehybridisation solution is made up as for normal prehybridisation
solution as in 2.2.9.5, except water is replaced for fonnamide. Formamide assists double
stranded DNA to remain denatured or single stranded, which is not required with
primers, as they are already single stranded.
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10 rnUmembrane or 40 mL of the oligonucleotide prehybridisation solution was added to
each tub with the four membranes and incubated at 420C, shaking in a hybridisation
oven for 1 hour.

5.2.11.3 Kinase 5' end labelling of oligonucleotides

This procedure is usefui for radioactive 5' end labelling of oligonucleotides (Promega,
1991). The kinase reaction requires that the 5' end has been previously
dephosphorylated, and the primers are already synthesised with the 5' end
dephosphorylated. Bacteriophage T4 polynucleotide kinase catalyses the transfer of the
radiolabelled y-phosphate of (y-32P)ATP (see Figure 5.4) to a 5' terminus of
dephosphorylated DNA (Sambrook, eta!., 1989).

Reaction:
bacteriophage T4
polynucleotide kinase
(y-32P)ATP
dithiothreitol
Mg2+

Reaction:
20 y,L Reaction

Final Concentration

HzO

4~L

Primers DS 866 or 869 (10 ng/~L)

6~L

3 ng/~L

lOX TM buffer (fris-MgCiz)

2~

50 mM Tris-HCI

(500 mM Tris-HCI, 100 mM MgCiz)

lOmMMgCiz

DDT (50 mM dithiothreito!)

5mM

(y.32P)ATP (10 ~Ci/~L)

2.5 ~Ci/~L

T4 PNK (3u/~)

0.15

ui~L

Total
The reaction was incubated at 37°C for 30 min.
The reaction was stopped by heating to 940C for 5 min, to denature the T4 enzyme.
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The 5'-cnd radiolabellod primer DS 866 (exon 8sk) was added to the prehybridisation
solution and membranes IA-4A. The 5'-end radiolabelled primer DS 869 (exon 6)was

added to membranes 1B-4B. The two hybridisations were left shaking overnight, at
420C. The membranes were washed at increasing stringencies as in 2.2.9.7, until the
activities were between 10-20 cpm. The membranes were autoradiographed with Dupont

Cronex 4 X-ray film with Quanta III autoradiography intensifying screens at

-sooc

overnight, or until images were readable.

5.2.12 PCR Assay of DNA fl'om Clones to Confirm that they Contained
Part of the TPM2 Gene.

Primers DS 869 (exon 6) and DS 866 (exon 8sk) were used with the purified DNA from

clones 2 and 4 to determine if the human inserts contained that part of the TPM2 gene. A
PCR was set up with the following conditions:

For a 25 f!L Reaction:-

7X Reaction
Mixture (f!L)

5X 2200 Buffer

5.0 f!L

35

Tth DNA polymerase (Biotech) (0.5 units/mL)

1.0 f!L

7

Primer mix DS 866 + 869 (20 ng/f!L)

2.0 f!L

14

H20 to 20 f!L

12.0 f!L

112

TOTAL

20.0 f!L

(5X Tth buffer, 10 mM MgCI2, I mM dNTP's)

Paraffin 1 drop OYerlay
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FIGURE 5.4

(y-' . , ATP Showing they Phosphate Position
(After Wilton, 1993)
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Target DNA
2X clone 2 DNA diluted IIIOOX (- IO ng/~L)
2Xclone4DNA"

"

"

I ~and4!JLofH20
I ~Land 4 !JL ofH20

"

IX Human Genomic DNA as positive control (I 0 ng/~L) 5

~L

5 ~L

IX Blank (H20)

20 ~of the reaction mixture was added to the target DNA.

PCR Cyclin& Conditions: 2 Step on Automatic Thermal Cycler

time
temp 94°C 5 min 30 sec (denaturing)

ssoc
# cycles

6 min (annealing and extension)

xi

4oc

x35

indefinitely

5.2.13 Sequencing the Clones and PCR Assays to Confirm they were
Specific to TPM2

Purified DNA from clones 2 and 4 was sequenced directly to confirm that they contained

part of the TPM2 gene. Because the human insert is only a portion of the phage DNA
more template DNA is required for sequencin!;. ABI protocols suggest using l J.tg of
phage DNA when sequencing (Appiied-Biosystems, I993). The protocols were the same
as 2.2.8.

The 1.5 kb TPM2 STS assay (using clones 2 and 4 DNA as the template from 5.2.12)

was also sequenced to confirm the clone's inserts were specific to TPM2. 200-300 ng of
TPM2 STS was used as the template for the sequencing as in 2.2.8.
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5.3 RESULTS AND DISCUSSION

5.3.1 Determining if the 1.5 kb TPM2 STS was in the Genomic Library

The 1.5 kb TPM2 STS primers were used on the EMBL3 SP6ff7 library to determine if
there was a clone that contained that part of the TPM2 gene (exon 6-Ssk). In Figure 5.5,
lanes l-3 show the STS product from the EMBL3 SP6!f7 genomic library. Lanes 4-6
show the STS using total human genomic DNA as a positive control. Therefore, there
were clone(s) present in the genomic library that contained exon 6-8sk of the gene and
the library could be used to isolate clones containing that part of the TPM2 gene for use

in FISH.

The DNA from the A. phage was able to be tarE,··eted by the primers, because the initial
heating period of 5 min denatured the phage's protein coat.

5.3.2 Primary and Secondary Screening of the Plaque l>•embrane Lifts

The initial titering of the eight plates to represent one genomes worth of DNA produced
an average of 50 000 pfu/plate, as was calculated. The plates were near confluent and
were ideal for the first screening of the duplicate membrane lifts. The labelling efficiency
of the 1.5 kb TPM2 STS was approximately 50%, as estimated by the PEl strip after the
random priming reaction.

Out of the eight plates that were membrane lifted, there were four duplicate plaques that
were positive on the autorads (See Figure 5.6). The agar plugs contained several plaque
colonies and not just the one that was positive, because the titre was so high and the
plaques were so close to each other. These four plaque colonies were picked as agar
plugs and replated for a secondary screening (see Figure 5.7 ).
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FIGURE 5.5

1.5 l<b TPM2 STS (Exons 6-Ssk) PCR Assay of the Genomic
Library.

Lanes 1-3

is the STS Present in the Genomic Library.

Lanes 4-6

is the STS from Human Genomic DNA.

Lane?

Blank

LaneS

A. Pst I Marker

2% Agarose Gel, IOOV for 45 min
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1--4
~

EMBL3 Hwnan ;
SP6{f7 Genomic~

~

I

1.5 kb TPM2 STS •
(exons 6-8sk)

II

I

....

~
~

FIGURE 5.6

Primary Screening Of Duplicate Membrane Plaque Lifts With
Radiolabelled 1.5 kb TPM2 STS (Exons 6-Ssk).
Those Plaques that showed up in Duplicate were
Considered Positive for Containing that Part of TPM2.

The Arrows Identify the Clones th<· t were picked for a
Secondary Screening.

Developed -80°C, for 16 hours with 1 intensifying screen.
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DUPLICATE MEMBRANE LIFTS

CLONE I

CLONE 2

CLONE 3

CLONE 4

FIGURE 5.7

Secondary Screening of Duplicate Membrane Plaque Lifts.
Those Plaques that showed up in Duplicate were
Considered Positive for Containing that Part of TPM2.
The Labelled Arrows Represent the Clones that were picked
for Tertiary Screening.
Developed ~80°C, for 18 hours with I intensifying screen.
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FIGURE 5.8

5' End Labelling of Primers DS 869.6F & DS 866.8skR on the Secondary
Membrane Lifts. Compare the Plaque Positions with Figure 5.7.

Developed -800C, for 24 hours with 1 intensifying screen.
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SECONDARY MEMBRANE LIFTS PROBED WITH TPM2 PRIMERS
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CLONE 4

PRIMER DS 866 EXON 8sk

PRIMER DS 869 EXON 6

5.3.3 Primers Polynucleotide Kinase 5' End-Labelled as Probes on the
Secondary Plaque Lifts to Determine if the Clones Contain both Exons 6
and 8sk

It was noted two of the (clones 2 & 4) had stronger positive signals on the autorads than
the other two clones ( 1 & 3). When the secondary screening was done this pattern was
repeated, clones 2 and 4 gave much stronger positive signals than clones 1 and 3 on the
autorad (Figures 5.6 & 5.7).

It was suspected only part of the radiolabelled 1.5 kb TPM2 STS was hybridising to
clones I and 3 giving the weak signal, while all of the radiolabelled STS was hybridising

to clones 2 and 4 giving stronger signals. The radio labelled 1.5 kb STS contained exons
6 to exon 8sk. It was therefore hypothesised that clones 1 and 3 only contained part of
this STS. The primers DS 869 (exon 6) and DS 866 (exon 8sk), were polynucleotide

kinase (PNK) 5' end labelled and one probe each was hybridised on one of the duplicate
secondary membrane lifts. If one primer hybridised to clones 1 and 3 membranes at the
previous positive plaque positions and the other primer didn't on the second lift, then it
would confirm that the human insert was cut somewhere between the two primers in
exon 6 and 8sk. If the two primers hybridised to the same plaque positions on clones 2
and 4 secondary membrane lifts, then it would confirm that the human inserts contained
both exons 6 and 8sk.

In Figure 5.8, for clones 2 and 4, the positive plaque positions were identical on the
duplicate autorads and both primers hybridised to the same plaques as the original
secondary screening (compare Figures 5.8 and 5.7). Therefore, clones 2 and 4 both
contained exon 6 and 8sk in the human insert.

However, for clones 1 and 3 the duplicate positive plaques were not identical and only
the labelled primer DS 869.6F (exon 6) hybridised to the same plaques as the original
secondary screening. The other primer DS 866.8skR (exon 8sk) for clones I and 3
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hybridised to non-matching plaques from the original secondary screening (compare
Figures 5.7 and 5.8). This meant that the human insert for clones 1 and 3 did not contain
exon 8 and that the insert was cut somewhere between the 1.5 kb between exons 6 and

8sk.

5.3.4 PCR Assay on Clones 1-4 Eluates

To confirm that clones l and 3 inserts were cut between exons 6-8sk in TPM2, a PCR
assay using primers DS 869.6F and 866.8skR was performed on eluates from plaque
colonies that had been selected. This was compared with the PCR assay of clones 2 and
4 eluates, which from the PNK experiment showed that these clonr,s contained exons 6-

Ssk. 5

~of

eluted phage from the clone eluates was used as template DNA for the

primers.

From Figure 5.9, it can be seen that the primers did not amplify the 1.5 kb TPM2 STS
from clone I (lanes 1-4) and clone 3 (lanes 7-11) insert DNA, but the STS was amplified
on clone 2 (lanes 5 & 6) and clone 4 (lanes 12-13) eluates. This confirmed the PNK
experiment that clones I and 3 insert DNA was cut somewhere between exons 6-Ssk in
the TPM2 gene and clones 2 and 4 contained these exons.

Therefore, from the positive results, clones 2 and 4 were chosen for isolation of DNA
using the plate lysate method as in 5.2.8. This was after the clones 2 and 4 were
rescreened five times so that almost 100% of the plaques showed up as positive.
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FIGURE 5.9

PCR Assay of Clone Eluates

Lanes 1-4

Clone 1 different chosen plaque eluates.

Lanes 5-6

Clone 2

"

"

"

"

Lanes 7-11

Clone 3

"

"

"

"

Lanes 12-13 Clone 4

"

"

"

"

Lane 14

Human Genomic DNA (Positive Control)

Lane 15

'/.. Pst I Marker

2% Agarose Gel, lOOV for 30 min

FIGURE 5.10

C!anes 2 & 4 DNA on a 0.8% Agarose Gel

Lane I

Clone 2 Lambda DNA and Human Insert (Before Purification)

Lane2

Clone 2

"

"

"

"

"

(After Purification)

Lane3

Clone 4

"

"

"

"

"

(Before Purification)

Lane4

Clone 4

"

"

"

"

"

(After Purification)

0.8% Agarose Gel, IOOV for I hr
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Clone 2 Unpurified
Clone 2 Purified
Clone 4 Unpurified
Clone 4 Purified
A. Pst I

J

Clone 1

J Clone 2

J

Clone 3

J

Clone 4
Genomic DNA

A. Pst I

5.3.5 Lysate Processing

The phage lysate from clones 2 and 4 were processed as in 5.2.8.4. The DNA from the
caesium chloride gradient did not form a distinct band at the 1.45 g/mL and 1.50 g/ml
interface. There was a debris band in the 1.45 g/mL gradient and a faint band below this

but the gradient interfaces were difficult to see after centrifuging. A pellet also fanned on
the bottom of the centrifuge tube. This made it difficult to collect the DNA, but the faint
band and the pellet at the bottom were collected and placed into different eppendorf tubes.

In future, a better technique would be to add to the phage 0.5 mg/mL of CsCl2 in IX
lambda dilution buffer, with 0.5 Jlg/mL ethidium bromide. After centrifuging the tube
could be placed over a transilluminator and the DNA extracted where it fluoresces in the
tube.

5.3.6 DNA Extraction

The extracted phage DNA in 5.2.8.5 from clones 2 and 4 was electrophoresed on a 0.8%
agarose gel at IOOV for one hour (see Figure 5.10). To the phage DNA was added
RNase (5

~g/mL)

and proteinase K (50

~g/mL)

and incubated at 650C for 15 min, to

digest any RNA and protein present. The DNA was run on a low melting point agarose
and excised and purified using the Wizard DNA Cleanup System (Promega). It can be
seen the phage DNA before purification was contaminated with RNA by the white smear
at the bottom of lanes 1 & 3, which was not present after purification (lanes 2 & 4).
Because RNA has a similar absorbance at 260 nm (RNA 1A=40 ng/~L) to DNA (DNA
1A=50 ng/p,L), accounts for the very high nucleic acid concentration of the unpurified
DNA as seen in Table 5.1. The recovery efficiency of DNA after purification from the gel
was quite low, using the Wizard DNA Clean-up System (Promega) as can be seen in
Figure 5.10 from the intensity of the bands before and after purification.
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Table 5.2
EMBL3 Clone's DNA Concentrations on Spectrophotometer

Mean

Mean

A zoo

Azso

Clone 2 (Unpurified) 0. 73

0.39

1.88

200X

7 300

Clone 2 (Purified)

0.039

0.019

2.1

25X

50

Clone 4 (Unpurified) 0.312

0.169

1.84

700X

10 000

Clone 4 (Purified)

0.007

1.6

25X

15

0.012

A26otA2so

Dilution Concentration
(ng/JlL)

Approximately 1 mL of clones 2 and 4 were obtained from the DNA

extrac~ion

in

5.2.8.4-5. From the spectrophotometer readings, 50 fig (50 ng/fiL = 50 fig/mL) of
clone's 2 DNA and 15 fig of clone's 4 DNA was isolated. This compared well the
ex pee ted recovery of 20 - 40 fig of phage DNA, from the approximate I 00 mL volume of
lysate (Clontech, 1994).

5.3. 7 Restriction Digests of Clones 2 and 4 DNA to Determine if they
were the same Clones

The restriction enzymes used on clones 2 and 4 DNA were BamH I, EcoR I and

Hind Ill. Each clone's DNA was cut with the different enzymes and all the combinations
using two enzymes per digest. This was to determine if the clones were identical, or if

the human inserts were different. Figure 5.11 shows the different combinations of
restriction digests on clones 2 and 4, mn on a l% agarose gel, at SOY for 4 hours. It can

be seen clearly that the two clones are different each having different human inserts. For
example, in lanes 3 and 4 (clones 2 and 4 cut with BamH I) there are three distinct bands
in lane 4, clone 4, that are not present in lane 3, clone 2.
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FIGURE 5.11

Restriction Digest of Clones 2 and 4 DNA
Lane 1
Lane2
Lane3
Lane4
LaneS
Lane6
Lane?
LaneS
Lane9
Lane 10
Lane 11
Lane 12
Lane 13
Lane 14
Lane 15
Lane 16
Lane 17
Lane 18
Lane 19
Lane20

:1. Hind III Marker
:1. Pst I Marker
Clone 2 cut with BamH I
Clone 4 " "
"
Clone 2 cut with EcoR I
Clone4 " "
"
Clone 2 cut with Hind III
Clone4 " "
"
:1. Hind lU Marker
:1. Pst I Marker
Clone 2 cut with
I
., BamH I and EcoR
"
Clone 4 "
"
"
Clone 2 cut with BamH I and Hind III
"
Clone4 " "
"
"
Clone 2 cut with EcoR I and Hind lii
"
Clone4 " "
"
"
:1. Hind lii Marker
:1. Pst I Marker
Clone 2 Uncut
Clone 4 Uncut

The products of the digests were run on a 1% agarose gel, at SOV for 4 hours.

FIGURE 5.12

1.5 kb TPM2 STS of Clones 2 And 4 Purified DNA.
2% Agarose Gel, lOOV for45 min

100

A Hindill

A. Pst I
~ ] BamHI

A Pst I
Clone 2
Clone 4

t-)
~

]

EcoR I

t-)

]

Hindill

~

A. Hindill
A. Pst I
~ ] BamHI& EcoRI
~ ] BamHI&Hindill
t-)

]

EcoR I & Hind ill

~

A. Hindill
A. Pst I
t-)
~

]

Uncut

From Figure 5.1 showing the restriction map of EMBL3 SP6ff7, and Figure 2.12

showing the restriction map of the 1.5 kb TPM2 STS, it can be seen none of the

restriction enzymes cut either the vector arms or the exon sequence of the TPM2 STS.

Therefore any lanes that showed more than two bands was due to the restriction enzymes
cutting the insert DNA, other than the exon sequence (exons 6-Ssk) of the STS.

This meant two different clones that contained part of the TPM2 gene had been isolated

and could be used in F1SH to

veri~r

each others localised position.

The size of clones 2 and 4 inserts cannot be determined precisely from Figure 5.10, but
can be estimated from the restriction digests in Figure 5.11. It was assumed all the lower
bands, were the insert DNA, because none of the enzymes used cut the vector EMBL3
SP6!f7 arms, as can be seen in Figure 5.1. Therefore, the lower molecular weight bands
must have been insert DNA that was cut. Using the A. Hind III and A. Pst I markers, the
band sizes can be added to give an approximate insert size.

For clone 4 in lane 12, three lower bands can be seen (1.5, 2 and 3.5 kb) that add up to

7 kb and if the band abov<>: these is 8 kb, then this gives an approximate insert size of 15
kb.

For clone 2 on another digest (data not shown) the insert was slightly larger than clone 4
and was estimated to be approximately 16-18 kb.

5.3.8 PCR Assay of Clones DNA Using the 1.5 kb TPM2 STS

Primers DS 869 (exon 6) and DS 866 (exon 8sk) were used on the purified clones 2 and
4 DNA to determine if the human inserts contained the 1.5 kb TPM2 STS. Figure 5.12

shows the STS from clones 2 and 4 in lanes 2 and 3 respectively with the 'J.. Pst I marker
in lane 1. Human genomic DNA was used as a positive control in lane 4, but it did not
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amplify. This showed that the purified DNA from clones 2 and 4 contained the 1.5 kb
TPM2 STS from exons 6 to 8sk.

5.3.9 Sequencing Clones 2 and 4 DNA and the 1.5 kb TPM2 STS

The most direct way of continuing that clones 2 and 4 contained part of the TPM2 gene
was to sequence the insert DNA using primers DS 869.6F (exon 6 forward) and DS
866.8R (exon 8sk reverse). 1 p,g of each clone was used to allow ensure sufficient
template. However, no useable sequence was obtained after using this method a few

times.

The next most direct method, was to sequence the 1.5 kb TPM2 STS using the two
clones as template DNA. Figure 5.13 shows the sequence of the TPM2 STS from clone

4 which has been summarised into Table 5.2. The sequence extended for approximately
450 bases from primer DS 869 in exon 6, to intron 6, exon 7 and into intron 7. When
the sequencing results were compared with that of Widada et al. (1988) TPM2 sequence,
out of 70 bases in exon 7 only one base was different and two bases could not be read
(ie. N). The one base that was different in exon 7 was a thymine from Widada's
sequence was substituted for an adenine. The thymine is conserved in all the TPM's. The
base mismatch is not likely to be real because the adenine was next to a 'N' in the
sequence, so it was not sequencing well at that point. The sequence variations were likely
to be due to the template preparation, the sequencing reaction or the sequencer tracking,
reading and analysing the fluorescent end labelled products. The sequencing from the
reverse primer (DS 866.8skR) in exon 8sk was not useable.
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FIGURE 5.13

Sequence ofTPM2 STS using Clone 4 as Template DNA from
Primer DS 869.6F in Ex on 6.
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Table 5.3
Sequence of Clone 4 compared to TPM2 and other TPM's

EXON 6

TPMl

t.Q.Qtttccga ga,sgctgaag gag

TPM3

ttcttactga .ta.Mct.Qaag gag

TPM4

ttctgtctga .Qa.Mctgaaa gag

TPM2

tgttggagga gaagctgaag gag

Clone 4

tgt.Qggagga

ga~gttgang

gag

EXON 7

TPMl

gctgagac.t,c gggctgagtt tgcggagagg tcggtaac.!;.a

TPM3

gcggagaccc g_tgctgagtt tgc.tgagagg tcggtggc.Qa

TPM4

gctgagaccc g,tgctgaatt tgcagagagg gcggt.tgcaa

TPM2

gctgagaccc gagcagagtt tgccgagagg tctgtggcaa

Clone 4

gctgagaccc nagcagagtt tgccgagagg tctgtggcaa

TPMl

agt tggag·aa aagcat.tgat gac.ttagaag

TPM3

ag.Qtgga,gaa g:ac2_at.tgat gacctggaag

TPM4

a£!.Qtggas_aa gacg_at.tgat gacctggaag

TPM2

agttggagaa aaccatcgat gacctagaag

Clone4

agttggagaa aaccaangat gacctagaag

From the TPM2 STS sequence of exon 7, it mRtched Widada et al. published sequence
by 96%. The underlined bases frw TPMs l, 3 and 4 and clone 4 are those bases that

differ to the TPM2 sequence. The 'me balded bases in clone 4 are those bases that are
only unique to TPM2. Therefore, it can be confident that clone 4 was specific to TPM2.
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Anthony Akkari at ANRI, also sequenced the STS product from primer DS 869.6F and
out of 35 readable bases in exon 6 only one base could not be read (ie. N) and all 70
bases in exon 7 matched Widada et al. sequence and also confirmed that clone 4 was
specific to TPM2.

Clone 2's sequencing results were not useable, but from the 1.5 kb TPM2 STS that was
amplified from the clone's DNA as template, it can be confident that the clone 2 was also
specific to TPM2.

Anthony Akkari also sequenced clone 2 from tt.o reverse primer DS 866.8skR. Out of 54
readable bases in exon 8sk, only three bases could not be read (ie. N) and matched
Widada et al.'s sequence by 94% and therefore confirmed that clone 2 was specific to

TPM2.

5.3.10 Hybridising Clones DNA to Genomic Blot

IIJg of clone 4 DNA was radiolabelled and hybridised to a human genomic blot that had
been cut with BamH I and Pvu I!. In Figure 5.14, the human DNA in lanes 1-6 and 8
and had been cut with BamH I. Lane 7 was a'}., Hind III marker and lanes 9-16 were
human DNA that had been cut with Pvu II. There were no discrete consistent bands
across either digest, except in lane 7 where the EMBL3 SP6ff7 arms, hybridised with

the A. phage DNA that had been cut with Hind lii. The probe hybridised unspecifically to
the digested human DNA as there were only smears in the lanes. It was hoped that the
probe would hybridise at distinct bands, indicating that the probe insert would hybridise

well with genomic DNA, especially when used for FISH.

Clone 2's hybridisation to human DNA that had been digested with EcoR I was also
unsuccessful as not enough template DNA was labelled (data not shown).
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The experiment was not repeated as the use of the labelled clones on genomic blots was
not essential to the project. It only gives an indication of the hybridising ability of the
clones to genomic DNA and time spent optimising the conditions was not a priority. The
clones may stiH hybridise successfully in FISH.
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FIGURE 5.14

Radiolabelled Clone 4 DNA Hybridised to a Genomic Blot
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CHAPTER 6
USE OF GENOMIC CLONES FOR FISH
6.1 INTRODUCTION

Approximately 10 J.lg of clones 2 and 4 DNA was sent to the Department of Cytogenetics
and Molecular Genetics, at Adelaide Children's Hospital, for use in FISH.

6.2 MATERIALS AND METHODS

The same methods were used as in 4.2.

6.3 RESULTS AND DISCUSSION

Clones 2 and 4 were used for FISH to metaphase spreads from three nonnal males.
Twenty-five metaphases from the first nonnal male were examined for fluorescent signal
with clone 2. Eighteen of these metaphases showed signal on one or both chromatids of
chromosome 9 in the region 9p13-p21; 95% of this signal was at 9pl3.1 (see Figure
6.1 ). There was a total of 11 non-specific background dots observed in these 25
metaphases. A similar result was obtained from hybridisation of this probe to 15
metaphases from the second nonnal male and from hybridisation using the probe of clone
4 to 20 metaphases from the 3rd normal male (data not shown) (Hunt, et al., 1995).

The 1.5 kb TPM2 STS that was used as a probe for FISH, didn't work, yet the genomic
clones 2 and 4 were both successful in FISH. All probes were reduced to 200-500 bp
fragments by the nick translation, and so were likely to be equally specific as probes for
the TPM2 gene. It was likely the greater amount of labelled DNA in the genomic clones

(-15-18 kb) was able to hybridise to the metaphase chromosomes and give a stronger
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signal, than the 1.5 kb TPM2 STS. This probably explains why the genomic clones
worked in FISH and the 1.5 kb TPM2 STS was unsuccessful.

The localisation to 9pl3.1 confinned and refined the somatic cell hybrid panel localisation
to chromosome 9.

'\'.
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FIGURE 6.1

Metaphase showing FISH with the probe TPM2.2.

(a) Normal male chromosomes stained with propidium iodide.
Hybridisation sites on chromosome 9 are indicated by arrows.

(b) The same metaphase as (a) stained with DAPI for chromosome
identification.
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TPM2 FISH TO 9p13.1

CHAPTER 7
IDENTIFICATION OF A POLYMORPHISM IN THE TPM2
GENE
7.1 INTRODUCTION

The majority of human DNA is not involved in coding sequences and is therefore not
subject to tight selection. If the sequence is compared in a noncoding autosomal region
from 10 individuals, then a nucleotide will be found approximately every 200 bp at which
there is a sequence vari::ttion (Gelehrter & Collins, 1990). These variations are usually
due to simple base changes and are called DNA polymorphisms (Gelehrter & Collins,

1990). A DNA polymorphism is, then, is a region of variable sequence between different
individuals.

A method to find polymorphisms involves testing approximately 10 people. If one allele
is polymorphic then the frequency of alleles having the polymorphism is approximately
5%, as 10 people each have two alleles. A polymorphism with a frequency less than this
would not be generally useful as a marker in the genome, as very few families would be
informative in demonstrating Mendelian segregation. If a polymorphism is identified,
then its frequency can be refined by screening 50- 100 individuals (Cichon, et al., 1994;
Rnlfs, et al., 1994; Shen, et al., 1994).

A technique to identify sequence variation is the single stranded conformation
polymorphisms (SSCP). SSCP is where a PCR amplified segment of the gene ( 100-350
bases) is denatured into single strands and snap chilled so the fragments collapse in the
most stable single stranded tertiary form. The PCR incorporates a radioactive nucleotide
such as (a.-P32) dCTP. The strands are separated OP.. a nondenaturing polyacrylamide gel
under constant voltage so the polymorphisms keep their tertiary forms. Any fractionated
bands that are different for different individuals indicate a polymorphism. These can be
Ill

I
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cut out, reamplified by PCR and sequenced to determine the different nucleotide sequence
between individuals. If the polymorphism is inherited in a Mendelian fashion, then the

polymorphism can be used for linkage studies and entered on the CEPH map (Hayashi,
1991; Wilton, 1993).

CEPH is the French Centre d'Etude du Polymorphisme Humain or the world database

centre for mapping human polymorphisms (Dausset, et al., 1990). CEPH makes
available DNA samples from a panel of reference families for the determination of

genotypes for various DNA polymorphisms, which may be used for the construction of a
genetic linkage map of the human genome. CEPH provides access to DNA from a
common set of families for researchers investigating this area. Forty families were
selected in 1984, based on large sibship size, with multigenerations to demonstrate
Mendelian segregation of discovered polymorphisms. Families were chosen for their
large sibship size and not for inherited diseases. The DNA of each individual was isolated
from cultured lymphoblastoid cell lines (LCL). Researching collaborators investigate the
genotypes with their probes, to test for segregation of these markers in the panel of
families. This then contributes to the linkage analysis database and the map construGtion

(Dausset, et al., 1990).

7.1.1 Polyacrylamide Gel Electrophoresis for Running SSCPs

Polyacrylamide gel electrophoresis is used to separate different DNA fragments.
Acrylamide is an organic monomer with the following structure:

H

H

CH2=CH-C-NH2
II

II

II

0

0

0

N,N'-methylenebisacrylamide

acrylamide

(Sambrook, et al., 1989)
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Acrylamide polymerises into long chains in the presence of free radicals, which are
usually supplied by ammonium persulfate (NH4)2SzOs and is stabilised by TEMED
{N,N,N',N'-Tetramethylethylene diamine). Cross-linking of the chains is performed by
N,N'-methylenebisacrylamide in the reaction. The porosity of the gel is determined by
the length of the chains and the degree of cross-linking (Sambrook, et al., 1989).

The length of the chains is determined by the concentration of the acrylamide (between
3.5% and 20% ). The greater the concentration is, the less porous and greater resolving
power of the gel to separate molecules of DNA (Sarnbrook, et al., 1989).

The acrylamide to bisacrylamide ratio also detennines the amount of cross-linking and
resolving power of the gel. For example an acrylamide to bisacrylamide ratio of 29:1 is
where I molecule of cross-linker is included for every 29 monomers of acrylantide. The
less the ratio is, or the more bisacrylamide, the greater the resolving power of the gel is,
as it has more cross-linking and so the gel is less porous (Sambrook, et al., 1989).

.,'

The resolving power of acrylamide gels is such that they can separate molecules of DNA
that differ in length by as little as 0.2% or for example, 1 bp in 500 bp (Sambrook, et al.,
1989).

7.2 MATERIALS AND METHODS

7.2.1 Amplifying Exons lsk to 2sk in clones DNA

TPM2 primers DS 84G (exon lsk forward) and DS 841 (exon 2sk reverse) were used on
clones 2 and 4 DNA in a PCR reaction to see if the clones contained exons lsk-

2si.~

of

the TPM2 gene which may be used to identify a polymorphism. The reaction was set up
as follows:
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Reaction Mixture

JX 20 UL

7X

Tth Buffer (S.z200J

Sfl,L

35 IlL

Primers 840 + 841 ( 10 ng/j.lL of each primer)

2fl,L

14 IlL

Tth (5 ..5 ufj.lL)

0.1

HzO

12.2 uL

90.3 ML

Total

20.0 uL

140.0 ML

IlL

0.7 IlL

Lanes I +2

2X genomic clone 2 (10 ng/f!L)

I j.lL + 4 fl,L HzO

Lanes 3+4

2X genomic clone 4 (15 ng/f!L)

I fl,L + 4 J.!L HzO

Lanes 6+7

2X total human genomic DNA (10 ng/fl,L)

5 IlL

Lane 8

IX blank (HzO)

5 IlL

The 7X reaction mixture was added with the target DNA to make a 25 J..LL reaction. So
20 j.lL of the reaction mixture was added to lj.lL of clones 2 and 4's DNA and ·1j.lL of
HzO. 20 IlL of the reactiorl mixture was also added to 5 J.!L of the human genomic DNA

and blank. Cycling and agarose electrophoresis conditions were the same as 2.2.2-4.

7.2.2 Amplifying Exon Ssk to 3' Untranslated Region of TPM2

TPM2 primers DS 870 (exon 8sk forward) and DS 867 (3'UTR reverse) were used on

clones 2 and 4 DNA in a PCR reaction to see if the clones contained the 3'UTR of the
TPM2 gene. Human genomic DNA was also used as a positive control. The experiment
was set up as in 7.'2.1, except the different primers were used.

7.2.3 TPM2 Exon Ssk - 3'UTR SSCP in 10 Unrelated Individuals

Primers DS 870 (8sk.F) and DS 867 (3'UTR.R) were used on 10 unrelated individuals

to attempt to discover a polymorphism that would have an allele frequency greater than
5%. The PCR conditions used were:
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For a 10

~tL

Reaction:-

Target DNA (50 ng)

5.0

~tL

5X )50 Buffer

2.0

~tL

Tth DNA polymerase (5.5 units/~tL)

0.1

IlL

Primer mix (870 + 867) (20 ng/j.tL)

1.0 j.tL

(a-P32) dCTP (10 j.tCurie/j.tL) (Bresatec)

0.1 j.tL

HzO

1.8

(10 ng/~tL)

(5X Tth buffer, 5 mM MgClz, 250 j.tM dNTP's)

TOTAL

10.0 j.tL

lOX unrelated individuals DNA (10 ngi!!L)

PCR

Cyclin~

~L

5.0 j.tL

Conditions: 3 Step on Automatic Cycler

time
temp 94°C

4.5 min

30 sec (denaturing)

62°C

1 min (annealing)

72°C

I min (extension)

# cycles
4°C

xl

x30

indefinitely

7.2.4 Pouring an Acrylamide Gel

1. The glass plates were thoroughly cleaned with hot water, Pyroneg detergent and a

cloth.

2. The plates were rinsed by spraying 100% ethanol and they were left standing upright
to dry.
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3. The front plate was silicor,ised under a fumehood by mixing 0.5 mL of dimethyl-

dichlorosilane with 5 mL of chloroform and wiping over the gel surface side of the plate
with Kimwipes (lint-free tissue paper). Tl1~.s was so the gel would lift freely off the front
plate and stay to the back plate. The back plate was lightly siliconised by wiping the
moist Kimwipes over the gel surface side of the back plate. This was to ensure that the

acrylamide gel poured easily and evenly between the plates.

4. The plates were assembled with the spacers and the bottom and sides of the plates
were taped to prevent the gel leaking. Bulldog clamps were placed down the sides of the

plates (see Figure 7.1). A plastic weclgo was used to slightly separate the plates.

5. 70 rnL of 12% or 6% non-denaturing acrylamide gel (39:1 acrylamide to
bisacrylamide) (see Appendix 2) was de-gassed in a 100 rrJ.... beaker for 20 min, to
remove the dissolved air. Otherwise fine bubbles come out of solution when the gel is
poured, over the surface of the plates.

6. 100 IlL of TEMED and I 00 IlL of 25% ammonium persulphate (APS) were added to

the accylamide and quickly mixed.

7. The plates were raised about 30° and immediately the gel mix was drawn up into a
50 mL syringe and carefully squirted between the glass plates next to the plastic wedge.
If the plates were clean, the gel should move up the plates as a uniform front with no air
bubbles. When the gel mix reached a few em from the top of the plates, the plates were
placed horizontal and the wedge was removed and the rest of the gap was filled by the

gel.

9. Any bubbles fmmed were removed by a thin plastic hook (Promega).
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FIGURE 7.1

Acrylamide Gel Electrophoresis

(Sambrook et al., 1989; ANRI, 1994)
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10. A 0.35 mm thick well fanner was placed in the top of the plates 3/4 of the way in and
clamped with buiidog clamps. Gel was poured around the well fanner occasionally to
prevent the acrylamide from drying out and shrinking back into the plates.

11. The gel was allowed to set for at least one hour. Usually the gel polymerised within
the first 5-10 min. To store the gel, damp paper towels were placed over the well former
and the top of the plates was wrapped in glad wrap to prevent the gel drying out. The gel
could be stored for several days at 4oc.
(ANRI, 1994; Sambrook, eta!., !989)

7.2.5 Running the Gel

l. The Hoefer Pokerface II electrophoresis equipment was used, which consisted of a
lower buffer tank, an upper buffer chamber and heat distributing back plate, two plastic
side clamps and electrodes.

The power pack used was the Biorad 3000Xi, which is capable of supplying constant
voltage up to !500V.

2. The clamps, paper and any glad wrap were removed.

3. The backing plate was fastened to the back glass plate with the side clamps.

4. The lower buffer chamber was filled with about 500 mL of IX TBE, or until the
buffer was a few em above the glass plates when the gel assembly stood in the lower
buffer chamber. The upper buffer chamber was filled with lX TBE, until it was a couple
of em above the top of the front glass plate.

5. The well fermer was removed and a sharks tooth well comb was inserted until the
teeth just entered the gel surface.
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6. After the PCR reaction (7.2.3), formamide loading buffer (FLB) was added to each
tube in a ratio of 1:1 (ie. 10 !!L). The PCR reaction and FLB were heated to 95oc for 5
min to denature the DNA. The samples were then snap chilled on ice to form single

stranded confonnation fragments in the most stable tertiary form. 1 JlL of each sample

was loaded in each lane.

7. The electrodes were attached and the samples were run into the gel by focusing at
1250V for 1 min.

8. The samples were then run at 400V, for 16-20 hrs, at room temperature, overnight.
400V was used so the gel did not overheat and denature the single stranded

confonnation.
(ANRI, 1994)

7.2.6 Fixing and Drying the Gel

1. The electrodes and gel assembly were removed and the top and bottom buffer
chambers were emptied down the radioactive flushing sink.

2. The gel assembly was disassembled by removing the side clamps and the backing
plates.

3. The glass plates were laid down horizontaily over the flushing sink and the plates
separated using a metal spatula. The front glass plate was removed.

4. Strips of tissue paper were placed around the edge of the horizontal gel and fixative
(10% acetic acid and 10% methanol, see Appendix 2) was poured over the entire gel. The
tissue paper acted to drain away the fixative.
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5. The fixative was successively poured over the gel for about 10 min so the entire gel
was well covered and washed (about 500 mL in total). The tissues were removed after 10
min and the fixative was allowed to drain away. The fixative ensured the DNA would
remain in the gel when vacuum blotting and stop it diffusing in the gel.

6. The gel was monitored using a geiger counter for the area of high activity and the
unneeded gel (lanes not used) was cut away using a scalpel and lifted using Whatman
3MMpaper.

7. A piece of Whatman 3MM paper was cut slightly larger than the remaining gel and laid
over the gel, avoid trapping air bubbles. The paper was pressed down gently on the gel
and lifted smoothly from one end. The gel should stick to the paper and come away flat.

8. The gel was covered with glad wrap and cut to the size of the paper. One comer was

cut to orientate the gel.

9. The gel lift was laid on a piece of 3MM in the gel drier and covered with the silicon
rubber seal. The vacuum was turned to full and the gel dried for one hour at 80°C.

10. Autoradiography was performed as usual with Dupont Cronex 4 X-ray film with
Quanta III autoradiography intensifying screens at -80°C, for an empirically detennined
time.

(ANRI, 1994)

7.2.7 TPM2 Ssk - 3'UTR SSCP on DNA from 97 Unrelated Individuals

Primers DS 870 and 867 were used on 97 unrelated individuals to detennine the allele
frequency of the polymorphism, using the methods described in 7.2.2-6. The samples
were run on a 6% non-denaturing acrylamide gel.
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7.2.8 TPM2 Ssk • J'UTR SSCP on DNA from 9 Families to Determine if

Polymorphb.m Segregates in a Mendelian Fashion

For those of the 97 individuals that had the rare allele, families were selected, based on
multigenerations to see if the polymorphism segregated in a Mendelian fashion. Nine
families were selected and primers DS 870 and 867 were then used on these families as
in 7.2.2-6.

7.2.9 Sequencing of the TPM2 Polymorphism from Exon 8sk.F-3'UTR.R
from Band Stabbing an Acrylamide Gel.

The -250 bp TPM2 STS (8sk-3'UTR) samples that were homozygous for the rare allele
were run together side by side on a 6% non-denaturing acrylamide gel, and the samples
for the conunon allele were run side by side, to compare all the alleles to see if there were
more than two alleles. The gel was exposed wet, so it wasn't vacuum dried. The lifted
gel was labelled with fluorescent ink and the at1torad was then matched back with the gel.
A flame heated iron needle was then pushed through the autorad and into the gel to mark
where rare and common alieles for several individual samples were. For each individual
sample, the four corners of the lane where the allele was present was stabbed. The bands
of 7 heterozygous individuals for the rare allele were cut out with a scalpel and placed
into separate 1.5 mL eppendorf tubes with 0.5 rnL of TE buffer. The gel bands for four
individuals, that were homozygous for the common allele, were cut out.

The gel with the cut out bands was then re-exposed to confirm that the bands were cut
out exactly where the rare and common alleles were.

Using the DNA eluted from the bands as template, a 50 J..LL PCR was set up using
primers DS 870 (ex on 8sk.F) and DS 867 (ex on 3'UTR.R) as in 2.2.6. I, except 5X
2100 (10 mM MgCl2, 500 11M dNTP's) buffer was used. Three individuals for the rare
allele and one individual for the common allele were amplified. 5 IlL of the eluted
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template was used with 20 ~of the reaction mixture. The cycling conditions were: 94oc

for 5 min, 30 cycles of 94°C for 30 sec and 60°C for 6 min. 3 J.LL of each product was
run on a 2% agarose gel, at IOOV, for I hr, with 3 J.LL of J..Pst I marker. The DNA from
each sample was then run on a low melting point agarose gel and purified using
WizardTM PCR Preps Purification System, as in 2.2.6.1-2. The DNA concentration was
then measured on the spectrophotometer.

50 ng each of the four samples were then used in the sequencing reaction as in 2.2.8.
Sequencing was from primer DS 870 (exon Ssk-forward) and from primer DS 867
(3'UTR-reverse) for each sample.

7.2.10 Sequencing Homozygous Individuals for the TPM2 (Ssk.F·
3'UTR.R) common and rare allele

After screening the 97 individuals and 9 families, two individuals were discovered to be
homozygous for the rare allele. The DNA from these two individuals were amplified
using primers DS 870 and 867 and the polymorphism sequenced as in 7 .2.8. The
sequence was compared by sequencing two homozygous individuals for the common

allele.

7.2.11 Restriction Digest of -250 bp TPM2 STS (8sk-3'UTR)

After finding a restriction site for the suspected polymorphism base change, a restriction
digest was set up using Bgl I. A PCR was performed using primers DS 870.F (exon

8sk) and DS R67.R (3'UTR) on total human genomic DNA from a heterozygous allelic
individual, a homozygous common allele individual and a homozygous rare allele
individuaL The subjects were chosen by looking at the SSCP gels. The conditions of the

PCR were:

122

.-

For a 25 LLL

__ ,.,

"'"·'-

-··--

.:

..._.

--·--~-_.,_,, __

Reaction:~

Reaction Mixture

Final Cone.

Target Genomic DNA (50 ng)

5.0~L

2ngi~

5X JIOO Buffer (buffer, nucleotides and MgC12)

5.0~L

I mM,IOO~

(5X Tth buffer, 5 mM MgCh, 500

~M

dNTP's)
~L

Tth DNA polymerase (Biotech) (5.5 units/mL)

0.1

Primer mix ( 10 ngi~L of each primer)

2.0~L

H20to25~

.!2.2..)!!.

TOTAL

25.0 ILL

0.22
0.8

u/~L

ng/~L

Target DNA
IX hetero7.ygous allelic individual

( 10 ng/~L)

5 ~L

IX homozygous common allelic individual

"

"

IX homozygous rure allelic individual

"

"

PCR Cycling Conditions: 2 Step on Automatic Thermal Cycler

time
temp 94°C 5 min 30 sec (denaturing)
60°C

# cycles
4oc

6 min (annealing and extension)

xl

x30
indefinitely

The STS product from the PCR was run on a 2% agarose gel at IOOV, for l hour as in
2.2.3-4.

The STS products from the three different individuals were digested using the restriction
enzyme Bgl I, as in 5.2.9, and run on a 3% agarose gel at IOOV for 1 hr and 20 min.
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The gel was stained with ethidium bromide (0.5 Jlg/mL) for I 0 min and observed on the
UV transilluminator as in 2.2.4. pGern marker was used to detennine fragment sizes.

7.3 RESULTS AND DISCUSSION

7.3.1 Amplifying Exons lsk to 2sk in clonal DNA

TPM2 primers DS 840 (exon lsk forward) and DS 841 (exon 2sk reverse) were used on
clones 2 and 4 DNA in a PCR reaction to see if the clones contained exons lsk ~ 2sk of

the TPM2 gene, which may be used for an SSCP. Clones 2 and 4, had DNA that was
specific to TPM2 and so was used as target DNA. The clones were used, as the primers
did not amplify a product when total human genomic DNA was used and by having more

specific template would increase the probability of the PCR working. There are about
200 bp between the primers using Clayton et al.'s (1988) structure of TPM3, in Figure
1.3, 100 bp in the muscle specific exons and 100 bp in the intron. An approximate 200
bp fragment was expected from TPM2, but there were no discernible bands from the
amplification when run on a 2% agarose gel (no data shown). This meant that clones 2
and 4 most likely did not contain exons 1sk and 2sk.

The average insert of the TPM2 clones was 15-18 kb, which were already shown to
contain exons 6- 8sk, in Figure 5.9. Since the TPM3 gene is approximately 42 kb long,
or 28 kb from exon lsk-8sk and assuming it has a similar structure to TPM2, then it was
expected that these clones would most likely not contain these exons (lsk- 2sk) because
of the limitations on the amount of DNA that can be cloned in the EMBL3 SP6!f7 vector
(Sambrook, et al., 1989). But it was still worth attempting to confinn this hypothesis.

7.3.2 Amplifying Exon 8sk to 3'UTR of TPM2

TPM2 primers DS a?O (exon 8sk forward) and DS 867 (3'UTR reverse) were used on
clones 2 and 4 DNA in a PCR reaction to see if the clones contained the 3'UTR of the
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TPM2 gene. Human genomic DNA was also used as a positive controL In Figure 7.2,
using the APst I markP-r, it can be seen an approximate 250 bp product was amplified in
clone 2 (lanes 1&2), clone 4 (lanes 3&4) and in human genomic DNA (lanes 5&6).
There are 259 bases from and including primer 870 (in exon 8sk) to primer 867 (in
3'UTR) using the published sequence of (Widada, eta!., 1988). Therefore, there is no 4
kb intron VIII, before exon !Xsk, which is in the 3'UTR as Clayton et a!., (1988)
suggests in TPM3, for the skeletal muscle isoform (see Figure 1.3). This would make
the TPM2 gene at least 4 kb less than the 42 kb TPM3, so the TPM2 gene would be
approximately 38 kb.

One can be confident that the amplified -250 bp TPM2 STS (8sk-3'UTR) was not a
pseudogene, because it was amplified from the two clones and because primer DS 870
was in a muscle specific exon (2.1.2.2). These clones contained a fragment of the TPM2
gene in the insert, as had already been shown by sequencing and both were localised and
the 1-1 ';11ers could only anneal to the target DNA present. The STS was repeated from the
human g~~lf\r:l\·,· • !NA, as a positive control, so it can be confident the STS was unique to
TPM2.

7.3.3 TPM2 Exon Ssk - 3'UTlt SSCP in 10 Unrelated Individuals

Primers DS 870 (8sk.F) and DS 867 (3'UTR.R) were used on 10 unrelated individuals
to attempt to discover a polymorphism that would have an allele frequency greater than
5%. In Figure 7.3, it can be seen in lanes 1 and 3, there was a SSCP. These individuals
were heterozygous for that allele. The other individuals were all homozygous. The
products were run on a 12% non-denaturing acrylamide gel at 400V for 24 hour." The
gel was exposed for 8 hrs at -sooc with an intensifying screen.

Lane~

11 .9.nd 1£ were a

positive control. The image is not clear, but the PCR and electrophoresis conditions were
optimised later.
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FIGURE 7.2

-250 bp TPM2 STS (Exons Ssk- 3'UTR) from Clones 2, 4 & Human Genomic

DNA
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-500bp TPM2 STS . . .
(exons 8sk-3'UTR)

..

FIGURE 7.3
SSCP of DNA from 10 Unrelated Individuals from the -250 bp
TPM2 STS (exon Ssk · 3'UTR)

12% SSCP Gel, Run at 400V for 24 hrs at Room TeiT'perature.
Developed After 8 hrs, at -80°C, I Quanta III Intensifying Screen.

Annealing Temperature 55°C
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7.3.4 TPM2 8sk - 3'UTR SSCP in 97 Unrelated Individuals

Primers DS 870 and 867 were used on 97 unrelated individuals to determine the allele
frequency of the polymorphism. Out of the 97 individuals, 16 individuals were
heterozygous with both alleles and one individual (sample 85) was homozygous for the

rare allele (Figure 7.4 shows samples 61-103). Therefore, the allele frequency was 0.09
for the rare allele, 0.91 for the common allele and the heterozygosity was 0.16. Note, the
SSCP running conditions were improved as a 6% non-denaturing acrylamide gel was
used to separate the alleles more and an annealing temperature of 620C, instead of ssoc
was used, which increased the annealing specificity of the primers.

7.3.5 TPM2 8sk - 3'UTR SSCP on DNA from 9 Families to Determine if
Polymorphism Segregates in a Mendelian Fashion

The SSCP was then run in nine families from the 17 individuals out of the 97 that had the
allele. The nine families were selected predominantly to demonstrate the segregation of
aiieles in a Mendelian fashion, so as many generation~ as could possibly be included in
the family was the main criterion, as well as large sibship size.

The segregation of the rare and common alleles was demonstrated in a Mendelian fashion
in all nine families except one. The segregation data will be shown for just two of these
families.

From Figure 7.5 showing the SSCP gel and family 1's pedigree, it can be seen that the
rare allele does not segregate in a Mendelian fashion. The granddaughter and grandson
(samples 5 & 6 respectively) are heterozygous for the alleles yet neither of their parents
(samples 3 & 4) are heterozygous, but are both homozygous for the common al1ele.
Likewise, the mothers grandparents (samples 1 & 2) are both homozygous for the
common allele. It was later demonstrated by microsatellite linkage analysis at Royal Perth
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FIGURE 7.4

SSCP Frequency • Unrelated Individuals 61 • 103.

6% SSCP Gel Run at 400V, for 16.5 hrs at Room Temperature.
Developed after 4 hrs, at -80°C with 1 Quanta III Intensifying Screen.
Annealing Temperature 62°C.
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FIGURE 7.5

Segregation of Polymorphic Alleles in Family 1.

6% SSCP Gel Run at 400V for 18.5 hrs at Room Temperature.

Developed after 3 hrs, at -80°C with one Quanta III Intensifying Screen.
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Segregation of Polymorphic Alleles in Family 2

6% SSCP Gel Run at 400V for 17.5 hrs at Room Temperature,
Developed after 1.5 hrs, at -sooc, with one Quanta III Intensifying Screen.
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Hospital, that there was a sample mix~up in the supplied DNA and that the father (sample
3) was really the son (sample 6), which then shows the rare allele segregating in the
family. This was quite a useful error to discover, as any other research trying to
demonstrate Mendelian segregation in this family, would also not have been able to do
so. It also demonstrates the polymorphism is real and segregates in families as it was able
to detect a sample mix-up, when blood samples were taken. Therefore, Family 1 was
very useful for demonstrating the segregation of the TPM2 polymorphic alleles.

Family 2 (Figure 7.6) was interesting, because two heterozygous parents for the TPM2
Ssk- 3'UTR allele (samples 1 & 2) produced a daughter that was heterozygous (sample
3) and a son who was homozygous for the rare allele (sample 4). The homozygous allele
can be seen quite clearly in Figure 7.6, sample 4 for Family 2.

It can therefore, be stated confidently that the TPM2 8sk-3'UTR allelic polymorphism
segregates in a Mendelian fashion.

The PCR and electrophoresis conditions were optimised for the SSCP and the conditions
listed in 7.2.3 were discovered to be optimal, when run on a 6% non-denaturing
acrylamide gel, at 400V, for 20 hours. Note, the annealing temperature 62°C was quite
high compared to nmmal PCR anne-aling temperatures.

7.3.6 Sequencing of the TPM2 Polymorphism from Exon Ssk -3'UTR
from Band Stabbing an Acrylamide Gel.

An SSCP gel of the first 55 unrelated individuals was run on a 6% no1J.-denaturing
acrylamide gel at 300V for 19 hours (see Figure 7.7). The PCR conditions were the same
as 7.2.3. Samples I, 3, 22, 26, 33,41, 45, and 51 were heterozygous for the allele and
were run together, to see clearly if there were only two different alleles. There were only
two alleles present and the rare alleles for these heterozygous individuals were cut out
using the band stabbing technique dei>cribed in 7 .2.9. The sample eluates were PCR
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FIGURE 7.7

Band Stab Gel of Rare Allele from Heterozygous Individuals and
Common Allele from Homozygous Individuals.

6% SSCP Gel run at 300V, for 19 hrs at Room Temperature.
Developed after 29 hrs, at Room Temperature with No Intensifying Screens.
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FIGURE 7.8

Band Stab Gel Re-exposed to Confirm Exact Alleles were Stabbed.

Developed after 2 days at Room Temperature with No Intensifying Screens.
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TABLE 7.1

Sequence of TPM2 SSCP from Gel Band Stabs
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SEQUENCE

clive2
'-

22/12/94

- --

OF

TABLE 7.1
TPM2 SSCP

-

Band Stab Ind3 870F \R
870F )A A

2. Band Stab 41
3. Band Stab 51
4. Fa'llily 2 {4)

5.

l:t~mll::!l

2!!1}

'-

Band stab 48
7. Frunily 1 (3)
8. Family 1 (3)

870F )R L
870F )E L

arn:a 1

E

867R 1M
9. TPM2(Widada et a1,) )M
0

N

1. Band Stab rnd3 870F )R
2. Band stab 41
870F )A A
3. Band Stab 51
4. I~amily 2 ( 4)

870F )R L

~.

IJ!i:ZB l

:EI.!JIIilY ::1 !11

6. Band Stab 48
7. Family 1(3)
8. Family 1(3)

TTAAAATCTA

870F }C L
870F }0 E

870F }E L
E

870F }C L
870F }0 E
867R )M

9. TPM2 {Widada et al.)

)M

210

110

Bad Sequen

TTAAAATCTA
AATCT

BAND

STABS

3f

•p

sp

NNNNCTC ATTNCGAGNC A'fGGCCATTA GCGAGGAACT
NNTN CNTNCTAGTN ATGGCCATTA GCGAGGANCT
NCCCGC ACCNCNGNGA ANAAATNAGA GNAGAAATGG
TANNGNATG TCTTTNGANA CGNCCTGGCA
TGCCCAGTAG ATGAAGTACA GAGGCCANTA GCGANGGNCT
ANGN ACGGNCATTA GCGAGGAACT
ce
NTTAANNN ATNCTATANA CAAGGTACNN
TTCCCAGTAG NTGAAGTNCA AGGCCATTAA CGAGGANTCT
ATGCC~.GAA GATGAAGTAC AAGGCCATTA GCGAGGAACT

"'G- Addition

6f
GGACAACGCA
GGACAANGCA
ACAGNGCATT
NTAGCACTCA
GGACAACACT
GGACAACGCA
NCTATAGGAN
GGACNACNCN
GGACAACGCA

710
CTCAATGACA
CTCAATGAGA
CAACTGCANA
TCNGACATCA
NTCNATGACA
CTCAATGACA
NCANTGACAT
CTCAATGACA
CTCAATGACA

Bf

910

ljO

TCACCTCCCT
TCACCTNCCT
TCACNTCCCT
CCTGCCACTC
TCACCTCCCT
TCACCTCCCT
CACCTCNACT
TCACCTCCCT
TCACCTCCC'r

CTGAGCCCCA
CTGGGTCCCA
CTGAGTCCCA
TGNNACCCCA
CTGATCCCNA
CTGAGCCCCA
CTGAANCNCA
CTGANCCCCA
CTGAGCCCCA

CACCAGNGTG
CACCAGNGTG
CACCAGCGAG
CACCAGNGTN
CACCAGCGTG
CGCCAGCGTG

p

0

CG~~CAGGGA

CGCCAGCGTG
CGCCCAGCGT
olymorphis m" 'Add-C

N

'-

Band stab IndJ
2. Band Stab 41
3. Band Stab 51

4. Family 2 {4)

:2. i:amil:i 2 ! ~ l
6. Band Stab 48
7. Family_ 1 {3)

8. Family 1 (3 1
9. TPM2{Widada et

'10
'10
'10
'10
'10
870F
GGCANCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG
870F )A A, GGCAACTCAG AGTCTCTNCT CTCNTCTCCT TCCCATTCTC TCTNTGGGGA
870F }R L ·, GGCAGCTNAG NNATCTCCTN TCTTNTCCTT CCCATNCTCT CTATGGAGAG
870F)EL' GGCAGCNCAG GTCTCTTCTC TCCTCTCCNN GCNANNCTCT CTATGGGGAG
S2:ZB l E GCCACCNCAT CTCTCTTCTC TCCTCNCCTT TCCATNCTCN CTATGGGGAG
870F }C L GGCACCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG
870F }0 E ATGACACCNC AGATCTCTGT CTCTCCTCTC CTTTCCATCC TCTCTATGGG
NCCACCTCAG CNCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG
867R }H
al.) )M
GCCACCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG
"'"Del-G & Sub-G->C
0

,.

N

. 1.

Band Stab Ind3 870F }R
2. Band stab 41
870F )A A
3. Band Stab 51
870F }R L
Family 2 ( 4)
870F }E L
:2. Elmlil::!l 2: I~ l
82:ZB l E

'-

6. Band Stab 48
7. Family 1 {3)
8. Family 1 {3)

870F }C L

870F }0 E
867R }H
9. TPM2(Widada et a1.) )M
0

N

1. Band Stab Ind3 870F )R
2. Band stab 41
870F )A A

3. Band Stab 51
4. Family 2{4)

.5.........-Ea.UY 2 {~l
6. Band Stab 48
7. Family 1(3)
8. Family 1 (3)

B70F }R L
870F }E L
BQ:ZB l E
870F }C L

870F )0 E
867R )M
9. TPM2(Widada et al.) )M
0

N

170
190
2~0
'10
'jo
I
I
GGGAGCAGNN AGGAGGAGCA GAAATTGNCA ACATTGNACA GNCAGGCTGG
GGGGAGGAGA GAGGAGGAGT AGAAATNGCC AATATTGNAN AGNCANTGTN
GGGAGCGAGG NAGGAGGAGC AGAAGTTGTA GCCATNGANN GAG,_,CAGGCA
GGGAGCAGGN AGGAGGAGCA GAANTTGGCA GCATTGAACA GT~_GGTTGG
GGGANNAGGC AGGAGGANCA GAAGTTNCCT ANNATTCACA ACCNGGCANN
GGGAGCAGGC AGGAGGAGCA GAAATTGCCA ACATTGGACA GCCAGGCTGG
GAGGGGAGCA GGCAGGAGGA GNAGAAATTG ACANCATTGA ACAGTCAGGT
GGGANNAGGC NGGAGGAGCA Gl~TTGCCT NCNATNCACA TCCNGGCTAG
GGGAGCAGGC AGGAGGAGCA GAAATTGCCA ACATTGCACA GCCAGGCTGG
"AG-D eletion

210

2)0
2)0
210
210
GAGGAGNCTA GGGAGAGCCC CCATCATGAC CACCACCCAC TCTGGNACTG
NGNAGGAGCG GGGGAGAGGC ACACATCATN ACCACCATCA NCTCCTGNAC
NGGGNGCAGT AGAGTGAGNG AGAGCCNTCN ATGATNACCC ACCNACCATT
GGGTAGCCTA GGGAGAGCCC CCATCATGNC CACCACCCAC TCTTANACTG
GANCAGCNTA AGAGAGANCC CCTNTNATAC NTTATCCACA CTANNGGNGN
GAGCAGNCTA GGGAGAGCCC CCATCATGCC CACCACCCAC TCTGGCACTG
TGGGGGTAGT CTAGGGAGAG NCCCCNTCAT GNCCACNTCC CACTCTGGGA
GATCATCCAA GAGAGAACCC CTAGAATNTC CNCTATCCAC TCTNNNNNGC
GAGCAGCCTA GGGAGAGCCC CCATCATGCC CACCACCCAC TCTGGCACTG

TABLE 7.2

Sequence ofTPM2 SSCP Homozygous Alleles
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TA~~i..tE

SEQUENCE

Clive SSCP2

OF

TP:b-12

7 .2
SSCP HOMOZYGOUS

ALLELES

22/12/9
210

110
1. Family 2 (4)
2. Family 2 (4)

3. Individual 85
4. Indiyidual 85
5. Family 2(12)
6. Family 2 {12)

870F }R
867R }A A
870F )R L
867R lE L
870F }C E

867R. )0 L
7. Band Stab tn48 867R. }M E
8. TPM2(Widada et al.J }M

·e

s,o

CCATTAGCGA
CCATTAGCGA
CCATTAGCGA
CCATTAGCGA
CATTAGCGAG
CGGTTAGNGA
CCATTAGCGA
CCATTAGCGA

GGAACTGGAC
GGAACTGGAC
GGAACTGGAC
GGAGCTGGGC
GNAACTGGAC

310

AGTCANGG
GAGTCTATGC CCAGAAGATG AAGTGCAAGG
AGNACAAGG
AAGTCTATNC CCAGGAGATG AAGNACGAGN
AGCCAAGGC
ATGN AGANACANGG
Bad Sequen ce
NAATCTATTC CCAGNAGATG ~GTACAAGN
AAGTCTATGC CCAGAAGATG AAGTACAAGG

TG~_NCANGAC

GGNACTGGAC
GGAACTGGAC

M

0
N

1. Family 2 (4)
2. Family 2(4)

670F )R
867R. }A A

3. Individual 85

870F )R L

1. lndh:idl.li:!l E!S

BJPB. lE L

5. Family 2 (12)
6. Family 2 (12)

870F )C E

867R )0 L
7. Band Stab In48 867R }M E
8. TPM2(Widada et al.)

}M

6f

70

80

90

110

AACGCACTCA
AACGCACTCA
AACGCACTCA
ANCGCACTCA
AACGCACTCA
GACTNANACA
AACGCACTCA
AACGCACTCA

ATGACATCAC
ATGANATNAC
ATGACATCAC
ATGACATCAC
ATGACATCAC
ATAANAACAC
ATGACATCAC
ATGACATCAC

CTCCCTCTGA
CTCCCTCTGA
CTCCCTCTGA
CTCCCTCTGA
CTCCCTCTGA
CTCCCTCTNA
CTCCCTCTGA
CTCCCTCTGA
Polym

GCCCCACACC
GCCCCACACC
GCCCCACACC
GCCCCACACC
GCCCCACGCC
ACCCAACTCC
GCCCCACACC
GCCCCACGCC
orphism"

AGCGTGGCCA
AGCGTGNCCA
AGTGTGGCCA
AGCNTGGCCA
AGCGTGGCCA
ATCNTGTCCA
AGCGTGGCNA
CAGCGTGCCA
'AddC 'Del

I

M

I

I

0

110

N

1. Family 2(4)

870F )R

2. Family 2(4}

867R )A A

3. Individual 85

1'

Im.U.:.:isi~il.l ~2

870F )R L
}:;; L

~6JB

5. Family 2 {12)
6. Family 2 {12 J

870F
867R
7. Band Stab In48 867R
8. TPM2(Widada et al.)

)C E
)0 L
)M B

}M
M

CCTCAGCTCT
CCTCAGCTCT
CCTCAGCTCT
CCTCAGCTCT
CCTCAGCTCT
CCTCAACTCT
CCTCAGCTCT
CCTCAGCTCT
-G

110

CTTCTCTCCT
CTTCTCTCCT
CTTCTCTCCT
CTTCTCTCCT
CTTCTCTCCT
CGTCTCTCCT
CTTCTCTCCT
CTTC'rCTCCT

0

1!0

N

1. Family 2 (4}
2. Family 2 (4)
3. Individual 85
1. Indiviffiwl 85

5. Fa'llily 2 {12)
6. Family 2{12)
7. Band Stab In48
8. TPM2(Widada et

870F )R
867R )A A.
870F )R L
867.B....ll; L
870F

}C

E

867R )0 L
867R )M E
al.) }M

M

GCAGGCAGGA
GCAGGCAGGA
GNAGGTAGGA
GCAGGCAGGA
GCAGGNAGGA
GCAGNCAGGA
GCAGGCAGGA
GCAGGCAGGA
"AG-Delet

-

110

GGAGCAGAAA
GGAGCAGAAA
GGAGCAGAAN
GGAGCAGAAA
GGAGNAt;ANN
GGAGCAGAAA
GGAGCAGAAA
GGAGCAGAAA
ion

110

CTCCTTTCCA
CTCCTTTCCA
CTCCTTTCCA
CTCCTTTCCA
CTCCTTNCAA
CTCCTTTCCA
CTCCTTTCCA
CTCCTTTCCA

ljO
TTGCCAACAT
TTGCCAACAT
TTGTCAACAT
TTGCCAACAT
TTGNCACCAT
TTNCCAACAT
TTGCCAACAT
TTGCCAACAT

110

110

TTCTCTCTAT GGGGAGGGGA
TTCTCTCTAT GGGGAGGGGA

TTCTCTCTAT
TTCTCTCTAT
TTCTCTCTAT
TTCTCTCTAT
TTCTCTCTAT
TTCTCTCTAT
110

NGCACAGNCA
TGCACAGCCA
NGCACAGCCA
TTCACAGCCA
CGNACAGCCA
TTCACANCCA
TGCACAGCCA
TGCACAGCCA

GGGGAGGGGA
GGGGAGGGGA
GGGGAGGGGA
GGGGAGGGGA
GGGGAGGGGA
GGGGAGGGGA
210

GGCTGGGAGC
GGCTGGGAGC
GGTTGGGAGN
GGCTGGGAGC
GGTTGGGAGC
GACTAAGAAC
GNCTGGGAGC
GGCTGGGAGC

0
N

1. i<amily 2(4)
2. Family 2 (4)

3. Individual 85

870F }R
867R }A A
870F )R L
1!27B lE L

~' InQiOlidyal !!5
5. Family 2(12)
870F )C E
867R )0 L
6. Family 2(12)
7. Band Stab In48 867R }M 8
8. TPM2 Ctndada et al.) }M
M

0
N

210

AGCCTAGGGA
AGCCTAGGGA
AGCCTAGGGA
AGCCTAGGGA
AGCCTAGGGA
ANCCTAGGGG
AGCCTAGGGA
AGCCTAGGGA

210

GAGNCCCCAT
GAGCCCCCAT
GAGCCCCCAT
GAGCCCCCAT
GAGCCCCCAT
GGNNCCCCNA
GAGCNCCCAT
GAGCCCCCAT

210

CATGCCCACC
CATGCCCACC
CATGCCCACC
CATGCCCACC
TATGCCCACC
AAGATNCCCA
CATGCCCACC
CATGCCCACC

210

ACCCANTCTG
ACCCACTCGT
ACCNACTCTG
ACCCACTCGT
ANCCACTCTG
CCACCCACTC
ACCCACTCGT
ACCCACTCTG

2i0

GTACTGGCTT
GNACTGGNTT
GCACTGGCTN
NTANGTNANG
GCACTGGCTT

amplified and sequenced. Samples 18, 32, 36, 48 that were homozygous for the

common allele were also cut out and amplified to c<,mpare the sequence between the two
alleles. The gel was then re~exposed to show if the exact alleles had been cut out. Figure
7.8, shows that the exact alleles were cut out.

Table 7.1 shows the sequence from the band stab amplifications. The samples were
sequenced from primer DS 870 (Rsk.forward) and also from primer DS 867
(3 'UTR.reverse ):

Lines
1-3.

Heterozygous Individuals 3, 41, 51 ) Band stabs of rare allele

4-5.

Family No.2 (sample No.4)

) Homozygous individual for the rare allele

6.

Homozygous lndividuai48

} Band stab of homozygous common allele

7-8

Family No.1 (sample No.3)

} Homozygous individual for common allele

9.

TPM2 sequence (Widada, eta!., 1988) ) Published sequence

The band stabs were only sequenced from primer DS 870, exon 8sk forward. Any
samples that were sequenced in the reverse direction (primer DS 867 .R) were rotated and

the complementary sequence was given in Table 7.1, using SeqEd™ 675 DNA
Sequencer Editor (ABI). This was to compare the sequencing data from the reverse
primer, with the forward primer.

There was a sequence difference between the rare and common alleles at base 92 where
all the rare alleles had an adenine base and Widada et al. and the common alleles had a
guanine base. The sequencing for individual473 (7) DS 870.8skF was quite bad though.
The sequencing was not ideal, as there were a lot of base changes between the samples.

It was noticed however, that the eequence from the samples in some places consistently
differed to (Widada, et al., 1988) published sequence in the 3'UTR. At base 93-96
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Widada's sequence had a CCCA, while the samples mostly just had a CCA, so Widada's
sequence had an extra C or insertion, which misaligned the bases until Widada has a G
deletion at 101-102 and a C substituted for a G, so the sequence is realigned after base
103 (see Table 7.1).

3'UTR
101

91

Widada et al

CGCCCAGCGT GCCACCT

Sequencing

CACCAGCGTG GGCACCT

•

**

It was also noticed that Widada had an extra AG at bases 1::)6-157, which were not
present in 6 out of the 8 samples. The other samples (Family 2 (4)-867.R and Family 1

(3)-867.R) had bad sequencing at this point. These two bases were not included in the
TPM2 sequence of Widada et al. in Table 7.1, as it would have meant the comparison
and alignment ofTPM2's sequence with the other samples would be difficult to follow,
but it is shown below:

3'UTR
151

161

Widada et al

GGGAGAGCAG GCAGGAG (AG inserted)

Samples

GGGAGCAGGC AGGAGGA

..

So there were five consistent changes in the sequence data from that of Widada et al.'s
published sequence, all in the 3'UTR, and a highly probable cause for the TPM2 SSCP
polymorphism.
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7.3.7 Sequencing Homozygous Individuals for the TPM2 (8sk • 3'UTR)

common and rare allele

Another homozygous individual for the rare allele was discovered when screening the 97

individuals. The most direct method for sequencing the polymorphism was now
therefore to amplify the DNA of the two individuals that were homozygous for the rare
allele and sequence the fragment. The sequence could then be compared

t0

ampliJ·ed

DNA from individuals that were homozygous for the common allele.

The samples were sequenced using primers DS 870 (8sk.F) and 867 (3'UTR) and the
results are shown in Table 7.2:

Lines 1-2 Family No.2 (sample No.4)

) Homozygous rare allele TPM2 exon S·.k3'UTR

Lines 3-4 Individual 85

) "

Lines 5-6 Family No.2 (sample No.12)

) Homozygous r<'""non allele

Family No.2 (sample No. 13)

"

"

"

) "

)"

Line 7 Band stab individual48

"

" Only used primer DS 867.R

To compare the sequencing from the reverse and forward primers, the sequencing results

from the 3'UTR

r~verse

primer (DS 867.R) were rotated and the complementary

sequence was given in Table 7.2.

The results were similar to the band stab sequencing, except the sequf':ncine was more
accurate and precise, when compared to Widada et al.'s published sequence. Family No.
2 (13) did not sequence very well, so the results were not included in Table 7.2. Tl •. _
band stab individual 48 was sequenced from primer DS 867 (3'UTR reverse), as the
template sequenced well last time in the forward direction in Table 7.1 and so it was
repeated in Table 7.2, in the reverse direction.
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The suspected polymorphism was at base 88 this time in Table 7 .2. All the rare alleles
were adenine again at this base. For the common alleles: sample 5 read a guanine, sample
6- a thymine and sample 7 (the band stab of individual 48) -an adenine, yet last time it
sequenced as a guanine. So out of 9 rare alleles sequenced, 9 out of 9 times it sequenced
as adenine, which is different to \'!idada et al.'s guanine. 4 out of the 6 common alleles
sequenced agreed with Wid:tda et al. 's guanine at the polymorphic site. The other two
samples read once an adenine and the other a;\ a thymine, though the thymine sequence
was quite bad (sample 6- Table 7.2). So the base change causing the polymorphism still
needed to be confirmed.

The variations from Widada's TPM2 sequence, mentioned in the band stab sequencing,
were repeated for these samples:

There was a cytosine addition in Widada's sequence at base 91. 14 out of 15 independent
sequencing samples of the rare and common alleles showed Widada et al. had an
additional C. This may be explained, as in 1988 they would have used manual
sequencing methods and it could have been fairly easy to read two C's in a row as three
C's, as the b<mds would have been very close (Laing, 1994a).

11 out 15 independent sequencing samples showed that Widada et al. had a guanine
deletion at base 97 in Table 7 .2. However, there was no C substituted for a G at base 98
like in Table 7.1 and it was likely that Table 7.2 sequencing was more accurate.

14 out of 15 independent sequencing samples showed Wid ada et al. had an AG insertion
after base 152 in Table 7.2. This was not shown in Widada's sequence, as otherwise all
the bases from the other samples after this insertion would not be aligr..ed with Widada's
sequence anrl the

~~-lJ'lence

would have been more difficult to compare.
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Therefore, there were four consistent base changes to Widada et al.'s published sequence
in·the 3'UTR from the sequencing results, which was similar to the sequencing in Table

7.1.

The sequence variation between the polymorphic aJleles still needed confirmation, but it
was suspected that the eleventh base in the 3'UTR was an adenine in the rare allele and a
guanine in the common allele that caused the polymorphism, seen in the SSCP gels.

7.3.8 Restriction Digest of 259 bp TPM2 STS (8sk - 3'UTR)

Using the consistent TPM2 STS sequence defined by primers DS 870 and 867, a 259
base

sequenc~

was typed into a computer application package DNA Strider version 1.0.

Two versions of the STS sequence were typed in, what was suspected for the common
allele (Figure 7.9) and the rare allele (Figu'e 7. 10). The application worked out most of
the restriction sites for the two STSs. At base 83 (guanine) in Figure 7.9 (the common
allele) there was a unique restriction site (Bgl I) present at the suspected site of the
polymorphism that was not present in base 88 (adenine) for the rare allele, in Figure
7.10. This can be seen more clearly in Figure 7.11 showing a simplified restriction map
of the common allele STS (a) and the rare allele STS (b). There is a unique restriction site
(Bgl I) at base 83 seen in (a), but not in (b).

The sequence where the restriction enzyme Bgl I splices DNA is:

Bgl I restriction enzyme

GCCNNNN/NGGC

Suspected 259 bp TPM2 STS polymorphism (common allele)

GCCAGCG/TGGC

Suspected 259 bp TPM2 STS polymorphism (rare allele)

ACCAGCG/TGGC

This meant a restriction digest could be carried out on a PCR STS from different
individuals. An STS from a homozygous individual for the rare allele would produce a
single 259 bp fragment on a gel, as there is no restriction site for Bgl I. Bgl I would cut
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an STS for a homozygous individual for the common allele into two fragments, a 88 bp
and 171 bp fragment. The STS for a heterozygous individual would be cut into three
fragments (88, 171 and 259 bp) as they have two alleles. One allele would not be cut by
Bgl I (259 bp) and the other allele would be cut producing the two fragments (88 & 171
bp) (see Figure 7.12).

The restriction digest in Figure 7.13 showed that the TPM2 STS was polymorphic at
base 88 and confirmed the sequencing results that it was ihe site for the polymorphism.
Therefore, primers DS 870 (exon 8sk.F) and DS 867 (3'U."R.R) can now be used as
unique markers in the human genome project for linkage analysis and entered on the
CEPH linkage map. The polymorphism is quite useful, because the TPM2 gene has been
localised to 9pl3.1 and so the polymorphi$m when it is entered on the CEPH map can be
correlated to the physical map.
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FIGURE 7.9

Restriction Sites for the 259 bp TPM2 STS Sequence of the Common Allele.
The Common Allele has an extra Restriction Site (Bgll) at Base 88.
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FIGURE 7.10

Restriction Sites for the 259 bp TPM2 STS Sequence of the Rare Allele
The Rare Allele does not have the Restriction Site (Bgl I) at Base 88.
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FIGURE 7.11

Graphic Map Showing the Restriction Sites of the 259 bp TPM2
STS

(A) The Common Allele has an extra Restriction Site (Bgl l) at Base 88.

(B) The Rare Allele does not have the Restriction Site (Bgl I) at Base 88.
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FIGURE 7.12

Predicted Restriction Digest of 259 bp TPM2 STS (Exon 8sk- 3'UTR)
Polymorphism using Bgl I

146

259bp
171 bp
88bp

Heterozygous

Homozygous
Common
Allele

Homozygous
Rare
Allele

FIGURE 7.13

Restriction Digest of 259 bp TPM2 STS (Exon 8sk - 3'UTR)
Polymorphism using Bgl I
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147

pGEM
Heterozygous Allele
Homozygous Common Allele
Homozygous Rare Allele
pGEM

CHAPTER 8
GENERAL DISCUSSION

8.1 Localised Inherited Muscle Disorders

At present there are no known inherited muscle disorders linked to the 9p t3 region
(Klinger, 1992). The alpha-tropomyosin gene TPMI has recently been localised to 15q22

(Eyre, et a!., 1994) and has been shown to be mutated ia some cases of familial
hypertrophic cardiomyopathy (Thicrfelder, et al., I 99~', ). The alpha·tropomyosin gene
TPM3 has been recently localised to lq22-q23 (Wilton, eta!., 1995) and has been shown
to be mutated in a family with autosomal

dom~nant

nemaline myopathy (Laing, et al.,

1994). Therefore, at present, TPM2 be\.:0mes a candidate disease causing gene for any
unlinked inherited myopathie.'i: ;,nJ muscle related disorders. Also, in the future inherited

muscle disorders may b..: linked to chromosome 9pl3 and, in this case, TPM2 would
become a candidate disea'ie causing gene.

8-2 Determining if the 259 bp TPM2 STS is a Pseudogene

It is extremely unlikely that the 259 bp TPM2 STS is a pseudogene as the STS was

sequenced and it had a muscle specific exon Ssk, which will not be found in processed
pseudogenes (2.1.2.2.). However, this STS could be excluded as a pseudogcne, if it
were radiolabelled and then the STS hybridised to a genomic blot cut with a restriction
enzyme, such as Taq I, that does not cut the STS. If the autorad revealed only a single
band, then the STS would be most likely hybridising to the TPM2 gene alone and not to

pseudogenes. However, because a

process~d

pseudogene has a similar sequence to the

real gene, it can be cut by the restriction enzyme, and travel in the gel to the same location
on the Southern blot as the real gene. So when

th~

probe hybridises as a single band it

could be hybridising to the real gene, or the pseudogene. By hybrictising the STS to a
few genomic blots, cut with different restriction enzymes, then if this probe hybridises as
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a single band to all the genomic blots, one can be confident the STS is belongs to the real
TPM2 gene. This is because it is extremely unlikely that the pseudogene would always
be cut at the same points as the real gene, with the different restriction enzymes. The
greater the number of different genomic blots, cut With different restriction enzymes, that
are used, the greater the certainty that this is the TPM2 gene.

8.3 Long Range PCR STSs for use in FISH

The methods of isolating genomic clones for use in FISH have almost been superseded
with the new technique of long range PCR. Since 1992 researchers have increased the
conventional range of PCR from typically 5 kb to now 5 kb to 40 kb,

···-'it.'

averages of

5- 15 kb in genomic DNA (Cheng, eta!., 1994; Kainz, eta!., 1992; Ponce & Mica!,
1992). The key to long range PCR is the new DNA polymerase, U/Tma ™ DNA
polymerase which has an inherent 3'- 5' exonuclease ("proofreading") activity which not
only increases the length of PCR fragments produced, but also the accuracy of the
amplified copies. Perkin Elmer have produced a PCR kit in 1994 that can perform long
-l

range PCR (Perkin-Elmer, 1994).

Producing long PCR fragments increases the amount of specific genomic DNA
comparable to genomic clones (8 - 21 kb) that can be used in FISH. This, therefore,
greatly reduces the time and effort in localising genes by isolating a genomic clone. The
only problem is that the technique is new and many of the PCR parameters still need to
be optimised. Also there is no guarantee that a long range PCR product will work in
FISH (Wilton, 1994). Likewise, however, there is no guarantee that isolating a genomic
clone for use in FISH will be successful.
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8.4 Linkage of the TPM2 Polymorphism

Linkage of a polymorphism is performed using known markers. These are usually

polymorphic regions of DNA like the polymorphism for TPM2 described in chapter 7.
The 259 bp TPM2 STS polymorphism is called a restriction fragment length
polymorphism (RFLP), because the restriction enzymes produce different sized

fragments in polymorphic STSs (Gelehrter & Collins, 1990).

Another more informative class of marker in the genome are microsatellites.

Microsatellites are tandem repeats of base sequences, usually less than 100 bp in total
length and occur on average approximately every 6000 bp in the human genome. Since
humans have 3xl09 bp in the genome, then there are about 5xl09 microsatellites, so
every gene should have a microsatellite near it (Cooper, 1994).

The function of microsatellites is not well understood, but one theory is that they are
conL'TIOB

!ocations for recombinations (Cooper, 1994). Of the microsatellite repeat

sequences, 76% of them in decreasing frequency are:

A, AC, AAAN, AAN, or AG

N = any nucleotide A G C or T

(Cooper, 1994)

Microsatellites are inherited in a strict Mendelian pattern, except for the rare occasions
when the number of repeats alters from one generation to the next by mutation. Different
alleles may vary in the repeat number, for example, there may be an (AC)n repeat on a
chromosome at a known locus. A mother may have 4 and 9 tandem repeats of the
sequence on the two different alleles at the locus and the father 6 and 3 repeats. Therefore
a child of theirs can only have one tandem repeat from either allele of the parent, with the
following possible combinations - 9,6; 9,3; 4,6; and 4,3 unless there is a mutation. These
microsatellites would be included in an PCR STS that can be identified by acrylamide gel
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electrophoresis, to detennine the segregation of alleles for different individuals in a
pedigree. In this way they are more informative than a RFLP, as there are more
combinations of microsatel!ite alleles at a locus, in a pedigree, than a single RFLP

(Sheffield & Stone, 1994).

Another marker is minisatellites or variable number of tandem repeats (VNTRs) which
were discovered before microsatellites. VNTRs a·" less common and less evenly
distributed through the genome, so they are not quite as useful as microsatellites. VNTRs
are bigger than microsate11ites and their repeating unit is 30 to 35 bp in length and have a
variable sequence but contain a repeating core sequence 10 to 15 bp in length.
Minisatellite repeats range in size from 200 bp up to several thousand bp and tend to
occur in greater numbers toward the telomeric ends of chromosomes. Because VNTRs
are much bigger than microsatellites they are harder to amplify using PCR. They are
separated on agarose (not acrylamide gels) or are probed on Southern blots (Cooper,

1994).

8.5 Linkage Results and CEPH Mapping

Helen Eyre and Dr John Mulley at the Department of Cytogenetics and Molecular

Genetics at Adelaide Children's Hospital, have linked the TPM2 polymorphism in CEPH
families, in comparison with known markers in the region 9p21-13. This confirms the
FISH localisation to 9p13 as well as the somatic cell hybrid localisation to chromosome

A

9.

'

The distance apart of two loci, is defined as in linkage terms as the Kosambi mapping
function, which is measured in centiMorgans (eM). If two loci are 1 eM apart, there is an
approximate, average probability of 0.01 of recombination taking place between these
loci. It is difficult to be more precise than this because recombination frequency varies

Utroughout the genome and between the sexes (Gelehrter & Collins, 1990).

151

I

I
I

I

FIGURE 8.1

Genetic linkage map of sex-averaged chromosome 9, showing CEPH
polymorphic markers. An asterix (*) next to a marker indicates loci with
heterozygosities of at least 70%. Microsatellite markers assayed by PCR are
shown in italics. The graphic chromosomal idiogram depicts the Giernsa staining
pattern. The D9S numbers to the right of the sex averaged map that point to the
chromosomal idiogram, indicate those markers that have been cytogenetically
mapped.
(NIH/CEPH Collaborative Mapping Group, 1992)
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The most likely location for the TPM2 SSCP was between markers D9S!9 (a Taq I
RFLP) and D9S 175 (an (AC) 0 microsatellite repeat) (the highlighted markers in Figure
8.1, were those found to be closely linked to the TPM2 polymorphism). The DS
numbers refer to the CEPH notation system. The 9 after the D refers to chromosome 9
and the numbers after the S are the order in which the polymorphic markers were found.

(Klinger, 1992).

TABLE 8.1
Markers and their Recombination Frequency with the TPM2
Polymorphism

Locus Symbol

Recombination Frequency

eM

with TPM2 Polymorphism
D9Sl04

0.02

19.7

D9S52

0.00

21.3

D9S43

0.00

22.1

D9Sl8

0.08

25.2

D9S19

0.00

33.0

0.08

47.2

TPM2SSCP
D9SI75

The low recombination values between the markers in Table 8.1 and the TPM2 SSCP
indicate that they are closely linked to TPM2. However, with a heterozygosity of 0.16,
the TPM2 polymorphism is relatively uninformative and the chances of recombination
between the TPM2 SSCP and these markers in the CEPH families is quite low. This
means that caution ntl:st be exercised in interpreting these results. A more informative
marker closely linked to TPM2 is required to confirm the localisation of TPM2 between

D9Sl9 and D9SI75.
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8.6 Finding a Microsatellite Close to the TPM2 Gene

The most informative markers used in gcae mapping projects today are microsatellites.
Had time permitted, the next stage of this project would have been the discovery of a

microsatellite closely linked to TPM2. There are two ways in which the identification of

such a microsatellite could have been achieved.

Firstly, from a yeast artificial chromosome or YAC cantle covering the presumed D9S 19
• D9Sl75 linkage region of TPM2, a Y AC clone(s) would have been isolated that
contained a TPM2 STS. Microsatellites would then be sought in any TPM2 positive
YAC(s).

Y ACs are cloning vectors that replicate as chromosomes in yeast cells and can

accommodate human DNA inserts as large as 1 million base pairs. These large inserts are
extremely useful for attaining long-range continuity in contig or overlapping maps and are
therefore useful in large-scale mapping of the human genome (Cooper, 1994).

A YAC contig covering the 9p13 region would have been identified using the MOSAIC
database program. The Y,\C(s) in the 9p13 contig containing all (or part) of the TPM2
gene would then be identified by PCR assay using the Y AC(s) as target DNA for the

TPM2 STS primers. Those YAC clones that produced a positive res 1Jlt must contain a
segment of the TPM2 gene. An important control for theY AC TPM2 STS PCR would be

the yeast DNA of S. cervisae and the TPM2 STS primers. S. cervisae is the yeast host
strain for the 9pi3 YAC contig. Homology between the TPM2 STS primers and S.

cervisae DNA does not occur (Genebank), nevertheless a negative yeast DNA control for
the PCR amplification is required (Laing, 1994a).

Positive TPM2 PCR STS assay isolated clones, would then be screened for di, tri, tetra
and penta nucleotide tandem repeat sequences (or microsatellites), especially tht. most
common (CA)n repeat most typical of microsatellite polymGrphisms. This would have
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been achieved by digesting DNA from isolated YAC clones specific to 1'PM2 STSs with
restriction enzymes and then identifying those fragments which anneal to 32p labelled eg.
(GT)to on a Southern blot. Once localised, these (CA)" containing fr.1gments would be
subcloned into a selected plasmid, wsing a modification to the technique described by
(Feener, et al., 1991). The sequence of the plasmid either side of the insert is known and

primers have been designed so the insert can be PCR amplified and then sequenced. An
insert less than 1000 bp would be ideal, as the maximum sequencing range from each
primer on either side of the insert is approximately 500 bp. If the insert is much larger

than 1000 bp, then the fragment would be cut again with another restriction enzyme and
reprobed on a Southern blot and then subcloned and sequenced. Alternatively new
primers could be designed from the information obtained at the end of one sequence to
continue the sequencing of the insert until the microsatellite is sequenced. Primers would
then be designed on either side of the microsatellite to produce an STS that includes the

microsatel!ite (Laing, 1994a; Sambrook, et a!., 1989).

A random population can be screened using these primers to determine the allelic
frequency of these microsatellite polymorphisms, as in 7.2.7. Once a suitable panel of
microsatellites had been identified, they would have been screened against the CEPH
panel of families in collaboration with Department of Cytogenetics and Molecular
Genetics at Adelaide Children's Hospital to localise the polymorphisms position on the

CEPH map (Laing, 1994a).

Similarly, somatic cell hybrids that contain parts of chromosome 9p13 can be isolated
using TPM2 STSs and the methods repeated, as for Y ACs to isolate a microsatellite
repeat that can be localised in the CEPH map, that would also have a physical location to

9pl3 (Laing, 1994a).

!55

8. 7 Conclusion

The somatic cell hybrid and FISH localisation of human skeletal tropomyosin (TPM2) to
'~

9pl3 paper has been accepted by the Cytogenetics and Cell Genetics Journal. (see
Appendix 3). The detection of the Bgl I RFLP in the 3'UTR of TPM2, and linkage of

this polymorphism will be submitted to Genomics and entered on the CEPH map.
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APPENDIX 1
TROPOMYOSIN GENE
SEQUENCES

1

j

TPMl - McLeod and Gooding,

(1988).

TPM2 - B tropomyosir1 - Widada et al.,
TPM3

Reinach and McLegd.

(1988).

0986!.

TPM4 - MacLeod, Talbot, SmiJ.lie, Houlker - J Mol Biol 194:1-10,

(1987).

cccgctccgtcctcctcgcctgccaccg
DS1095 TPMl-Exl-F

ccgcgcgctcgccccgccgctcctgctgcagccccaggcccc'.:.cgccgccgccacc
DS1083 TPM2-Exl-:;>

gtgcacccagtccgctcacccagcccagt;.ccgtccggtcctcaccgcctgccggccggcccaccccccaccgcaggcc
DS886 TPM3 (14)
ttgcqccagtctccagttctqca9tgttcacaggtgagcctaccaacagccactgctc

Exon Isk

atggacgccatcaagaagaagatgcaga tgctgaagctcgacaaggagaacgccttggatcgagctgagcaggcggag
DS840 TPM2, lskF

atggacgccatcaagaagaagatgcagatgctgaagctggacaaggagaacgccatcgaccgcgccgagcaggccgaa
atggaggccatcaagaaaaagatgcagatgctgaagtt agacaaggagaatgctctggatcgggctgagcaagctgaa
DS1094 TPMl-Exl-R

gccgacaagaaggcggcggaagacaggagcaagcag
DS1082 TPM2-Exl-R

gccgacaagaagcaagctgaggaccgctgcaagcag
DS1018 TPM3-2002
gctgagcagaagca99cagaagaaagaagtaaacag-

Exon II.sk
ctggaagatgagctggtgtcactgcaaaagaaactcaagggc

ctggaggaggagcagcaggccctccagaagaagctgaagggg
ctggaggatgagctggcagccatgcagaag-aag-ctgaaaggg
accgaagatgaactggacaaatactctgaggctctcaaagatgcccaggagaagctggagctggcagagaaaaaggcc
DS841 TPM2.IIskR

acagaggatgaggtggaaaagtattctgaatccgtgaaggaggcccaggagaaactggagcaggccgagaagaaggcc
acagaggatgagctggacaagtattctgaagctttgaaggatgcccaggagaagctggaactggcagagaagaaggct
accgat

actgat
gctgat

Exon II
gctgaagccgacgtagct tctctgaacagacgcatccagctggt tgaggaagagt tgga tcgtgcccaggag

gctgaggcagatgtggcctccctgaaccgccgcattcagctggttgaggaggagctggaccgggcccaggag
gctgagqctgaggtggcctqcttgaaccgtaggatccagctggttgaagaagagctggaccgtgctcaggag
DS1372gctgaaggtgatgtggccgccct_caaccgacgcatccagctcgttgaggaggagttggacagggctcaggaa
cgtctggcaacagctttgcagaagctggaggaagctgagaaggcagcagatgagagtgagag

cgcctggctacagccctgcagaagctggaggaggccgagaaggcggctgat::gagagcgagag
cgcct ggcc a ctgccc t gca a a a gc t gga a ga a gctga a a a a gc tqc tga t Q'a ga gt gagag:
TPM4IIF
cgactggccacggccctgcagaagctggaggaggcagaaaaagctgcagatgagagtgagag

1
·,1.

1

Exon III
aggcatgaaagtcatt
aggaatgaaggtcatc
aqgtatqaaggttatt
aggaatgaaggtgata
gagagtcgagcccaaaaagatgaagaaaaaatggaaattcaggagatccaactgaaagaggccaagcacattgctgaa
gaaaaccgggccatgaaggatgaggagaagatggaactgcaggagatgcagctgaaggaggccaagcacatcgctgag
qaaaacCgggccttaaaaqatqaagaaaaqatqgaactccaggaaatccaactcaaaqaaqctaaqcacattqcaqaa
gaaaaccgggccatgaaggatgaggagaagatggagattcaggagatgcagctcaaagaggccaagcacattgcggaa
gatgccgaccgcaaatacgaagag
gattcagaccgcaaatatgaagag
gaqgcagataggaagtatgaagag
DS1373 - TPM4IIIR
gaggctgaccgcaaatacgaggag

Exon IV
gtggcccgtaagctggtcatcattgagagcgacctggaacgtgcagaggagcgg
gtggccaggaagctggtgatcctggaaggagagctggagcgctcggaggagagg
gtggctcgtaagttggtgatcattgaaggagacttggaacqcacagaggaacga

DS1052 TPM4.4F
gtagctcgtaagctggtcatcctggagggtgagctggagagggcagaggagcgt

gctgagctctcagaagg
gctgaggtggccgagag
gctgagctqgcagagtc
gcggaggtgtctgaact

Exon Vsk
g

g

TPMla=rat

caaatgtgc~gagcttgaagaagaattgaaaactgtgacgaacaacttgaagtcactggag

DS752 TPM2.VF
taaatgtggggacctagaggaggagctgaaaattgttaccaacaactt~aaatccctggag

taagtgttctgagctggaggaggagctgaagaatgtcaccaacaacctcaagtctcttgag

gctcaggctgagaag
gcccaggcggacaag
gctcaggcggagaag

Exon VI
tactcgcagaaggaagacagatatgaggaagagatcaaggtcctttccgacaagctgaaggag

DS869 TPM2.6F
tattccac~aaagaagataaatatgaagaggagatcaaactgttggaggagaagctgaaggag

tactctcaaaaagaagataaatatgaggaagaaatcaagattcttactgataaactcaaggag

DS'/54 - TPM4a
tattctgaaaaggaggacaaatatgaagaagaaattaaacttctgtctgacaaactgaaagag

Exon VII
TPMlb=rat
gctgagactcgggctgagtttgcggagaggtcagtaactaaattggagaaaagcattgatgacttagaag

DS868 TPM2.7F

DS753 TPM2.7R

gctgagacccgagcagagtttgccgagaggtctgtggcaaagttggagaaaaccatcgatgacctagaag
gcagagacccgtgctgagtttgctgagagatcggtagccaagctggaaaagacaattgatgacctggaag

DS755 TPM4b
gctgagacccgtgctgaatttgcagagagaacggttgcaaaactggaaaagacaattgatgacctggaag

Exon VIIIsk
acgagctg

atgaagtc
atgagctc
tacgctcagaaactgaagtacaaagccatcagcgaggagctggaccacgctctcaacgatatgacttccata

DS870 TPM2 . SF
DS866 TPM2. 8R
tatgcccagaagatgaagtacaaggccattagcgaggaactggacaacgcactcaatgacatcacctccctc
tatgccca~aaactyaagtacaaggccattagcgaggagctggaccacgccctcaatgacatgacctctatg

3' untranslated
taagtt

tgagcc
;t.aatta

tctttgcttcacttctcccaagactccctcgtcgagctggatgtcccacctctctgagctctgcatttgtctattctc
ccacgcccagcgtgccacctcagctctcttctctcct~tcctttccattctctctatggggaggggagagcaggcagg

tcaccgtttctgctctgttctggatctgccccctttactcctcggggaacccaaggccccactctggctctggattcc
cagctgaccctggttctctctcttagcatcctgccttagagccaggcacacactgtgctttctattgtacagaagctc

aggagcagaaattgccaacattgcacagccaggctgggagcagcctaggg-agagcccccatcatgcc-::.accacccact
atttgggtcagcctggctggtccccaaggcattaggatgggggagcaaaaagcaacttatgtattttcttccaccccc
ttcgtttcagtgtcaaataaacactgtgtaagctaaaaaaa

DS867 TPM2.3'UTR
ctggcactggcttcatcctttacctatccccttccaccctcctttgcttgcttaataaattctgaacttggaaaaaaa
accccaaattaaaatgttaagctgctggaaaaaaaaaa

aa

---------------~ --~----·-
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APPENDIX 2
BUFFERS AND SOLUTIONS
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GENERAL SOLUTIONS
% Agarose

Weight agarose per volume in !X TAB
ie. 1% Agarose gel= lg agarose in 100 rnL !X TAB

O.SM EDTA (pH 8.0)

Add 186.1 g of disodium ethylenediaminetetra-acetate·2H20 to 800 rnL of H20. Stir
vigorously on a magnetic stirrer. Adjust the pH to 8.0 with NaOH (-20g of NaOH

pellets). The disodium salt of EDTA does not go imo solution until the pH of the solution
is adjusted to approximately 8.0 by the addition of NaOH. Dispense into aliquots and
sterilise by autoc1aving (Sambrook, et al., 1989).

10% SDS (Sodium dodecyl sulfate or sodium lauryl sulfate

Dissolve 100 g of electrophoresis-grade SDS in 900 mL of H20. Heat to 680C to assist
dissolution. Adjust the pH to 7.2 by adding a few drops of concentrated HCI. Adjust the

volume to 1 L with HzO. A mask was vvorn weighing out the SDS as the fine crystals
dispersed easily (Sambrook, et al., 1989).

2ox sse
Disse!ve 175.3 g of NaCl and 88.2 g of sodium citrate in 800 rnL of H20. Adjust the pH
to 7.0 with a few drops of a 10 N solution of NaOH. Adjust the volume to 1 L with
H20· Sterilise by autoclaving (Sarnbrook, eta!., 1989).

1

STE (Sodium Chloride, Tris, EDTAl

0.1 MNaCI
10 mM Tris.CI (pH 8.0)
I mM EDTA (pH 8.0)

(Sambrook, et al., 1989)

TE {Tris EDTA Buffer)

TE is used as a buffer for DNA. DNA being a weak acid will undergo autocatalysis in the
absence of a buffering agent (Sambrook, et al., 1989).

IM Tris

Dissolve 121.1 g of Tris base in 800 mL of H20. Adjust the pH to the desired value by

adding concentrated HCI. Allow the solution to cool to room temperature before making
the final pH adjustments, as the pH ofTris is temperature dependent. Adju.st the volume
to I L with H20. Sterilise by autoclaving (Sambrook, eta!., 1989).

SX Tth Buffer

335 mM Tris HCI (pH8.8) at 25oc

83 mM (Nfl4)2 S04
I mM each dNTPs
!OmMMgCI2,
I mg gelatin/ml
2.25% Triton (X-100)
(ANRI, 1994)

2

ETHIDIUM BROMIDE

STOCK CQNCENTRATION

STAINING CONCENTRATION

10 mg/mL (lg Ethidium Bromide in IOOmL H20 0.5

~g/mL

ELECTROPHORESIS BUFFERS

BUFFER

WORKING SOLUTION

CONCENTRATED STOCK
SOLUTION (per litre)

Tris-acetate

IX:

0.001 MEDTA

(fAE)

Tris-borate
(!'BE)

0,04 M Tris-acetate

IX:

0.09 M Tri-borate
0.002MEDTA

SOX:

242 g Tris base

57.1 mL glacial acetic acid

lOX : 108 g Tris base
27.5 g boric acid
20 mL 0.5 M EDTA (pH 8.0)

use double distilled water as
lOX TBE otherwise

precipitates

(Sambrook, et al., 1989)
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GEL LOADING BUFFERS

BUFFER TYPE

BUFFER

STORAGETEMPERATURE

0.25% bromophenol blue

room temperature

Agarose Buffer
Ficoll (6X)

0.25% xylene cyanol FF
15% Fico II (Type 400;

Pharmacia in water

SSCP Buffer
Formamide (2x)

I mL de ionised forrnamide

40C

I EDTA (pH 8.0)

0.025% bromophenol blue
0.025% xylene cyanol FF

(ANRI, 1994)
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BACTERIAL MEDIA AND REQUIRED SOLUTIONS

1.5% bottom agar

Add agar (Difco Laboratories) weight to volume of 2X YT and made to 10 mM MgS04

and 0.2% maltose.

For example to make I L of bottom agar added:
15 g agar/L and autoclave to sterilise and cool to approximately sooc. Usually some
volume is lost so make to 980 mL with distilled water.
At sooc add 10 mL 20% maltose and 10 mL I M MgS04. The solution was left to cool

to around SOOC because at high temperatures the maltose caramelises.
(Sambrook, et a!., 1989)

0.7% top agarose

Add agarose (Progen Industries) weight to volume of 2X YT and made to 10 mM
MgS04 and 0.2% maltose.

For example to make 100 mL of top agarose added:
0.7 g agarose to 100 mL of 2X YT and boiled in microwave until dissolved.
Cooled to 'pproximately SOOC and added 1 mL of20% maltose and 1 mL 1M MgS04.
(ANRI, 1994)

DNA denaturing solution

1.5 M

NaCI

0.5 M

NaOH
(Clontech, 1994)
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lOX Lambda dilution bull'er

58.3 g

l.OMNaCl

24.65 g

0.1 M MgS04.1H20

350.0mL

1.0 M Tris-HCl (pH 7.5) (final concentration 0.35 M)

Added HzO to a final volume of l L. Autoclaved and stored at 40C (Clontech, 1994).

IX Lambda dilution bull'er

100 mL lOX Lambda dilution buffer
5 mL 2% Gelatin
Added HzO to a final volume of I L. Autoclaved and stored at 40C (Clontech, 1994).

100 mL 20% Maltose

20 g maltose in 80 mL HzO. Filter sterilised (ANRI, 1994).

100 mL l M MgS04

Added 24.65 g MgS04 with HzO to make l 00 mL. Filter sterilised using 0.22 f(m pore
filter unit (Millipore- Millex- OS) and 50 mL syringe (Terumo) (ANRI, 1994).

Phenol: Chloroform

Mix equal amounts of equilibrated phenol and chloroform. Equilibrate the mixture by

extracting several times with 0.1 M Tris-HCI (pH 7.5). Store the equilibrated mixture
under an equal volume ofO.Ol M Tris-HCI (pH 7.5) at 40C in dark glass bottles.
Phenol must be equilibrated to a pH > 7.8 because DNA will partition into the organic

phase at acidic pH (Sarnbrook, et al., 1989).
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Chloroform:Isoamyl Alcohol (24:1)

A mixture of chloroform is mixed with isoamyl alcohol in

L~e

ratio of 24: 1 respectively.

The mixture is used to remove proteins from nucleic acids. The chlorofonn denatures
proteins and facilitates the separation of the aqueous and organic phases, and the isoamyl
alcohol reduces foaming during extraction from the SDS. The chloroform:isoamyl
alcohol mixture is stored under 0.1 M Tris-HCI (pH 8.0) in a dark bottle at 40C for
periods of up to one month (Sambrook, et al., 1989).

Tris neutralising solution

1.5 M

NaCI

0.5 M

Tris-HCI (pH 7.5)
(Clontech, 1994)

2X YT Medium

Per litre:
To 900 mL of MilliQ water (deionised water)
Bacto-trypone

16g

Bacto-yeast extract

lOg

5g

NaCI

Mixed until solutes had dissolved and made up to 1 L with H20
Sterilised by liquid autoclave.
(Sambrook, et al., 1989)
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POLYACRYLAMIDE GEL ELECTROPHORESIS FOR SSCP
GELS AND SOLUTIONS USED

40% Acrylamide Stock (39:1 Acylalmide:Bisacrylamide)

Wearing a face mask, 390 g acyrlamide and 10 g bisacylarnide were dissolved in 600 mL
of MiiiiQ water. The solution was deionised by adding two dessert spoonfuls of Mixed
Bead Resin (AG 501-X8 (D) Resin, 20-50 mesh, Bio-Rad) and stirring for 30 min. The
solution was filtered using 305 rnrn diameter Postlip Paper (Hollingsworth & Vase Co.
Ltd). The bottle was wrapped in foil and kept at 4°C (Sambrook, et al., 1989).

6% or 12% Nondenaturing SSCP Gel

To make a 12% nondenaturing SSCP gel, 300 mL of the 40% acrylamide stock was
dissolved in 600 mL of Mi!liQ water and 100 mL of !OX TBE was added.

To make a 6% nondenaturing SSCP gel, 150 mL of the 40% acrylamide stock was
dissolved in 750 mL of MilliQ waler and 100 mL of !OX TBE was added.

Ammonium persulphate

Ammonium persulphate was made up at 25% weight/volume in MilliQ water and store.d

at 4oc, usually 2.5 gin 10 mL ofMilliQ water (ANRJ, 1994).

Fixative (10% Methanol and 10% Acetic Acid)

Usually malce 1L by adding 100 mL of glacial acetic acid and 100 mL of methanol to 800
mL ofMilliQ water in a fumehood cupboard (ANRl, 1994).
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Au~tralia

by

Abstract. A sequence tagged site (STS) was developed for the human beta
tropomyosin gene (TPM2). The STS was used to amplify DNA from somatic cell
hybrids to localise TPM2 to human chromosome 9. Genomic clones isolated with the
STS product were in turn used in fluorescence in situ hybridisatlon to metaphase
chromosome spreads to further localise TPM2 to 9p13.

Each muscle-specific gene should be associated with an inherited muscle disease,
unless mutations do not occur in that gene or all mutations of that gene are lethal.
Precise mapping of muscle genes therefore becomes important in relation to mapping
muscle diseases (Eyre

et al., 1993).

Tropomyosin is one of the components of the thin filaments of muscle, binding to
actin, and, together with troponin, regulating contraction in a calcium-dependent
manner (Cho et al., 1990). There are at least four distinct tropomyosin genes in
vertebrates and each may encode six different isoforms of tropomyosin by alternate
splicing (Navy et a!., 1993; Macleod et al., 1988). The alpha-tropomyosin gene
TPM1 has recently been localised to 15q22 (Eyre et al., 1994) and has been shown
to be mutated in some cases of familial hypertrophic cardiomyopathy (Thierlelder et
a!., 1994). The alpha-tropomyosin gene TPM3 has be<:ln recently localised to 1q22q23 (Wilton et al., 1994) and has been shown to be mutated in a family with
autosomal dominant r.emaline myopathy (manuscript submitted).

We describe the mapping of the human beta tropomyosin gene TPM2 (Widada et al.,
1988) to 9p13 by development of a sequence tagged site (STS) (Olson et al., 1989),

testing of a somatic cell hybrid panel, and fluorescence in situ hybridization (FISH)
(Callen et al., 1992).

2

Materials and

Methods

STS for the TPM2 gene.

The eDNA sequence of the skeletal muscle transcript of the TPM2 gene (Widada, et al.,
1988) was used along with the known conserved exon pattern of the tropomyosin genes
(Ruiz-Opazo et al., 1987; Clayton et a/., 1988) to design primers for amplification
which would amplify across intronic sequences. The primers were chosen such that at
least one was located in a skeletal muscle specific exon (Clayton, et a/., 1988;
Opazo &

Nadai~Ginard,

Ruiz~

1987; Widada, et ai., 1988) to avoid amplifying pseudogene

sequences. The primers eventually used were in the muscle specific exon Vlllsk
(TPM2.8R: 5'-AGTIACTGTAGTGGAGGGAG·3') and the common exon VI (TPM2.6F: 5'ATICCACCAAAGA.~GATAAA-3')

(Widada, eta/., 1988). These primers amplified an STS

product of approximately 1.5 kb long. The amplification conditions for a reaction volume
of

25~1

were:

5~1

of SX buffer (335mM Tris HCI [pH8.8] at 25°C; 83mM (NH4)2 S04,

1 mM dNTPs, 10 mM MgC/2, 1 mg gelatin/ml, and 2.25% Triton X-100), 50 ng target
DNA and 0.5 Unit of Tth polymerase (Biotech International). Thermal cycling conditions
were: 35 cycles of 94oc for 30 sees, saoc for 6 mins, with an initial denaturing period
at 94oc for 4.5 mins. The 1.5 kb product was sequenced using an ABI 373A DNA
sequencer tc confirm that the STS product did indeed contain parts of the TPM2 gene.

Isolation of genom;c clones

The genomic library was constructed in AEMBL3 SP6ff7 (Cionetech) following a partial
BamH1 digestion. The library was plated out at

S~fold

redundancy and duplicate lifts

made using Hybond N+ colony/plaque screening membranes (Amersham). The probe used
was the 1.5 kb PCR amplified STS of the TPM2 gene which was radiolabel/ed with o: p32
dCTP (Bresatec) using a random-prime kit (Promega). The duplicate lift!': were
hybridised with probe at 42°C for 16 hours in a
formamide, 10%

dextran~sulphate,

hybridi~ation

1M NaCI, 50mM

Tris~HCI

solution of 50%

pH7.5, 0.1 mg/ml

herring sperm DNA. Lifts were washed in 0.1% SDS and 0.1x sse at 65°C for 30
minutes. Autoradiography was carried out with Dupont Cronex 4

3

X~ray

film with Quanta

Ill autoradiography screens at ~8ooc overnight. Plaques showing up in duplicate on the
autoradiographs were considered positive. Confirmation of the TPM2 sequence in the
genomic clones was ensured by STS PCR assay and sequencing.

Pure clones were then amplified by the plate lysate method (Sambrook

et al., 1989).

Phage were eluted in Lambda dilution buffer (100mM NaCI, 10 mM MgS04.?H20, 100
mM Tris pH 7.5, 0.01% gelatin solution) at 4oc overnight. Eluates were collected and
phage were purified on caesium chloride gradients (Sambrook,

et al., 1989} and DNA

extracted. Di\JA integrity was checked by running each sample on a 0.8% agarose gel at
100 volts for 30 minutes and ntaining with

ethidium~bromide.

Extracted DNA was

confirmed to contain the TPM2 gene by STS PCA and sequencing. Whole clones were then
used for In situ hybridisation.

In situ hybridisation
The probes were nick-translated with biotin-14-dATP and each was hybridized in
situ at a final concentration of 20 ng/!ll to metaphases from two normal males. The
fluorescence in situ hybridization (FISH} method was modified from that previously
described

(Callen et a/., 1990} in that chromosomes were stained before analysis

with both propidium iodide (as counterstain) and DAPI (for chromosome
identification). Images of metaphase preparations were captured by a CCD camera
and computer enhanced.

Cell fines

A panel of rodent-human somatic cell hybrids was obtained from the National
Institute of General Medical Sciences Human Genetic Mutant Cell Repository
[NIGMS/mapping panel #2]. The construction of the mouse-human hybrid cell lines
was described by Dubois and Naylor (1992}.
performed with 50 ng of hybrid

1

PCR amplification of the STS was

!A and the primers TPM2.6F and TPM2.8R as

above.

4

Results and discussion
Somatic cell hybrid panel

The TPM2 STS gave an amplification product from only the control human DNA and
the somatic cell hybrid GM/NA10611 (Dubois et al., 1992) (data not shown). Only
chromosome 9 was unique to this cell line indicating that TPM2 is on human
chromosome 9.

FISH

The STS PCR product was used as a hybridization probe to the genomic library which
has an average lnsei1 size of 15 kb. Four positive plaques were picked and respread
at lower density enabling individual plaques to be isolated. The STS primer set was
used to assay selected pure plaques. Two of those which gave positive STS signals,
TPM2.2 and TPM2.4 , were further propagated.

TPM2.2 and TPM2.4 were then used for FISH to metaphase spreads from three
normal males. Twenty-five metaphases from the first normal male were examined
for fluorescent signal with TPM2.2. Eighteen of these metaphases showed signal on
one or both chromatids of chromosome 9 in the region 9p13-p21; 95% of this
:;;ignal was at 9p13.1 (Fig. 1). There was a total of 11 nonNspecific background dots
observed In these 25 metaphases. A similar result was obtained from hybridization
of this probe to 15 metaphases from the second normal male and from hybridization
using the probe TPM2.4 to 20 metaphases from the 3rd normal male (data not
shown).

The localization of TPM2 to 9p13 should be of interest to laboratories positional
cloning inherited muscle disorders, especially any that have already linked such
diseases to this region.
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Figure Legend
Figure 1

Metaphase showing FISH with the probe TPM2.2. a) Normal male
chromosomes stained with propidium iodide. Hybridization sites on
chromosome 9 are indicated by arrows. b) The same metaphase as (a)
stained with DAPI for chromosome identification.
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